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Abstract 
Primary Immunodeficiency Diseases (PIDs) are a heterogeneous group of 
genetic disorders characterised by malfunctioning of the immune system that 
predisposes to different patterns of infections, allergy, autoimmunity and cancer. 
To date, more than 300 gene defects have been identified to cause PIDs. PIDs 
are considered to be ‘experiments of nature’ as they provide in vivo assessment 
of the functional consequences when specific genes are defective and help our 
understanding of the basic cellular pathways and mechanisms of host defence 
in the human immune system. For this reason, many clinical and molecular 
studies have focused on the forward genetic potential of PIDs.  
In my study, I identified two novel PIDs characterised by increased viral 
susceptibility and immune dysregulation. Firstly, I investigated a patient who 
developed fatal illness after routine immunization with live attenuated vaccine 
measles, mumps and rubella (MMR) vaccine. By investigating type I interferon 
(IFN) signalling and performing targeted sequencing, I identified a homozygous 
mutation in the IFNα receptor 2 (IFNAR2) as the causative variant in the patient 
as well as in a newborn sibling. This phenotype emphasises the important role 
played by type I IFN signalling in antiviral immunity. 
Secondly, I investigated two siblings from a consanguineous marriage who 
presented with immune dysregulation characterised by lymphoproliferative 
disease (chronic lymphadenopathy, hepatosplenomegaly progressing to 
lymphoma) and susceptibility to herpesviruses. In addition, both patients 
developed autoimmunity.  A clinical diagnosis of autoimmune 
lymphoproliferative syndrome (ALPS) was made, supported by laboratory 
findings that showed impaired FAS-mediated apoptosis and increased double 
negative (DN) T cells. By using the approach of combined whole exome 
sequencing and homozygosity mapping, I identified a homozygous missense 
mutation of Ten Eleven Translocation 2 (TET2) as the disease causing variant. 
TET2 is involved in epigenetic regulation of gene expression by converting 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in the DNA 
demethylation process, amongst other mechanisms.  
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The identification of these two novel gene defects in the two different PIDs 
provides new understanding and broadens our knowledge about physiological 
and pathophysiological pathways in the human immune system. Furthermore, 
knowledge of these genetic defects can help in providing better care and 
treatment to future patients. 
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Chapter 1: Introduction 
1.1 Primary Immunodeficiency Diseases (PIDs) 
1.1.1 Overview  
Primary Immunodeficiency Diseases (PIDs) are a heterogeneous group of 
genetic disorders characterised by malfunctioning of the immune system 
(McCusker and Warrington, 2011). The immune system comprises of innate 
and adaptive immunity in which innate is the first line of defence against 
infections whereas adaptive immunity occurs later after innate immune 
responses take place. Defects within either of these two main components of 
the immune system may result in immunodeficiency. PIDs fully meet the 
definition of “experiments of nature” (Garrod, 1924; Ochs et al., 1999) in that 
they provide in vivo assessment of the functional consequences when specific 
genes are defective. For this reason, many clinical and molecular studies have 
focused on the forward genetic potential of PIDs (Ochs et al., 1999; Fischer, 
2007). 
The number of genetically defined PIDs has grown from only a handful in 1990 
(Ochs et al., 1999), to more than 300 distinct disorders by 2015 (Picard et al., 
2015). With the existence of increasingly advanced diagnostic technologies and 
fruitful international collaborations between PID centres worldwide, it is 
expected that more PIDs will be understood at genetic level. It should be noted 
that secondary immunodeficiencies can occur as a result of malnutrition, 
infections or immunosuppressive drug treatments (McCusker and Warrington, 
2011) and may lead to similarly impaired development and function of the 
immune system (Notarangelo, 2010). Most of the genetic changes described in 
PIDs are loss of function mutations, however, there are several that lead to gain 
of function (Fischer, 2007).  
It is estimated that the prevalence of overall PIDs is 1:10 000 to 1:100 000 
(Joshi et al., 2009; Bousfiha et al., 2013; Nijman et al., 2014) of live births and 
thus that it is a rare disease, although individual PIDs disorders vary in 
incidence (Chapel et al., 2014). The clinical presentation of PIDs can be as 
early as within few days of life to adulthood, and while symptoms may be mild in 
certain forms, other PIDs are severe or fatal in infancy.  Early diagnosis has a 
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demonstrably favourable impact on outcome for many PIDs. Hence, the Jeffrey 
Modell Foundation has developed a list of 10 warning signs in order to assist in 
the early recognition of PID (Table 1.1). The following criteria should raise 
suspicion: recurrent sinus or ear infections or pneumonias within a one year 
period; failure to thrive; poor response to prolonged use of antibiotics; persistent 
thrush or skin abscess; or family history of PID(McCusker and Warrington, 
2011). 
  
Table 1.1. 10 warning signs of immune deficiency in paediatrics 
suggested by ‘The Jeffrey Modell Foundation’. This table is reproduced from  
Jeffrey Modell Foundation: Primary Immunodeficiency Resource Centre. 
Available at http://www.info4pi.org/library/educational-materials/10-warning-
signs. 
 
Most PIDs present with increased susceptibility to infection (McCusker and 
Warrington, 2011). The pattern of susceptibility can be restricted to a certain 
pathogen (e.g. candida species or herpes simplex encephalitis) or extend to 
various pathogen types (e.g. common variable immune deficiency (CVID)) 
(McCusker and Warrington, 2011). Nevertheless, with increasing numbers of 
identified PIDs, more PIDs have also been associated with other clinical 
presentations such as autoimmunity and malignancy (Ochs et al., 1999). For 
example, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED), immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome and autoimmune lymphoproliferative syndrome (ALPS) are all 
monogenic disorders that present with dysregulation of the immune system.  
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As the numbers of molecular defects known to be associated with PID are 
increasing tremendously every year, the classification of PIDs are revised and 
updated frequently by the International Union of Immunological Societies expert 
committee. In the latest update (2015), PIDs were classified into nine major 
categories on the basis of the affected immunological compartment including 
combined immunodeficiencies, antibody deficiencies, diseases of immune 
dysregulation and defects of innate immunity (Picard et al., 2015). It is quite 
difficult to adhere strictly to the classification as most PIDs are complex 
diseases in which certain conditions can be classified under several categories 
(Picard et al., 2015). In addition, different mutations of the same gene may 
cause different disease phenotypes, complicating both diagnosis and disease 
classification. As it is expected that more new PIDs will be discovered, the 
classification will also undergo major revision and update.  
Since my work centres around novel PIDs with viral susceptibility and immune 
dysregulation, subsequent sections will introduce normal immune responses 
involving innate antiviral immunity, adaptive immunity and immune homeostasis 
as well as a selection of PIDs where these mechanisms are defective. Finally, 
at the end of this chapter, I will discuss approaches that have been used in the 
identification of disease causing variants in PIDs and the importance of 
identifying the molecular defect for the patients and family members.   
1.2 PIDs involving innate antiviral immunity 
1.2.1 Overview 
Innate immunity refers to non-specific protective mechanisms that act as the 
first line of defence against pathogens. Components of innate immunity include 
physical and chemical barriers, such as epithelial surfaces of the skin, 
respiratory tract and gastrointestinal tract, which prevent the entry of microbes, 
and the pH acidity in the stomach, which prevents the growth of pathogens 
(Abbas et al., 2007). Nucleated cells possess a variety of intrinsic, anti-infective 
mechanisms that are activated by exposure to microbes and can be powerfully 
amplified by cytokines such as interferons. The immune system contains 
specialised innate effectors such as dendritic cells, neutrophils, macrophages, 
Natural Killer (NK) cells and circulating plasma proteins including members of 
the complement system.  
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Viral infections in children and young adults are mainly asymptomatic or result 
in mild clinical presentations. These patients are able to mount an effective 
immune response that either eliminates the virus from the body or restricts it to 
a latent or low level form without further problems. The innate antiviral immune 
response plays an important role in controlling viral infections at the early stage 
of the infections. However, it is insufficient to clear viral pathogens. Therefore it 
requires the adaptive immune response to be generated, in order to fully 
eradicate the viral infection.  
Individuals with primary immunodeficiency disorders have a genetic defect 
causing an inability to mount effective immune responses. Recently, 
susceptibility to viral infections due to genetic defects of innate antiviral 
immunity has been described. Some of these mutations predispose to specific 
viral infections, while others predispose to viruses and other pathogens 
(Dropulic and Cohen, 2011). In order to understand how these mutations result 
in increased viral susceptibility, it is necessary to know how innate antiviral 
immunity functions in healthy individuals. 
1.2.2 Innate Antiviral immunity 
1.2.2.1 Virus replication 
Viruses are intracellular pathogens that infect and replicate within host cells and 
exploit the host’s cellular machinery for their survival. Viruses exist outside the 
cell as virion particles, each of which contains a genome consisting of either a 
double stranded or single stranded DNA or RNA wrapped in a protein coat 
called a capsid (Strauss and Strauss, 2008). Viruses infect the cells through 
attachment to a surface receptor which leads to the penetration of the genome 
into the cytoplasm. The genome is then transcribed, translated, and replicated 
(Strauss and Strauss, 2008). Most viruses bud from the cell, thereby producing 
progeny virions which then can infect new cells. Some viruses however spread 
from cell to cell without forming new virions.  The host cell may be killed as a 
direct result of virus infection, but certain viruses can persist in live cells 
especially in a transcriptionally inactive or “latent” form.  
Healthy individuals have the ability to control viral infections through effective 
innate and adaptive antiviral immune responses. Critical mediators in the innate 
immune response are interferons (IFNs), which are cytokines that induce the 
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transcription of hundreds of genes (the IFN-stimulated genes, ISGs) involved in 
blocking or impairing viral replication in the host cells. In addition, IFNs also 
have a profound immunomodulatory effect and stimulate the adaptive immune 
response (Goodbourn et al., 2000).  
1.2.2.2 Interferons (IFNs) 
Interferons are widely expressed cytokines that have an antiviral effect, regulate 
cell growth and activate the immune system (Goodbourn et al., 2000). The 
interferons are classified into three distinct types, type I, II and III. Type I IFNs 
are produced in direct response to virus infection and include IFNα (which can 
be subdivided into 13 subtypes IFNα1, -α2,- α4, -α5,- α6, -α7, -α8, -α10, -α13, -
α14, -α16, -α17 and -α21), IFNβ and others of unknown significance in humans 
such as  IFN-δ, IFN-ε, IFN- ƙ, IFN-τ and IFN-ω (Platanias, 2005). Most 
nucleated cells can both produce IFNα/β and respond to it through the 
ubiquitously expressed type I IFN receptor, which is composed of two subunits, 
IFNα-receptor 1 (IFNAR1) and IFNα-receptor 2 (IFNAR2) (McNab et al., 2015).  
Mouse models have played a pivotal role in understanding type I IFN biology. 
Mice lacking either IFNAR1, IFNAR2  or components of the downstream 
JAK/STAT signalling pathway were shown to be extremely susceptible to a 
large number of viruses such as vesicular stomatitis virus (VSV), Semliki Forest 
virus (SFV), vaccinia virus, lymphocytic choriomeningitis virus (LCMV) (Muller et 
al., 1994; Van Den Broek et al., 1995; Meraz et al., 1996; Park et al., 2000), 
dengue virus (Züst et al., 2014), herpes simplex virus 2 (Ank et al., 2008) and 
Theiler’s virus (Fiette et al., 1995).  
IFNγ is the only member of type II IFNs. Rather than being induced directly by 
viral infection, IFNγ  is predominantly synthesised in response to the recognition 
of infected cells by T cells and natural killer (NK) cells and can act on broad 
ranges of cells that express the IFNγ receptor (Goodbourn et al., 2000; 
Platanias, 2005). Similarly to type I IFN, type II IFN also has antiviral properties 
and its antiviral role was demonstrated by mouse models that lack the IFNγ 
receptor. These mice were shown to be unable to mount efficient responses to 
viruses including Theiler’s virus, LCMV and vaccinia virus (Huang et al., 1993; 
Muller et al., 1994; Fiette et al., 1995; Van Den Broek et al., 1995). Importantly, 
the mouse studies revealed that for the control of certain viruses, both type I 
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and type II IFNs are required, each playing a non-redundant role in the antiviral 
defence.  
Type III is another class of IFNs, comprising  IFN-λ1, -λ2, -λ3 and newly 
identified –λ4 (O'Brien et al., 2014). Type III IFNs signal through their receptor 
complex consisting of IL-10Rβ and IL-28Rα chains (Ank et al., 2008). Type III 
IFNs are directly induced by virus infection and although their receptors are 
different, they signal via the same JAK/STAT pathway as type I IFN (Onoguchi 
et al., 2007; Ank et al., 2008). In addition, type III IFN also triggers similar 
antiviral effects as type I IFN by inducing the expression of the same set of 
genes (Sommereyns et al., 2008). However, expression of the IFNλ receptor is 
mainly on epithelial surfaces (Sommereyns et al., 2008; Witte et al., 2010), in 
contrast to IFNα/β receptors which are expressed in most cell types. Due to this, 
it is suggested that innate protection against viral invasion at the epithelia, for 
example skin and mucosal surfaces, is mainly governed by type III IFN (Ank et 
al., 2008; Sommereyns et al., 2008; Durbin et al., 2013). In contrast to type I 
IFNs, the pathways or mechanisms that induce the production of type III IFNs 
are still unclear.   
1.2.2.3 Induction of Type I IFN 
Type I IFNs, IFNα and IFNβ, are produced early in response to viral infections 
(Biron, 1998). Most cells can produce IFNα/β but plasmacytoid dendritic cells 
(pDC) do so particularly readily and are a major source of IFNα in humans 
(Colonna et al., 2002). When cells are infected, it results in the stimulation of 
receptors known as pattern recognition receptors (PRRs) which are located in 
the cytosol or endosomal compartment (Muller et al., 1994). These receptors 
are able to detect pathogen-associated molecular patterns (PAMPs), e.g. viral 
nucleic acid.  In the cytoplasm, the main receptors are the RNA helicases 
retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated 
gene 5 (MDA-5) which are responsible for detecting the double stranded RNA 
(dsRNA) of viruses. Both RIG-I and MDA-5 are ubiquitously expressed in most 
tissues (Goodbourn et al., 2000). Upon stimulation, both RIG-I and MDA-5 
recruit and activate a mitochondrion-associated adaptor variously called CARD 
adaptor inducing IFNβ (Cardiff)/virus-induced signalling adaptor 
(VISA)/mitochondrial antiviral signalling protein (MAVS)/IFNβ promoter 
stimulator protein 1(IPS-1) (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 
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2005; Xu et al., 2005). This recruitment then leads to the activation of the IRF3 
and NF-κB pathways. Prior to induction, both IRF3 and NF-κB are in the 
cytoplasm. Once the signal is received, the interaction of TANK-binding kinase 
1 (TBK-1) and IKKε leads to phosphorylation of IRF3 and its migration into the 
nucleus. Similarly, NF-κB is held by the inhibitor of NF-κB (IκB) in the cytoplasm 
until stimulation, when the IκB is phosphorylated and degraded, causing the 
release of NF-κB which then translocates into the nucleus. In the nucleus, 
phosphorylated IRF3 and NF-κB bind to the IFNB promoter with other co-factors 
such as CBP/p300 and RNA polymerase II (Randall and Goodbourn, 2008), 
leading to the stimulation of transcription of IFNα/β. 
Besides the cytosolic receptors, Toll-like receptors such as TLR3, TLR 7,TLR8 
and TLR9 also activate pathways that result in production of IFNα/β. TLR3 
recognizes double stranded RNA (dsRNA) (Alexopoulou et al., 2001), whereas 
TLR7 and TLR8 detect viruses that contain single-stranded RNA (ssRNA) 
genomes (Diebold, 2008). In addition, TLR9 detects unmethylated CpG motifs 
in DNA viruses (Krug et al., 2004). Specialised cells such as conventional (cDC) 
and plasmacytoid dendritic cells (pDC) produce IFNα via these TLR pathways 
(Colonna et al., 2002). These TLRs are located intracellularly in the endosomal 
compartment. Upon infection, viral nucleic acid is internalised into endosomes 
by endocytosis which then activates the TLR signalling pathway (Randall and 
Goodbourn, 2008). TLRs such as  TLR7, 8 and 9 signal through the adaptor 
molecule myeloid differentiation factor 88 (MyD88 ) and the recruitment of  
interleukin-1 receptor-associated kinase 4 (IRAK-4) and IRAK-1 (Randall and 
Goodbourn, 2008), whereas TLR3 mediates its signal through the Toll-like 
interleukin-1-resistance (TIR) domain-containing adaptor inducing IFNβ (TRIF) 
(Yamamoto et al., 2003). This recruitment then leads to the activation of NF-κB 
and IRF3 pathways, similar to the activation via RIG-I and MDA5.  
Based on several sources of evidence, activation of the IRF3 pathway leads to 
an initial ‘first wave’ of IFNβ production which then triggers the transcription of 
IRF7 (Marié et al., 1998; Honda et al., 2006; Randall and Goodbourn, 2008). 
Except in specialised cells such as pDC, IRF7 is normally absent or present in 
very low amounts (Randall and Goodbourn, 2008). Once upregulated, IRF7 is 
activated in the same way as IRF3 and provides a positive feedback loop to 
enhance the transcription of the primary IFN genes and allows transcription of a 
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second wave of IFN genes including the IFNα genes (Marié et al., 1998; Sato et 
al., 1998; Randall and Goodbourn, 2008). IRF3 and IRF7 are considered as the 
main IRF family members important for IFNα/β production. There are others 
such as IRF1, IRF5 and IRF8 that can also induce production of IFNα/β but 
their importance still remains unclear (Honda et al., 2006; Randall and 
Goodbourn, 2008). The induction of IFNα/β via the cytosolic receptors and 
TLRs pathways are summarised in Figure 1.1. 
 
Figure 1.1: Pathways of type I Interferon (IFNα/β) induction. Pattern 
recognition receptors (PRR) such as RIG-I, MDA-5 and TLRs detect viral 
nucleic acid leading to induction of IFNα/β transcription, which is mediated by 
the NF-κB and IRF3 pathways. IRF-7, which is present due to feedback action 
of IFN, is activated similarly to IRF-3. 
 
1.2.2.4 IFN signalling and induction of IFN-stimulated genes (ISGs) 
Type I IFN signalling has been firmly established and characterized in 
comprehensive reviews (Platanias, 2005; Randall and Goodbourn, 2008). IFN-
mediated signalling induces the transcription of IFN-stimulated genes via the 
Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 
pathway.  IFNα/β binds to and signals through a heterodimeric transmembrane 
receptor composed of IFNAR1 and IFNAR2. The IFNAR1 is associated with 
tyrosine kinase 2 (TYK2) whereas IFNAR2 is associated with the tyrosine 
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kinase Janus kinase 1 (JAK1). The binding of IFNs results in phosphorylation of 
JAK1 and TYK2. These subsequently phosphorylate STAT1 on tyrosine 701 
and STAT2 on tyrosine 690 (Randall and Goodbourn, 2008). The 
phosphorylated STAT1 and STAT2 interact strongly with each other, forming a 
stable pSTAT1-pSTAT2 heterodimer which then translocates into the nucleus. 
There, the pSTAT1-pSTAT2 heterodimer interacts with the DNA-binding protein, 
IRF9, forming a heterotrimeric complex known as IFN-stimulated Gene Factor 3 
(ISGF3). The heterotrimeric complex ISGF3 then binds to IFN-stimulated 
response elements (ISRE), leading to the transcription of the several hundreds 
of IFN-stimulated genes including dsRNA-dependant protein kinase R (PKR), 
2’5’-oligoadenylate synthetase (OAS), Mx and numerous other potent antiviral 
effectors such as ISG15, 54 and 56 (Goodbourn et al., 2000). The genes 
mentioned are among those that are studied intensively and were demonstrated 
to play an important role in the antiviral response (Randall and Goodbourn, 
2008). For example PKR is involved in inhibiting the translation of viral mRNAs 
(Balachandran et al., 2000), whereas Mx proteins were demonstrated to 
interfere with virus replication (Stranden et al., 1993). 
Besides the ISGF3-dependent canonical signalling pathway mentioned above, 
IFNα/β also signals through STAT1 homodimers, which are the principal 
mediators of IFNγ-mediated signalling (George et al., 1998). The STAT1 
homodimer translocates into the nucleus and binds to the specific IFNγ 
activating site (GAS) that is present in the promoter of ISGs, thereby promoting 
their transcription (Platanias, 2005). The IFN signalling pathway is summarised 
in Figure 1.2. 
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Figure 1.2: Signalling pathways activated by IFNα/β. IFNα/β binds to its 
receptor and activates the JAK-STAT pathway. The activation leads to 
phosphorylation of STAT1 and STAT2, which then translocate into the nucleus, 
together with IRF9, forming a heterotrimeric complex, ISGF3. ISGF3 binds to 
ISRE, leading to the transcription of ISGs. IFNα/β can also signal through 
STAT1 homodimers, which are commonly associated with IFNγ-mediated 
signalling, bind to GAS and initiate gene transcription. 
 
In addition, it should also be noted that there are other members of the STAT 
family such as STAT3, STAT4 and STAT5.  These can also be activated by 
IFNα/β to induce the transcription of a broad range of genes that encode 
cytokines, chemokines, antibacterial effectors and metabolic mediators, in 
addition to those dedicated to viral restriction (Ivashkiv and Donlin, 2014; 
McNab et al., 2015). The resulting changes in gene expression are important in 
activating DCs, enhancing NK cell and macrophage function and promoting 
survival and effector functions of T and B cells (Christensen and Thomsen, 
2009), implying that IFNα/β’s role in antiviral immunity is not restricted to direct 
antiviral activities only but is also important for modulating the innate and 
adaptive immune response. 
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1.2.2.5 Role of the innate cellular components in antiviral immunity 
As discussed in detail in the above section, IFNα/β are critical mediators of 
innate antiviral immunity by inducing the expression of a broad range of genes. 
This results in the secretion of cytokines and chemokines which recruit innate 
cellular components such as natural killer (NK) cells and macrophages to local 
virus-infected tissues. In turn, in addition to IFNα/β, these cells also produce 
other cytokines and chemokines that enhance the innate antiviral response.  
NK cells are found in the blood, liver, spleen and also in lymph nodes 
(Christensen and Thomsen, 2009). They can migrate to the site of infection 
after being activated. NK cells are proposed to play two effector functions in 
controlling viral infection (Luca and Francis, 2001). Firstly, they can recognise 
the virus-infected cells at the very early stage of infection by expressing a 
repertoire of receptors including NKG2D, through which NK cells are able to 
distinguish between uninfected and infected cells (Eagle and Trowsdale, 2007; 
Christensen and Thomsen, 2009). NKGD2 ligands such as  MHC-class-I-
polypeptide-related sequence A (MICA) and MICB are expressed on the 
infected cells (Eagle and Trowsdale, 2007), which also may downregulate 
inhibitory ligands such as class I MHC molecules. Following recognition of 
infected cells, activated NK cells bring various effector mechanisms into play 
including the directed release of cytolytic granules.  Secondly, they augment the 
local innate inflammatory response by secreting pro-inflammatory cytokines 
including IFNγ and TNFα, which are required for the activation and expression 
of other cytolytic effector functions in the control of a large variety of DNA and 
RNA viruses (McNab et al., 2015). 
Another cellular component is macrophages, whose activation represents a key 
role in the early clearance of many virus infections. Upon activation by viruses, 
macrophages secrete pro-inflammatory cytokines such as IFNα/β and TNFα 
that have direct antiviral activity. They also produce other cytokines that have 
indirect immunomodulatory functions, e.g. Interleukin-12 (IL-12) and IL-18. Both 
interleukins were demonstrated to have antiviral activities by inhibiting the 
replication of several number of viruses including HSV (Carr et al., 1997) and 
vaccinia virus (Tanaka-Kataoka et al., 1999) in vivo, but these antiviral activities 
are thought to be due to the possibility that these cytokines can induce IFNγ by 
NK cells (Luca and Francis, 2001; Dinarello and Giamila, 2003), rather than 
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having a direct antiviral potential themselves. In addition, macrophages also 
produce chemokines including CCL3/macrophage inflammatory protein (MIP-
1α), CCL5/normal T cell-expressed and secreted (RANTES), CCL2/monocyte 
chemotactic protein-1 (MCP-1) and CXCL10/IFN-γ-inducible protein of 10 kDa 
(IP-10) (Luca and Francis, 2001; Melchjorsen et al., 2003).  These chemokines 
were shown to be upregulated when infected with either respiratory syncytial 
virus (RSV) (Haeberle et al., 2001) or Influenza virus (Dawson et al., 2000),. 
Nitric oxide, which is produced by activated macrophages via the inducible nitric 
oxide synthase (iNOS)-dependant pathway (Biron, 1998), also has antiviral 
activity, as it was shown that this substance is able to inhibit the replication of 
various viruses including vaccinia virus, HSV, poliovirus, rhinovirus and VSV  
(Reiss and Komatsu, 1998). 
Both plasmacytoid (pDC) and conventional dendritic cells (cDC) are also 
involved in the innate antiviral response. Apart from being major producers of 
IFNα/β (Colonna et al., 2002), DCs also secrete antiviral cytokines, including 
TNFα, IL-12 and IL-18 following activation (Luca and Francis, 2001). In resting 
conditions,  immature DCs are  poor at stimulating T cells, however following 
stimulation by e.g. IFNα/β upon viral infection (Le Bon and Tough, 2002), they 
become mature DCs which are able to present antigens and activate T cells as 
well as stimulate the differentiation and proliferation of B cells (Luca and Francis, 
2001). This important role contributes to the development of the adaptive 
immune response during viral infections.  
From the overall discussion above, it is clear that the induction and signalling of 
IFNα/β as well as the arrival of the innate effector cells play a direct role in 
controlling the initial phase of the viral infection. Furthermore, the activation of 
this innate immune response is critical in promoting the initiation of the adaptive 
immune response which relies upon the cytolytic T cell (CTL), helper T cell (Th) 
and B cell functions. The adaptive immune response will be discussed in detail 
in the adaptive Immunity section. 
1.2.2.6 Viral evasion strategies to the IFN response 
As the IFN system provides a powerful defence against viral infection, it is not 
surprising to discover that viruses have evolved numerous mechanisms to 
evade it (Goodbourn et al., 2000; Haller et al., 2006; Randall and Goodbourn, 
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2008). Despite their small genomes, many viruses express IFN-antagonists 
which are multifunctional proteins that interact with multiple viral or host cells 
components (Haller et al., 2006). These IFN-antagonists use several strategies 
such as inhibition of the different components of IFN induction, the IFN 
signalling cascade or even specific IFN-induced antiviral genes.  
Several viruses were shown to produce proteins that inhibit NF-κB as well as 
IRF3, to prevent the induction of IFNα/β (Powell et al., 1996; Ronco et al., 1998); 
African Swine Fever virus (ASFV) encodes a homologue of IκB that inhibits the 
activity of NF-κB (Powell et al., 1996), whereas E6 protein of human 
papillomavirus type 16 (HPV-16)  binds IRF3 and inhibits its virus-induced 
transcriptional activation function (Ronco et al., 1998). In addition, the hepatitis 
C virus (HCV) protein NS3/4a blocks the TLR3 signalling cascade by cleaving 
the TLR3 adaptor protein, TRIF, and reducing its abundance (Li et al., 2005). In 
contrast, RIG-I-mediated signalling is inhibited by NS1 protein of Influenza virus 
(Guo et al., 2007; Opitz et al., 2007) but the mechanism is unclear. All these 
inhibitory activities by viruses minimise the IFN production, thereby leading to 
efficient viral transcription and replication in the host cells. 
Other viruses target IFN signalling, either by IFNα/β or IFNγ or even both 
(Goodbourn et al., 2000). For example, the paramyxovirus human parainfluenza 
virus 2 (hPIV2) targets only STAT2 (Young et al., 2000), resulting in blocking 
the IFNα/β signalling, whereas V protein of  the paramyxovirus simian virus 5 
(SV5) and Sendai Virus (SV) targets STAT1 for proteasome-mediated 
degradation, therefore blocking both IFNα/β and IFNγ signalling (Young et al., 
2000). Interestingly, in contrast, respiratory syncytial virus (RSV, another 
paramyxovirus) was demonstrated not to block any of the IFN signalling 
pathways but was able to replicate efficiently in human cells (Young et al., 
2000), indicating that it uses a different circumvention strategy. Thus, even 
within a single virus family (paramyxoviruses), distinct virus-specific 
mechanisms are used to circumvent the IFN response. Another strategy of the 
virus in evolving the IFN response is by inhibiting the activity of antiviral genes. 
For example, the activity of PKR  is inhibited by the binding of the non-structural 
protein NS5A of HSV (Gale Jr et al., 1997) and PK2 protein of baculovirus 
(Dever et al., 1998).  
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Intriguingly, there are also viruses that produce IFN-antagonistic proteins that 
use a combination of these strategies. One example is the NSs protein of Rift 
valley fever virus which has the ability to block IFN production by inhibiting the 
IFNβ promoter activity (Billecocq et al., 2004). Surprisingly, the same viral 
protein was also demonstrated to activate  the cellular suppressor of STATs, 
SOCS-1, thereby blocking IFN signalling (Haller et al., 2006), indicating that the 
Rift valley fever virus has the ability to evade the IFN response through 
inhibiting both IFN induction and signalling. Hence, this allows the virus to 
enhance its replication and spread rapidly from the infected cells to 
neighbouring cells, as it has suppressed the antiviral state.   
By producing IFN-antagonistic proteins which target the components of the 
antiviral response, viral pathogens are able to multiply extensively and establish 
a solid infection in the host cells. An important corollary of this is that without 
these proteins, their ability to evade the immune response becomes limited. 
Attenuated, mutant viruses that lack the IFN-antagonists are generated in many 
laboratories in order to have a better understanding of viral pathogenesis and 
the IFN system. This is one of the approaches that is being used to study a 
disease mechanism which will be described later in Chapter 3.  These viruses 
also open up the possibility of therapeutic application as live attenuated 
vaccines in which the viral IFN antagonists have been deleted and thus will 
provide a robust IFN and immune response against the viral infection.  
 
1.2.2.7 Mutations affecting the IFN induction and signalling pathway  
Mutations affecting the IFN pathway have been described in humans and 
represent a form of Primary Immunodeficiency Disease (PID) (Dropulic and 
Cohen, 2011).  These include lesions that affect the production of IFN and 
those that affect IFN signalling.  These mutations predispose individuals to 
severe viral infections mainly, but some are also associated with infections by 
other organisms such as fungi and mycobacteria. 
Mutations of the TLR3 signalling pathway have been linked mainly to herpes 
simplex encephalitis (HSE) in children (Dropulic and Cohen, 2011). Two 
patients with autosomal recessive homozygous mutations in UNC-93 homolog 
B1 (UNC93B1) have been reported. The functions of this protein are in TLR7 
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and TLR9 trafficking from the endoplasmic reticulum to endosomes and in TLR3, 
TLR7, TLR8 and TLR9 signalling (Casrouge et al., 2006; Kim et al., 2008). 
Another genetic cause of HSE is the heterozygous autosomal dominant 
mutation in TLR3 in two siblings (Zhang et al., 2007). Interestingly, it was noted 
that disease associated with this mutation shows incomplete clinical penetrance 
as other family members who also had the same mutation did not have any 
clinical manifestations. In addition, autosomal recessive homozygous mutations 
in TLR3 were also identified that predispose the individual to HSE whilst having 
normal resistance to other infections (Guo et al., 2011b). 
One child with HSE that recovered was reported with an autosomal dominant-
negative mutation in tumour necrosis factor receptor-associated factor 3 
(TRAF3) (Pérez de Diego et al., 2010), a protein downstream of UNC93B and 
TLR3 in the cytoplasm. The mutation results in the impaired production of Type 
I IFN. Furthermore, autosomal recessive or autosomal dominant mutations in 
TRIF, another protein downstream of the TLR3, have also been observed to 
cause HSE (Sancho-Shimizu et al., 2011). Since no other severe viral infection 
was observed in these patients, all these mutations demonstrated that impaired 
TLR3 signalling via UNC93B-TRAF3-TRIF dependant pathway causes selective 
susceptibility to Herpes Simplex Virus (HSV-1) infection in the central nervous 
system.  
The IRF3-mediated pathway is activated by most of the PRRs that play an 
important role in the induction of IFNα/β. Very recently, a new and incompletely 
penetrant autosomal dominant disorder of IRF3 was identified in a 15 years old 
adolescent with HSE (Andersen et al., 2015). This is the first identification of a 
mutation in a member of the IRF family that is involved in the induction of type I 
IFNs. The NF-кB-mediated pathway is another pathway that induces the 
production of type I IFNs in the cells. It was identified that hypomorphic 
mutations in inhibitor of NF-кB kinase γ, known as NEMO (NF-кB essential 
modulator), cause susceptibility to herpesviruses (e.g. CMV sepsis and colitis, 
HSV stomatitis, pharyngitis and encephalitis) (Orange et al., 2004). However, 
this mutation results in combined immunodeficiency  with susceptibility to other 
organisms as well as, such as susceptibility to pyogenic bacteria and atypical 
mycobacteria (Orange et al., 2004).  
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Susceptibility to viruses in patients with mutations affecting IFN signalling have 
also been described. Homozygous complete autosomal recessive (AR) 
mutations of STAT1, which cause both defective IFNα/β and IFNγ signalling, 
were identified in two patients. Both patients presented with disseminated 
Bacille Calmette -Guerin (BCG) disease but died due to recurrent HSE caused 
by HSV-1 (Dupuis et al., 2003). In addition, one of two patients with partial AR 
STAT1 deficiency was reported to suffer severe herpesviral infections in 
addition to salmonellosis (Chapgier et al., 2009). Other mutations that also 
predispose to increased susceptibility to severe infections with herpesviruses 
and certain respiratory viruses were homozygous or heterozygous dominant-
negative mutations in IFNγ receptors 1 or 2; however, these mutations primarily 
predispose to disseminated infections with mycobacteria (Dorman et al., 1999). 
Binding of IFNα/β to its receptor, composed of IFNAR1 and IFNAR2, leads to 
the phosphorylation of JAK1 and TYK2. TYK2 deficiency due to a homozygous 
mutation has been described in a 22 year old boy with a complex phenotype 
(Minegishi et al., 2006). Initially the patient was diagnosed with autosomal 
recessive hyper-Immunoglobulin E syndrome as he exhibited recurrent 
staphylococcus abscesses, respiratory tract infections and markedly increased 
serum Immunoglobulin (Ig) E concentrations (> 2000IU/ml). However, he also 
demonstrated unusual susceptibility to various microorganisms such as HSV-1, 
mycobacteria and salmonella. Evaluation of the patient’s immune response 
revealed defects in multiple cytokine signalling pathways including IFNα/β, IL-6, 
IL-10, IL-12 and IL-23, implying that TYK2 is essential in multiple cytokine 
signals involving innate and acquired immunity. Subsequently other TYK2-
deficient patients have been described with similar broad susceptibility to 
infection but without the hyper-IgE element of this phenotype (Kreins et al., 
2015). Finally, another defect of the IFN signalling pathway was reported by our 
group to be a homozygous autosomal recessive mutation in STAT2; here, the 
index patient developed disseminated vaccine strain measles following routine 
immunization (Hambleton et al., 2013). Given the severity of viral susceptibility 
in the Stat2-deficient mouse model (Park et al., 2000),  it was surprising to find 
that the STAT2-deficient patient could cope well with common viral infections 
and remained generally healthy, with no obvious defects in adaptive immunity. 
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Figure 1.3: Known mutations affecting the IFN induction and signalling 
pathway. Mutated genes are coloured in grey. 
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1.3 PIDs involving adaptive Immunity 
1.3.1 Overview 
Adaptive antiviral immunity implies a highly specific and potent immune 
response to infection. In contrast to innate immunity, it does not act immediately 
but requires up to several days to generate a primary response. Once 
established, it can be extremely effective in eliminating infection, although this 
varies from one virus to another. It is distinct from innate immunity in two 
important respects: 1) it exhibits fine antigenic specificity against the invading 
pathogen, and 2) it has the ability to form memory against previously 
encountered pathogens, responding more rapidly upon second encounter. Two 
major cell types that participate in adaptive immunity are B lymphocytes and T 
lymphocytes. B cells mediate humoral immunity by developing into plasma cells 
that secrete antibodies, whereas T cells play a central role in cell-mediated 
immunity; extensive cross-talk also occurs between T and B cells. 
Adaptive immune responses are required to eliminate not just viruses but also 
other pathogens such as bacteria, parasites and fungi. Patients with numerical 
deficiency of T cells suffer severe combined immunodeficiency (SCID) which is 
marked by susceptibility to multiple viruses, bacteria and fungi, resulting in 
severe and fatal illness (van der Burg and Gennery, 2011).  Less catastrophic 
defects of T cell development and function produce varying patterns of 
susceptibility to infection as well as immunodysregulatory phenomena such as 
autoimmunity and lymphoproliferation. Likewise disorders of antibody 
production vary in degree and consequence, according to the particular defect. 
In order to understand how PIDs impair cellular and humoral immune response, 
subsequent sections will introduce lymphocyte biology involving their 
development, activation and tolerance as well as highlighting the genetic 
defects that have been identified in humans within these processes.  
1.3.2 T lymphocyte biology and function 
1.3.2.1 T lymphocyte development 
Both T and B cells are derived from common lymphoid progenitor (CLP) cells 
which in turn originate from haematopoietic stem cells (HSCs), cells that are 
found in the bone marrow and have self-renewal potential, to maintain the 
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number of blood cells to ensure lifelong production. Besides lymphocytes, CLP 
also gives rise to NK cells which play a more important role in the innate 
immune response, as has been described in the innate antiviral immunity 
section earlier. Besides CLPs, HSCs also differentiate into common myeloid 
progenitors that give rise to macrophages, granulocytes, mast cells, 
erythrocytes and platelets. For T lymphocyte development, CLPs migrate via 
the blood to the cortex of the thymus.  Here, the precursor T cells lacking 
expression of T-cell receptor (TCR), CD4 and CD8 are known as double 
negative (DN) thymocytes. DN thymocytes further differentiate in a series of 
four stages (DN1, DN2, DN3 and DN4 ) (Germain, 2002). These cells can 
develop into either TCRαβ or TCRγδ-expressing cells (E Robey and Fowlkes, 
1994; Germain, 2002), but the majority will give rise to TCRαβ-expressing cells.  
It is during the DN3 stage that the commitment to be either αβ or γδ-TCR 
expressing cells is made (Ochs et al., 1999). At this stage, the rearrangement of 
the VDJ segments of the TCRβ chain occurs, which requires the expression of 
Recombination-activating Gene 1 (RAG1) and RAG2 (Germain, 2002). If the 
TCRβ chain successfully pairs with the pre-TCRα chain to form a pre-TCR, the 
DN3 cells undergo proliferation and proceed to further development into DN4 or 
late pre-T cells. DN4 cells that expand successfully undergo transition into 
double positive (DP) cells that express both CD4 and CD8. Replacement of the 
pre-TCRα chain with the newly rearranged TCRα-chain yields complete TCRαβ 
expression on the cell surface (Germain, 2002). Cells that fail the TCR gene 
rearrangement process will die through apoptosis.  
As the DP thymocytes move d eeper into the cortex, they encounter self-
antigens presented on MHC molecules and positive and negative selection 
occurs. The fate of the DP thymocytes is determined by the quality of these 
interactions. DP cells whose TCR binds with low affinity to peptide-MHC 
complexes undergo positive selection resulting in cell survival and expansion of 
cells that can recognise MHC complexes at least weakly. If they are not able to 
bind MHC, they are eliminated by “death by neglect”. On the other hand, DP 
cells whose TCR recognises self-antigens with high affinity are subject to 
negative selection. These cells, which might otherwise be harmful, are 
eliminated mainly by apoptosis although other processes such as anergy 
(Hammerxing et al., 1991) and receptor editing (McGargill et al., 2000; 
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Nemazee, 2006) have been described; it is unclear how prominent the latter 
processes are in establishing central tolerance of T cells (Holman et al., 2003; 
Hogquist et al., 2005).  
During positive selection, another process also occurs which is known as 
CD4/CD8 lineage commitment. If the TCR on the DP cells recognises peptide-
loaded MHC class I molecules, the cells become single positive CD8+ T cells, 
and if the TCR recognises peptide-loaded MHC class II molecules, the cells 
become single positive CD4+ T cells. These SP cells proliferate, then leave the 
thymus and populate the peripheral tissues. Most thymocytes die during the 
developmental processes and only few of them successfully emerge from the 
thymus and become mature competent T cells in the periphery (Ochs et al., 
1999). The development of T cells is summarised in Figure 1.4 
 
 
Figure 1.4: Overview of T cell development in the thymus. DN-double 
negative, TCR-T cell receptor, DP-double positive.  
 
It should be noted that a variety of cytokines and transcription factors are 
involved in initiating and maintaining lymphopoiesis including Interleukin-7 (IL-7), 
which is known to be critical for the early development of T cell progenitors (He 
and Kabelitz, 1994) along with GATA-binding protein 3 (GATA3), RUNT-related 
transcription factor (RUNX) and several others transcription factors (Naito et al., 
2011) which are involved at various stages of T cell development.  
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Several genetic defects affecting T-cell development have been described to 
cause PID (Picard et al., 2015). These include mutations in genes encoding 
components of the IL-7 signalling cascade such as Interleukin-2 (IL-2) receptor 
common γ chain (IL2RG) (Noguchi et al., 1993), IL-7 receptor α chain (IL7R) 
(Puel et al., 1998) and Janus kinase 3 (JAK3) (Macchi et al., 1995).  Defects of 
several components of the TCR associated CD3 complex also prevent T cell 
development by their failure to support positive selection. The above all lead to 
T-B+ SCID, in which T- but not B-cell development is affected; NK cell 
development is also impaired in both IL2RG- and JAK3-SCID but spared in 
deficiencies of IL7R or CD3.  Another type of SCID, T-B- most frequently 
involves mutations in RAG1 or RAG2 which result in defective VDJ 
recombination and affects both T- and B-cell compartments. Different 
genotypes of SCID can result in unique symptoms but most SCID patients 
presented with failure to thrive and severe recurrent infections of multiple 
pathogens including bacteria, protozoa, fungi and viruses (Kalman et al., 2004). 
The symptoms usually present in the first few months of life and if not treated 
early, it leads to the death of the patient.  
1.3.2.2 Antigen presenting cells (APCs) 
As described in section 1.2.1.1, once T cells completed their development in the 
thymus, they emerge into the periphery in response to chemokine cues. Naïve 
T cells circulate from the blood into lymphoid organs and back until they 
encounter their cognate antigen. Most cells can present antigen but only 
specialised cells, which are known as professional APCs (pAPCs) are capable 
of priming naive T cells (Jacques et al., 2000). APCs act by processing the 
protein antigens to peptides and displaying them on the MHC-complex to be 
recognised by T cells in the presence of a co-stimulatory signal. There are 3 
major pAPCs that  play important roles in the antigen presentation process 
including dendritic cells (DCs), B cells and macrophages (Abbas et al., 2007). 
Immature DCs reside in most tissues. Although they are poor at antigen 
presentation, they are efficient in capturing antigens (Banchereau and Steinman, 
1998). When they encounter pathogens, their pattern recognition receptors 
(PRRs), such as the Toll like receptors (TLRs), recognise these and activate the 
DCs to mature and migrate to lymphoid tissues such as lymph nodes and 
spleen (Murphy et al., 2012). DC maturation sees the upregulation of co-
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stimulatory molecules (e.g. CD80/86) which contribute importantly to the 
activation of T cells (Banchereau and Steinman, 1998).  
There are two main classes of DCs 1) conventional DCs (cDCs) and 2) 
plasmacytoid DCs (pDCs). Both classes of DCs are involved in antigen 
presentation, but cDCs mostly participate in antigen presentation and activation 
of naïve T cells, whereas pDCs are important in generating a large amount of 
type I IFN especially important in the response against viral infections (Murphy 
et al., 2012). The CD141+DC subset of cDCs is specialised in the cross-
presentation of exogenously acquired antigens on class I MHC molecules, 
whereas conventional peptide loading is restricted to endogenously expressed 
proteins. Another class of dendritic cells, known as inflammatory DCs (infDCs) 
have been discovered and they are monocyte-derived cells (Geissmann et al., 
2003). The infDCs are recruited to the inflamed tissues and also have the ability 
to participate as antigen presenting cells (Geissmann et al., 2003; Hespel and 
Moser, 2012) 
B cells also act as professional APC. In addition to their role in secreting 
antibodies, they are also capable of presenting antigens and express co-
stimulatory molecules that result in the priming and differentiation of T cells. B 
cells acquire antigen through binding to their cell-surface immunoglobulin, the 
BCR, and internalize the antigen by receptor-mediated endocytosis (Abbas et 
al., 2007). The internalised protein antigen is processed into peptide fragments 
and displayed as peptide: MHC Class II complexes which are recognised by 
CD4+ T cells, driving their differentiation. Antigen uptake through the endocytic 
pathway is considered to be a highly efficient mechanism, especially for 
antigens that are present as soluble protein, as most toxins are.   
Macrophages are phagocytic cells that are ubiquitous in most tissues including 
lymphoid organs (Murphy et al., 2012). Several types of tissue macrophage 
have been described which are characterised based on their location and 
specialised function, for example Kupffer cells in the liver and microglia in the 
central nervous system (Murphy et al., 2012). Inflammatory macrophages can 
also be generated by the ingress of blood monocytes to inflamed tissues. 
Macrophages are involved in engulfing the microbes and particulate antigens 
which are then enzymatically destroyed by phagosome-lysosome fusion. This 
function leads to the generation of peptide fragments which can be loaded onto 
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MHC Class II molecules for surface presentation. Similarly, like the other two 
major APCs that have been mentioned, macrophages are also capable to 
upregulate co-stimulatory molecules which promote the activation of T cells.   
1.3.2.3 T cells activation 
For the full activation, proliferation and differentiation of naive T cells into 
effector cells, they require two important signals. The first signal is provided by 
peptide–MHC interaction with the TCR/CD3 complex of naïve T cells and this 
interaction predominantly occurs in the lymphoid tissue. Naïve CD4 T cells 
recognise peptide-MHC II, whereas naïve CD8 T cells recognise peptide-MHC I 
complexes.  The second signal is provided by the co-stimulatory molecules 
CD80/86 (also known as B7 family) that interact with CD28, a co-receptor 
protein which is expressed on T cells.  The expression of these co-stimulatory 
molecules is upregulated on pAPCs.  
TCR/CD3 ligation initiates a signalling cascade which culminates in the 
transcriptional induction of a variety of genes that are important for the 
regulation of T cell growth, survival and differentiation. The binding results in the 
recruitment of Src protein tyrosine kinases, Lck and Fyn, to the TCR/CD3 
complex which then phosphorylate immunoreceptor tyrosine-based activation 
motifs (ITAM) on CD3 molecules. Phosphorylation of ITAM allows the 
recruitment of ζ-chain associated protein kinase of 70 kDa (ZAP70) which 
results in its activation. Activated ZAP70 then recruits the linker for the 
activation of T cells (LAT). LAT then recruits phospholipase C-γ1 (PLC-γ1) 
which also interacts with IL-2 inducible T cell-kinase (ITK) and this mediates the  
hydrolyses of membrane lipid PIP2 into diacylglycerol (DAG) and inositol 1, 4, 5-
triphosphate (IP3). DAG activates two major pathways involving the Protein 
Kinase C θ (PKC θ) and RAS. RAS mediates the mitogen-activated protein 
kinase (MAPK) pathway that results in the activation of extracellular signal-
regulated kinase 1 (ERK1) followed by activation of activator protein-1 (AP-1), a 
transcription factor which forms a component of many transcriptional complexes. 
PKC θ activation leads to the activation of transcription factor of NF-κB. IP3 
opens Endoplasmic reticulum (ER) Ca2+ store leading to Ca2+ flux into the 
cytoplasm. Increased intracellular calcium activates calcineurin that is required 
for the activation of the transcription factor Nuclear Factor Activated T-cells 
(NFAT). The TCR signalling cascade is summarised in Figure 1.5.  
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Figure 1.5: TCR signalling cascade. The binding of antigen to TCR activates 
the signalling cacade. Early signalling events include the activation of Lck, Fyn 
and Zap70, resulting in activation of LAT. Following this, PLC-γ signalling 
pathway is initiated, leading to activation of transcription factors AP-1, NFAT 
and NF-κB. 
 
The importance of TCR signalling for T cell responses in humans have been 
elucidated through the discovery of several genetic defects in PIDs. For 
example, AR deficiency of ZAP70 results in the typical phenotypes of SCID 
despite the presence of residual T cells in the periphery (Elder, 1996). LCK 
deficiency leads to combined immunodeficiency, considered to be generally 
less profound than SCID (Picard et al., 2015); patients displayed recurrent 
infections with bacteria and fungi, severe inflammation in the gut and mucosa 
(Hauck et al., 2012). In contrast to ZAP70 deficiency, both CD4 and CD8 counts 
were reduced in LCK deficiency. Similar to some cases of ZAP70 deficiency 
(Picard et al., 2015), the patient also displayed features of autoimmunity.   
1.3.2.4 Effector T cells 
Upon receiving activating signals and depending upon the context of antigen 
presentation, the CD4+ T cells polarise towards the expression of different 
cytokines and transcription factors characteristic of alternative subsets of CD4+ 
T helper cells including T helper (Th)1, Th2, Th17 ,T regulatory (Treg) and T 
Follicular helper (Tfh)cells. Naïve CD8 T cells differentiate into cytotoxic T cells 
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(CTLs). Each of these effector cells has their own role in mediating T-cell 
immune responses.  
1.3.2.4.1 Th1 
The critical cytokines that are involved in differentiating naïve T helper cells to 
Th1 cells are IL-12 and IFN-γ (Luckheeram et al., 2012). The transcription factor 
T-bet is the master regulator as it also enhances the production of IFN-γ for Th1 
differentiation and upregulates the expression of IL12Rβ (Luckheeram et al., 
2012). In addition, the transcription factor signal transducer and activator of 
transcription 1 (STAT1) is activated by IFN-γ which in turn stimulates the 
expression of T-bet. This provides a positive amplification loop that drives the T 
helper cells towards Th1 differentiation (Luckheeram et al., 2012). The principal 
effector function of Th1 cells is in eliminating intracellular pathogens. They 
mainly secrete IFN-γ, TNFα, and IL-2. Both IFNγ and TNFα have antiviral 
properties, i.e. they are able to inhibit viral replication, thus they are important in 
eliminating viral infections. In addition, IFNγ is important for the activation of 
phagocytic activity and killing by macrophages as well as stimulating production 
of immunoglobulins from B cells that opsonise the microbes for phagocytosis. 
Another cytokine, IL-2 helps in promoting CD8+ memory after antigen priming, 
hence it participates in a robust secondary immune response. 
1.3.2.4.2 Th2 
The differentiation of Th2 cells is regulated by IL-4 and IL-2. STAT6 is the 
transcription factor that is involved in upregulating the expression of GATA-
binding protein (GATA3), both of which are considered major transcription 
factors for Th2 differentiation (Luckheeram et al., 2012). The function of Th2 as 
effector cells is to support eosinophil/mast cell-mediated immune reactions 
including those towards helminths and other extracellular parasites (Murphy et 
al., 2012). Furthermore, Th2 cells are involved in the induction and persistence 
of asthma as well as other allergic diseases. The Th2 subset secretes IL-4, IL-5 
and IL-10 which are involved in stimulating B cells to produce antibodies. In 
addition IL-5 also activates eosinophils to release their granule contents that are 
capable of destroying the helminths.  
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1.3.2.4.3 Th17 
The major cytokines that are involved in Th17 differentiation are IL-6, IL-21, IL-
23, and TGF-β as well as the transcription factors of RORγT and STAT3 
(Murphy et al., 2012). Th17 cells are responsible for mediating the immune 
response against extracellular bacteria and fungi (Murphy et al., 2012) and they 
release mainly cytokine IL-17 (IL-17A, IL-17F), which gives rise to their name, 
and other cytokines including IL-21 and IL-22.   
IL-17 promotes the secretion of IL-1, IL-6, IL-8, CXC ligand 1 and TNF from 
stromal, epithelial and endothelial cells. These proinflammatory cytokines are 
involved in recruiting neutrophils to the site of infection, thus providing an acute 
immune response at the infection site (McKenzie et al., 2006). Sustained IL-17 
production supports ongoing recruitment of neutrophils, contributing to long 
term maintenance of antimicrobial responses such as granuloma formation and 
other immune responses during chronic bacterial infection (as demonstrated in 
a Klebsiella lung infection model (McKenzie et al., 2006)). In addition to its role 
in recruiting neutrophils, IL17 is also important in resisting Candida albicans 
infection. This role has been elucidated in humans with a disease known as 
Chronic Mucocutaneous Candidiasis(CMC) (McDonald, 2012), a unique form of 
PID. Mutations in the cytokine or its receptors IL17RA, IL17RC and  IL17F 
result in recurrent infections at the skin, nails and mucosal membrane with 
Candida albican and, to a lesser extent, with Staphylococcus aureus, indicating 
that Th17 responses are essential for mucocutaneous antifungal immunity (Puel 
et al., 2011).  A similar vulnerability results in the context of impaired Th17 
development (STAT3 loss-of-function) or autoantibody neutralisation of IL17 
(APECED, resulting from AR mutations in AIRE). 
1.3.2.4.4 Treg cells 
The crucial function of Tregs is in maintaining the peripheral tolerance of 
autoreactive T cells. They are also known as ‘suppressor T cells’ as they limit 
inappropriate or excessive responses of conventional T cells (Workman et al., 
2009). There are two types of Tregs; natural Tregs (nTregs) and induced Tregs 
(iTregs) (Workman et al., 2009).  
nTregs develop in the thymus during positive and negative selection stages and 
they comprise 5-10% of peripheral CD4+ T cells (Workman et al., 2009). nTregs 
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express the transcription factor Forkhead family transcription factor (FOXP3) 
which is a master regulator of Treg development and function (Sakaguchi et al., 
2008). The importance of FOXP3 in nTregs was first identified in the mouse 
strain scurfy which bore a defect of the Foxp3 gene (Brunkow et al., 2001). The 
scurfy mouse displayed hyperactivation of CD4+ T cells and increased pro-
inflammatory cytokine production (Brunkow et al., 2001; Sakaguchi et al., 2008). 
Consistent with the finding in mice, a conserved role of FOXP3 in regulating 
Treg function had also been validated in humans in which mutations in FOXP3 
results in a genetic disease of immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome (IPEX) (Le Bras et al., 2006). In addition to 
FOXP3, nTregs also express high levels of  IL-2 receptor α chain(CD25), 
CTLA4 and glucocorticoid-induced TNFR-related protein (GITR) (Wan and 
Flavell, 2009) which is also important for nTreg function. The critical cytokine in 
nTreg development and maintenance is IL-2. IL-2 was shown in vitro to be 
involved in sustaining the expression of FOXP3 and CD25 in nTregs and to 
enhance their suppressive function (Fontenot et al., 2005). The importance of 
CD25 to humans is highlighted by the fact that AR mutations of CD25 
predispose to an IPEX-like syndrome which is clinically indistinguishable from 
that caused by FOXP3 mutations (Caudy et al., 2007) 
Another type of Tregs is the adaptive or also known as induced Tregs (iTregs) 
which, unlike nTregs,   develop in peripheral lymphoid organs after antigen 
priming. There are two main subsets that are generated from iTregs; type 1 
regulatory T cells (Tr1) which are induced by IL-10 and T helper 3 (Th3) which 
are induced by TGFβ (Workman et al., 2009). Similar to nTregs , both Tr1 and 
Tr3 express CD25, GITR and only Th3 express FOXP3 (Workman et al., 2009). 
They mediate their suppressive function through the same cytokines that are 
responsible for their induction, IL-10 and TGFβ, which are also produced at high 
levels by nTregs. IL-10 and TGFβ are considered inhibitory cytokines and 
represent the major mechanism of suppression utilized by Tregs. 
Besides producing inhibitory cytokines, it is proposed that other modes of 
maintaining peripheral tolerance and suppressive mechanism by Tregs are 
through cytolysis and modulation of APC function (Vignali et al., 2008). Tregs 
kill autoreactive T cells through granzyme-dependent apoptosis (Vignali et al., 
2008; Workman et al., 2009). In addition, Tregs also suppress target T cells by 
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downregulating APC function through CTLA-4 dependant mechanism, for 
example it may  downmodulate CD80/86 expression on APC or stimulate 
dendritic cells to form the enzyme indoleamine 2, 3-dioxygenase, which this 
enzyme is involved in catabolising  the essential amino acid tryptophan to 
kynurenines that are toxic to T cells (Workman et al., 2009).  
1.3.2.4.5 Tfh cells 
Tfh cells express high levels of CXCR5, the receptor for Chemokine (C-X-C 
motif) ligand-13 (CXCL13) which is secreted by follicular stromal cells in the B 
cell zone.  Tfh cells are found enriched in the edge of the B cell zones and 
follicular regions and germinal centres (GCs) (Wan and Flavell, 2009; Ma et al., 
2012). Tfh express effector molecules such as ICOS, CD40 Ligand (CD40L), 
OX40, PD-1 and BTLA-4  which are critical for their development and function 
and through these molecules Tfh provide help to B cells by promoting the 
activation, differentiation and survival of B cells (Ma et al., 2012). For example, 
CD40L interaction with CD40 expressed on B cells results in activation and 
promotes their proliferation whereas ICOS induces the production of B helper 
cytokines such as IL-10 and IL-21 (Ma et al., 2012). 
1.3.2.4.6 Cytotoxic T cells (CTLs) 
CTLs are the only cells that are differentiated from CD8+ T cells. CD8+ T cells 
undergo expansion and differentiate into CTLs with the help from cytokines 
such as IL-12, IL-15 and IL-17. The main function of CTLs is in eliminating 
infected target cells which is mediated through the perforin-granzyme and death 
ligand pathways (Abbas et al., 2007), both of which eventually lead to 
programmed cell death or apoptosis of the infected target cells. In addition, 
CTLs are also major producers of cytokines including IFNγ, TNFα and to a 
lesser extent IL2 (Luca and Francis, 2001). 
1.3.2.4.7 Memory T cells 
Once the T cells have become activated and differentiated into effector cells, 
these cells circulate and peak for a week. At the end, most of these will die, 
however a small proportion of primed CD4+ and CD8+ T cells will persist as 
memory T cells (MacLeod et al., 2010). Memory cells differ from naïve T cells in 
their superior ability to respond very quickly to subsequent exposure to the 
same antigen; this is very useful in preventing future infections and disease 
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from the same pathogens (MacLeod et al., 2010). There are two types of 
memory cells, central memory T cells (TCM) and effector memory T cells (TEM) 
which differ in terms of their homing capacity and effector function (Sallusto et 
al., 2004).  
TCM express CCR7 and CD62L which are important for cell extravasation 
through high endothelial venules and migration to the T-cell area of secondary 
lymphoid organs (Sallusto et al., 2004). They are highly sensitive to antigenic 
stimulation and are less dependent on co-stimulation than naïve T cells 
(Sallusto et al., 2004). TCM mediate the reactive memory; following TCR 
triggering, TCM produce mainly IL-2 and proliferate, after which they efficiently 
differentiate into effector cells (Sallusto et al., 2004) 
TEM are memory cells that have lost the expression of CCR7 but express 
CD62L and exhibit chemokine receptors and adhesion molecules that are 
required for homing to inflamed tissues (Sallusto et al., 2004). In contrast to 
TCM cells, they mediate protective memory and provide rapid effector function 
by producing cytokines or displaying cytotoxic function within hours of antigenic 
stimulation (Sallusto et al., 2004).  
1.3.2.5 Peripheral tolerance of T cells 
Central tolerance of T cells occurs during T-cell development in the thymus. 
Although central tolerance mechanisms are potent and efficient, not all self-
reactive T cells are eliminated and a small number escape and exit from the 
thymus. Therefore, peripheral tolerance mechanisms exist (Xing and Hogquist, 
2012) including anergy, apoptotic deletion and suppression of T cells, to control 
these self-reactive T cells (Xing and Hogquist, 2012). If the peripheral tolerance 
breaks down, this results in autoimmune tissue damage and disease. 
T cell activation requires recognition of antigen by TCR (signal 1) and ligation of 
the co-stimulatory molecule CD28 by CD80 and CD86 (signal 2). T cell 
activation in the absence of signal 2 results in a state of long term 
hyporesponsiveness or “anergy”, characterised by repressed TCR signalling 
and failure to express IL2.  Anergy can also result when TCR stimulation is 
accompanied by negative second signals delivered via co-receptors such as 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1). 
CTLA-4 is a structural homologue of CD28 and competes with CD28 for 
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CD80/CD86 binding sites, stripping these ligands from the APC. Hence it 
attenuates the costimulatory signal and inhibits TCR signalling. Interaction of 
PD-1 with its ligands, PD-L1 and PD-L2, inhibits TCR signalling, leading to 
inactivation of T cells and anergy (Xing and Hogquist, 2012). The roles of 
CTLA-4 and PD-1 are highlighted in mice lacking CTLA-4 or PD-1, which 
develop autoimmune diseases. Heterozygous mutations in CTLA-4 have also 
been identified in humans in patients with immune dysregulation and 
autoimmune phenomena (Schubert et al., 2014), similar phenotypes as the 
mouse model. 
Tolerogenic DCs, the subset of DCs that is involved in inducing tolerance, are 
thought to be generated from incomplete maturation of DCs (Xing and Hogquist, 
2012). They present antigen without the co-stimulatory second signal, resulting 
in anergy in cognate T cells. Depletion of DCs in mice breaks self-tolerance of 
CD4+ T cells and results in fatal autoimmunity (Ohnmacht et al., 2009; Saei and 
Hadjati, 2013), further strengthening the crucial role of tolerogenic DCs in 
peripheral immune tolerance. 
As mentioned earlier, self-reactive lymphocytes in the thymus are eliminated by 
apoptosis. Similarly, the deletion of self-reactive T cells in the periphery is 
achieved through apoptotic cell death. There are two major pathways that lead 
to apoptosis, the death receptor (extrinsic) and mitochondrial (intrinsic) 
pathways. Both pathways will be discussed in detail in chapter 4.3.  
1.3.3 B lymphocyte biology and function 
1.3.3.1 Early B cell development in the bone marrow 
Similar to T cells, B lymphocytes derive from CLPs which are formed from 
HSCs in the bone marrow. In contrast to T cells, B-cell development takes place 
in the bone marrow.  Each stage of B cell maturation is marked by a specific 
pattern of gene expression and immunoglobulin heavy (H) chain and light (L) 
chain gene rearrangements[10] by RAG-dependent V(D)J recombination as for 
TCR rearrangement (Tob et al., 2013). CLPs first differentiate into pro B cells. 
At this stage, the RAG1/RAG2 dependent-arrangement of D-gene and J-gene 
segments of H chain from germline commences (Pieper et al., 2013). This is 
followed by the second rearrangement joining an upstream V region to the 
rearranged DJ segment. The next cell stage is the pre B cells where the 
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functional H-chains (VDJ-Cμ) pair with V-pre B and λ-like, leading to the 
formation of the pre-BCR which is not detected on the surface but expressed 
within the cells (Pieper et al., 2013). The formation of the pre-BCR induces 
signals for shutting down RAG expression, preventing rearrangement of the 
second H-chain allele, and allowing the cells to proliferate. Subsequently, RAG 
genes are re-expressed to initiate V-J rearrangements of L chains. Successfully 
rearranged κ or λ chain replaces the V-preB/λ and pairs with H chain (Pieper et 
al., 2013). This then results in the formation of cells expressing BCR of class 
IgM on the cell surface. At this stage the cells are now known as immature B 
cells. As mentioned earlier in the T cell development section, null mutations of 
RAG1 and RAG2 lead to complete failure of T and B cell development and 
result in T-B- SCID. Hypomorphic mutations of RAG1 or RAG2 were also found 
to cause Omenn syndrome (Villa et al., 2008). Affected patients displayed 
severe susceptibility to infection similar to SCID, such as viral or fungal 
pneumonitis, chronic diarrhoea, and failure to thrive but they also present 
additional features such as enlarged lymphoid tissue, severe erythroderma, 
increased IgE levels, and eosinophilia. These features reflect immunopathology 
caused by excessive expansion of oligoclonal and dysregulated T cells in the 
presence of very low levels of VDJ recombination. In addition, a low or absent 
number of B cells is a characteristic of Omenn syndrome due to RAG1/RAG2 
mutation.  Milder missense mutations within RAG1/2 can lead to more subtle 
immunodeficiency states still. 
In the development of B cells, their autoreactivity is screened at several check 
points due to the enormous diversity of antibody specificities (Pieper et al., 
2013). The first checkpoint occurs when the pre-BCR is expressed, which is 
between the differentiation of pro into pre B cells (Pieper et al., 2013). The next 
checkpoint is when the immature B cells express BCR, where the BCR is tested 
for reactivity against autoantigens. The fate of B cells that recognise self-
antigen is determined by BCR signal strength. A strong BCR signal by binding 
with high affinity to autoantigen will lead to negative selection of the respective 
B cell. It is estimated that 75% of the human early immature B cells express 
BCRs that are specific for self-antigens (Wardemann et al., 2003). Some of 
these self-reactive immature B cells are deleted via apoptosis or induced to 
change their BCR specificity by receptor editing (Tob et al., 2013). Receptor 
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editing involves further antibody gene rearrangements, resulting in an altered 
specificity of the BCR and allowing the cells to escape negative selection.  
The immature B cells that escape negative selection travel to the spleen, to 
complete their maturation before migrating to other peripheral lymphoid organs. 
On arrival in the spleen, the immature B cells pass through two transitional 
stages designated transitional 1 (T1) and T2. From transition of T1 to T2 phase, 
the B cells express IgD in addition to IgM on the cell surface. Subsequently, the 
T2 B cells finalize their early development by differentiating into follicular B cells, 
recirculating cells that proliferate in germinal centres (GCs), or into marginal 
zone B cells (MZs) that populate the marginal zones. The mechanism(s) that 
determine(s) differentiation towards the follicular or MZ phenotype are not really 
understood, however, it is suggested that it may be due to the BCR specificity 
(Cariappa and Pillai, 2002). 
It should be noted that while immature B cells enter the spleen and become 
transitional B cells, they receive survival signals generated by the binding of B-
cell activating factor (BAFF) to BAFF-receptor (BAFF-R). BAFF-R is first 
expressed on immature B cells in bone marrow and increases when the 
transitional cells differentiate into MZ and GC B cells. This survival signal is 
important for the maturation and maintainance of B cells in the periphery. The 
role of BAFF-R in B cell survival in humans was demonstrated in patients with  
common variable immunodeficiency (CVID) in which these patients had low 
numbers of B cells with impaired development and homeostasis of follicular, 
IgM memory/marginal zone, and class-switched memory B cells (Warnatz et al., 
2009). 
1.3.3.2 BCR signalling 
The development and survival of B cells in providing effective humoral response 
is dependent on signalling pathways which are similar downstream of both pre 
BCR and BCR (Pieper et al., 2013). Ligation of the BCR leads to conformational 
changes, allowing the binding of spleen tyrosine kinase (SYK) and initiation of 
the signalling cascade. SYK phosphorylates Igα/Ig and adaptor protein, B-cell 
linker protein (BLNK) which serves as a scaffold for Bruton Tyrosine Kinase 
(BTK). Following this, the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) 
and phospholipase C (PLCγ2) pathways are activated. The PLCγ2 signalling is 
33 
 
mediated through Protein kinase C (PKC) which then interacts with caspase 
recruitment domain-containing protein 11 (CARD11), mucosa-associated 
lymphoid tissue lymphoma translocation protein 1 (MALT1) and B-cell 
lymphoma 10 (BCL10) to activate the transcription of NF-κB.  PLCγ2 also 
activates the transcription factor, serum response factor (SRF), through 
mitogen-activated protein kinase (MAPK). In addition, PLCγ2 also activates 
transcription of NFAT through IP3. As for the PI3K pathway, it is mediated by 
AKT which induces the protein synthesis and cellular fitness, prolonging cell 
survival (Pieper et al., 2013). The preBCR/BCR signalling cascade is 
summarised in Figure 1.6. 
 
Figure 1.6: BCR signalling cascade. Ligation of BCR leads to the binding of 
SYK, initiating the signalling cascade. Syk phosphorylates Igα/Igβ and BLNK, 
which act as a scaffold for BTK. This results in the activation of PI3K and PLCγ2 
signalling pathway, followed by the activation of transcription factors NFAT, 
SRF and NF-κB. 
 
BTK is involved in proximal BCR signalling. In humans, the role of BTK was 
demonstrated by the identification of mutations in the BTK gene located on the 
X chromosome, causing a disease known as X-linked agammaglobulinemia 
(XLA, also known as Bruton’s disease) (Tsukada et al., 1993). This mutation 
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results in a lack of peripheral blood B cells that leads to severely reduced 
antibody titres of all Ig isotypes. In addition, analysis of the patients’ bone 
marrow samples revealed abnormalities of the pre-B cell numbers and 
proliferation, indicating that BTK is involved in the early progenitor cells. Similar 
phenotypes are also observed in patients with BLNK deficiency (Minegishi et al., 
1999), suggesting that both genes are important for  the development of early B 
cell progenitors . Another mutation that has been identified in humans in the 
downstream signalling cascade is homozygous deletion of CARD11, resulting in 
an accumulation of transitional B cells due to blocking of B cell differentiation 
(Snow et al., 2012). 
1.3.3.3 Development of follicular B cells in germinal centres of the spleen 
Activation of follicular B cells in GCs results in the development long lived 
plasma cells that secrete antibodies, and switched memory B cells (Pieper et al., 
2013). For their differentiation and proliferation, follicular B cells require antigen-
induced BCR signalling in addition to signals from cytokine receptors and co-
stimulatory receptors (Rickert, 2013).  Furthermore this occurs in a T-cell 
dependent manner, requiring help from Tfh cells through the interaction of 
CD40L expression on Tfh cells and CD40 expression on B cells. Within GCs, 
the follicular B cells undergo somatic hypermutation (SHM) of the variable 
regions of the rearranged immunoglobulin genes, leading to a process of affinity 
maturation of the antibody response. Mutations that result in surface 
immunoglobulins with low affinity to antigens prevent the B cells from becoming 
activated efficiently, therefore these B cells are eliminated by apoptosis. 
Whereas B cells with mutated immunoglobulins that have improved ability to 
bind to antigens survive. In parallel, the cells also undergo immunoglobulin 
class-switch recombination (CSR) which replaces the IgM constant region with 
those of IgG, IgA or IgE (Pieper et al., 2013). The SHM and CSR machineries 
require two essential enzymes that are expressed on the follicular B cells, 
activation-induced cytidine deaminase (AID) (Rickert, 2013) and uracil-N-
glycosylase (UNG) (Pieper et al., 2013).  
Genetic defects of AID (Revy et al., 2000) and UNG (Kavli et al., 2005) have 
been identified in humans and result in Hyper IgM syndrome, a form of humoral 
immunodeficiency characterised by low or absent IgG and IgA despite relatively 
preserved levels of IgM in patients’ serum. Both AID and UNG deficiency 
35 
 
present with increased susceptibility to bacterial infections, lymphoid 
hyperplasia, and a failure of both CSR and SHM (Etzioni and Ochs, 2004). 
Mutations of CD40L have also been identified in humans, causing X-linked 
Hyper IgM syndrome. This accounts for 65-70% of all cases of Hyper IgM 
syndrome, mostly affecting males in early infancy (Etzioni and Ochs, 2004). The 
typical presentation is with interstitial pneumonia caused by Pneumocystis 
jirovecii (PCP) and/or bacterial sinopulmonary infections, other features being 
autoimmunity, cryptosporidiosis and resulting hepatobiliary disease (DiSanto et 
al., 1993). Another gene in which autosomal recessive mutations can cause 
Hyper IgM syndrome is CD40, which is normally expressed on B cells as well 
as a variety of APCs and epithelia. Similar to CD40L, patients with CD40 
deficiency display susceptibility to opportunistic infections including 
cryptosporidiosis (Etzioni and Ochs, 2004) as well as bacterial infections. The 
phenotypes of CD40L and CD40 deficiency thus demonstrate that both partners 
in this interacting pair are essential, not only for normal humoral responses but 
also for effective cellular immunity.  
Finally, after SHMs and CSR processes, long lived plasma cells are generated 
which then leave the germinal centres and travel to peripheral tissues such as 
bone marrow, spleen red pulp and mucosal-associated lymphoid tissues (MALT) 
where they live for a long period and are a source of long-lasting high affinity 
antibodies(Tangye, 2011). In addition, long lived memory B cells are also 
generated after these processes (Tangye, 2011). 
1.3.3.4 Development of marginal zone B cells 
Another type of B cells are the marginal zone B cells which, after leaving the 
bone marrow, migrate to the marginal zone (MZ) of the spleen. MZ B cells 
provide an early and rapid immune response against blood-borne pathogens, 
mainly in a T-cell independent manner. Within a few days of encountering 
antigens, the MZ B cells rapidly differentiate and proliferate into short lived 
plasma cells that secrete antibodies, mainly consisting of IgM with limited 
switching to some IgG subtypes (Abbas et al., 2007). The full development of B 
cells in bone marrow, spleen and lymph nodes up to the production of plasma 
cells and memory cells is summarised in Figure 1.7. 
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Figure 1.7: Overview of B-cell development. The early stage of B cell 
development is in bone marrow (HSC, CLP, Pro B cells, Pre B cells,immature B 
cells). Immature B cells leave bone marrow and travel to spleen and enter as 
transitional B cells (T1 then T2 transitional cells).  They complete the early 
development either as follicular B cells or marginal zone (MZ) B cells. In GC, 
upon antigen encounter, follicular B cells are activated in a T cell-dependant 
manner. After undergoing SHM and CSR, long lived plasma cells are generated 
and travel to peripheral tissues providing long lasting antibodies. Memory B 
cells are also generated from these process. As for MZ B cells, once they 
encounter antigen, they will develop into short lived plasma cells secreting 
mainly IgM antibodies. 
 
1.3.3.5 Memory B cells 
Memory B cells are defined as long-lived quiescent B cells expressing 
somatically mutated Ig V genes that are capable of eliciting rapid and robust 
responses compared to naïve B cells (Tangye and Tarlinton, 2009). It has been 
postulated that memory B cells are generated from GCs B cells in a T-cell 
dependent manner, however, Berkowska et al. demonstrated that there are 
several distinct memory B cell subsets based on their antigen-experienced 
phenotype and differential expression of CD27 and IgH isotypes (Berkowska et 
al., 2011). These memory cells subsets are differentiated from three different 
origins and occur in T-cell dependent and T-cell independent manner. 
CD27+IgA+ and CD27+IgG+ memory B cell subsets are considered as true 
memory B cells (Good et al., 2009) due to high expression of activation and 
extensive replication history compared to naïve B cells (Berkowska et al., 2011). 
They develop in GCs in a T-cell-dependant manner. Two subsets have been 
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identified that develop in a T-cell independent manner: natural effector cells, 
which originate from MZ of spleen and CD27-IgA+ cells from the gastrointestinal 
system. The fact that these cells were found in patients with CD40L deficiency 
suggests that they develop in a T-cell independent manner (Berkowska et al., 
2011). In contrast to GC memory B cells, these two subsets are characterised 
by limited replication history and reduced degrees of SHM.  
1.3.3.6 Peripheral tolerance of B cells 
Similar to T cells, some of the autoreactive B cells manage to evade central 
tolerance mechanisms and enter the periphery. Peripheral tolerance 
mechanisms of B cells include the induction of anergy. Anergy in B cells is a 
state of unresponsiveness in which B cells that are capable of a normal initial 
response to antigen fail to receive secondary signals (Cambier et al., 2007). 
This occurs when self-reactive B cells are exposed to self-antigens in the 
absence of T cell help (Cambier et al., 2007). Therefore, anergy silences 
potentially harmful self-reactive cells in the periphery and blocks the cells from 
forming plasma and memory cells expressing high affinity autoantigens. 
Another mechanism is through apoptotic deletion. B cells that manage to 
escape any of these mechanism result in autoreactive cells, causing 
autoimmune diseases.   
1.4 PIDs involving immune dysregulation 
1.4.1 Overview 
So far, I have described the normal innate antiviral immunity and adaptive 
immune response. It is clear that both systems play an important role in 
preventing the host from susceptibility to infection. Any defects affecting either 
one or both arms of the immune response results in immunodeficiency, which 
has been elucidated by genetic defects identified in PIDs.  
In addition to immunodeficiency, many PIDs with immune dysregulation have 
also been identified recently, thus implying that it is important that the immune 
response must be counterbalanced by regulatory mechanisms to contract the 
size and activity of the antigen-specific population. During normal immune 
responses, as mentioned before, the production of co-stimulators and cytokines 
allows the clonal expansion and differentiation of lymphocytes into effector cells. 
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In addition, anti-apoptotic genes of the Bcl2 family are upregulated, providing 
survival stimuli for the lymphocytes. In normal homeostasis of the immune 
system, after successful elimination of the pathogenic foreign antigens, these 
survival stimuli also decline and the lymphocytes will return to their basal resting 
state. The majority of the activated cells will die through apoptosis either via the 
activation-induced cell death (AICD) pathway which involves the upregulation of 
the expression of death receptors such as Fas on the lymphocytes surface and 
the binding of Fas to its ligand, or by passive apoptosis via the mitochondrial 
pathway, i.e. induction of the expression of the proapoptotic protein Bim (both 
mechanisms will be described in detail in Chapter 4.3). Defects in immune 
homeostasis may lead to a lymphoproliferative disorder that could predispose to 
the formation of lymphoma, a type of lymphocyte cancer. Another important 
aspect that has been discussed in earlier sections is the lymphocyte tolerance. 
A failure of immune tolerance results in autoreactive immune cells attacking 
their own host cells and leads to autoimmunity. 
According to the latest update of the International Union of Immunological 
Societies’ (IUIS’) PID classification, genetic defects that are associated with 
immune dysregulation, autoimmunity and lymphoproliferation are classified 
under diseases of immune dysregulation (Picard et al., 2015). Five diseases 
have been categorized under this classification including autoimmune 
lymphoproliferative syndrome (ALPS), haemophagocytic lymphocytosis (HLH), 
T regulatory genetic defects, immune dysregulation with colitis and type 1 
interferonopathies (Picard et al., 2015). For the purpose of my work, ALPS and 
HLH will be discussed in detail.  
1.4.2 Autoimmune lymphoproliferative syndrome (ALPS) 
The importance of the death receptor pathway, mediated by the interaction of 
Fas receptor with its ligand FasL, in maintaining lymphocyte homeostasis was 
first discovered in two related mouse strains with lymphoproliferation (denoted 
lpr) and generalised lymphoproliferative disease (denoted gld) (Sneller et al., 
1997). The lpr mice were found to have a complete defect of Fas expression 
whereas the gld mice had a recessive defect of Fas ligand; both defects 
abrogated the function of the respective protein. As well as lymphoproliferation, 
these mice showed autoantibody formation and autoimmune nephritis. Later, a 
human disease with similar features of coexistent lymphoproliferative disease 
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and autoimmunity was found to be caused by heterozygous Fas mutations 
(Rieux-Laucat et al., 1995). The disease of these patients was called 
autoimmune lymphoproliferative syndrome (ALPS). ALPS is defined as a 
genetic disorder “resulting in a failure of apoptotic mechanisms to maintain 
lymphocyte homeostasis, permitting accumulation of lymphoid mass and 
persistence of autoreactive cells that often manifest in childhood with chronic 
nonmalignant lymphadenopathy, hepatosplenomegaly, and recurring multi 
lineage cytopenias “ (Rao and Oliveira, 2011). 
1.4.2.1 Clinical Features and diagnosis 
The typical onset of ALPS is usually in early childhood; however, it can also 
occur later in life, from 18 to 35 years of age (Oliveira, 2013). The main clinical 
features of ALPS are the presence of chronic, non-malignant lymphadenopathy 
and/or splenomegaly, in addition to which the majority of patients develop 
autoimmunity, commonly autoimmune cytopenias such as haemolytic anaemia 
and/or thrombocytopenia (Fleisher et al., 2010). Other autoimmune disorders 
such as glomerulonephritis, polyneuropathy and autoimmune hepatitis have 
also been documented (Fleisher et al., 2010). A life-threatening complication of 
ALPS is lymphoma, a type of cancer that arises from lymphocytes, of either 
Hodgkin’s (HL) or non-Hodgkin’s (NHL) type. The risk of developing HL is 150 
time greater and NHL is increased 61-fold compared with the general 
population(Price et al., 2014). Laboratory features that are useful in diagnosing 
ALPS are elevated numbers of T cells that express TCRα/β but neither CD4 nor 
CD8 co-receptors (CD4-CD8-, called double negative T (DNT) cells), and high 
serum or plasma levels of IL-10, IL-18, soluble Fas ligand and vitamin B12 (Rao 
and Oliveira, 2011). The demonstration of defective Fas-mediated lymphocyte 
apoptosis in vitro is highly supportive (Oliveira et al., 2010). Oliveira and 
colleagues proposed a set of diagnostic criteria for ALPS, shown in Table 1.2. 
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Table 1.2. Diagnostic criteria for ALPS. A definitive diagnosis is made when 
the patient demonstrates both required criteria and one primary accessory 
criterion. A probable diagnosis of ALPS is considered when the patient presents 
with both required criteria and one secondary accessory criterion. The table is 
adapted from (Oliveira et al., 2010). 
 
For a definitive diagnosis of ALPS, the patients should show both chronic non-
malignant lymphadenopathy or splenomegaly and elevated DNT cells, plus one 
of the primary accessory criteria. 
1.4.2.2 Genetics and classification 
So far, several causative mutations within the FAS-mediated pathway have 
been identified in patients with ALPS (Oliveira and Fleisher, 2004; Fleisher et al., 
2010; Oliveira et al., 2010; Rao and Oliveira, 2011). The majority of ALPS 
patients bear autosomal dominant germline heterozygous mutations of FAS. 
However, it was demonstrated that as many as 60% of family members who are 
carriers of the same genetic defects have mild or absent phenotypic expression 
of the disease, indicating that other factors such as haploinsufficiency and gene 
modifier may be involved in determining the phenotypic expression (Price et al., 
2014). Germline FAS mutations affecting the intracellular portion of the Fas 
protein are associated with severe clinical manifestations and higher 
penetrance (Jackson et al., 1999). These patients have been reported to have 
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increased risk of developing HL and NHL (Price et al., 2014). Somatic Fas 
mutations have also been described in a small number of patients with sporadic 
ALPS (Fleisher et al., 2010).  
Apart from Fas, heterozygous or homozygous mutations in Fas ligand (FASL) 
have also been identified, with homozygous mutations causing a severe ALPS 
phenotype (Del-Rey et al., 2006). Other mutations that affect the Fas-mediated 
apoptosis pathway, such as germline mutations of caspase 10, have also been 
described (Wang et al., 1999). All these mutations contribute to the 
classification of ALPS. Initially, the classification of ALPS was based on 
numbers, however, due to chaotic nomenclature, the classification has been 
changed to simpler nomenclature (Oliveira et al., 2010). The full previous and 
revised classification of ALPS is shown in Table 1.2. 
 
Table 1.3: Revised classification ALPS and ALPS-related disorders. 
FASLG – Fas Ligand, RALD- RAS-associated autoimmune leukoproliferative 
disease. This table is adapted from (Oliveira et al., 2010). 
 
In addition, there are also apoptotic disorders that cause distinct phenotypes, 
now classified as ALPS-related disorders. Patients with mutations in the gene 
encoding caspase 8 demonstrate typical features of ALPS such as 
lymphadenopathy, splenomegaly, elevated DNTs and defective Fas-induced 
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apoptosis. However, they also show additional features such as defective T-, B- 
and NK-cell activation with consequent recurrent bacterial and viral infections 
(Chun et al., 2002). Somatic mutations of NRAS and KRAS are also classified 
under ALPS-related disorders; they share the clinical features of ALPS but 
without defective Fas-mediated apoptosis as NRAS and KRAS regulate the 
intrinsic-mitochondrial apoptosis pathway. Patients with RAS-associated 
autoimmune leukoproliferative disorder show chronic persistent monocytosis 
and significant leucocytosis (Oliveira et al., 2007; Niemela et al., 2011). 
Recently, evaluation of a patient who presented with chronic lymphadenopathy, 
splenomegaly, autoantibodies, elevated immunoglobulin levels and natural killer 
cell dysfunction associated with chronic, low-grade Epstein-Barr virus infection 
revealed a novel homozygous, loss-of-function mutation in the gene encoding 
Protein kinase C delta (PKCδ) (Kuehn et al., 2013). This mutation results in B 
cell hyperproliferation and defective apoptosis with consequent lymphocyte 
accumulation, a phenotype that is mirrored in the PKCδ knock out mouse model 
(Kuehn et al., 2013). Furthermore, homozygous loss-of-function mutations in 
LPS-responsive and beige-like anchor (LRBA) have been discovered very 
recently by whole exome sequencing analysis in three patients from unrelated 
families presenting with ALPS-like features with raised serum Fas ligand levels 
and defective Fas-mediated apoptosis (Revel-Vilk et al., 2015). In addition, 
another mutation that has been identified through whole exome sequencing is 
FADD deficiency in which the patient exhibited typical ALPS features with 
severe susceptibility to bacterial and viral diseases as well as recurrent 
hepatopathy and encephalopathy, and cardiac malformations (Bolze et al., 
2010).  Interestingly, these patients did not display any autoimmune features. 
Both of these newly identified gene mutations contribute to the expanding list of 
genes underlying ALPS-like diseases.  
In addition to the ALPS classifications described above, there is ALPS-U, in 
which the patients present with ALPS features, but the genetic defect is 
unknown. It is estimated that about one third of patients fall into the ALPS-U 
group. It is likely that more advanced technologies such as whole exome 
sequencing will help in identifying the molecular defect in these patients. It is 
important to know the genetic defect for establishing a diagnosis in order to 
enable proper care and follow up of patients with this disease. 
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1.4.2.3 Treatment for ALPS  
Almost half of ALPS patients in a large US series underwent splenectomy in 
order to manage their chronic and refractory cytopenias (Rao and Oliveira, 
2011), however, in the recent study by Price et al. demonstrated that patients 
underwent splenectomy, likelihood to have cytopenia relapse, estimated about 
30% by 4 years and exceeded 70% by 20 years (Price et al., 2014). In addition, 
young patient who underwent splenectomy had increased risk of developing 
sepsis (Price et al., 2014). Cytopenias may also be successfully treated with 
immunosuppressive drugs such as corticosteroids, as well as intravenous 
Immunoglobulin G, rituximab and the mTOR inhibitor rapamycin (sirolimus) 
(Teachey et al., 2009). Besides treating the cytopenias, rapamycin is also useful 
in reducing the lymphoproliferation as well as significantly reducing the numbers 
of DNT cells. However, due to its toxicity, patients on rapamycin need to be 
monitored for a long time. As most ALPS patients respond to these treatments, 
haematopoietic stem cell transplantation (HSCT) is rarely considered and so far 
the role of HSCT in ALPS patients is not really clear (Rao and Oliveira, 2011). 
However, HSCT has been successful in treating selected ALPS patients with 
lymphoma or a very severe phenotype of FAS mutation and refractory 
cytopenias (Sleight et al., 1998). Failures of HSCT have also been observed, 
which were due to progression of malignancy, ineffective engraftment resulting 
from non-myeloablative conditioning and opportunistic infections (Rao and 
Oliveira, 2011). Finally, the morbidity and mortality of ALPS depends on the 
severity of autoimmune disease, hypersplenism (or susceptibility to fatal sepsis 
secondary to splenectomy) and development of lymphoma. As mentioned 
earlier, intracellular FAS mutations usually result in severe phenotypes with 
increased risk to develop lymphoma, therefore these patients need diligent 
lifelong follow up. Since ALPS patients develop multiple problems, they 
sometimes require collaborative follow up from multiple subspecialists that are 
familiar with ALPS for long term monitoring. 
1.4.3 Haemophagocytic Lymphohistiocytosis (HLH) 
The term HLH describes a pattern of immune dysregulation marked by 
overwhelming immune/inflammatory responses. It arises due to a reactive 
process resulting from persistent and excessive activation of antigen-presenting 
cells (macrophages, histiocytes) and T cells (Filipovich, 2009) and 
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overproduction of cytokines such as IFN-γ, IL-6 and IL-10 (Faitelson and 
Grunebaum, 2014). There are two forms of HLH, primary and secondary. 
Primary HLH results from inborn errors of the immune system and includes 
familial HLH (fHLH) and X-linked lymphoproliferative diseases (XLP). Typically, 
disease onset in fHLH is during infancy or early childhood and may be triggered 
by infection such as Epstein Barr virus (EBV), cytomegalovirus or parvovirus 
(Henter et al., 1993), while EBV is the classic trigger in boys with XLP.  
HLH may also occur outside the context of PID in response to overwhelming 
activation of the immune system, for example severe inflammatory reactions to 
viral infection, including EBV, HIV and Avian influenza (Henter et al., 2007). 
This form is called virus associated haemophagocytic syndrome (VAHS) and 
has been demonstrated to occur with increased frequency in 
immunocompromised patients (Henter et al., 2007). In addition, other 
precipitating factors for HLH are autoimmune diseases (e.g. rheumatoid arthritis) 
and malignancies (e.g. leukaemia, lymphoma). The term “macrophage 
activation syndrome” (MAS) is used interchangeably with HLH especially in the 
rheumatological context (Henter et al., 2007) where this is a feared complication. 
1.4.3.1 Genetics of primary HLH 
Several autosomal recessive genetic defects have been linked to fHLH and 
interfere with the mechanisms responsible for cytotoxicity. The first gene linked 
to fHLH was PRF1, encoding perforin, a soluble, pore-forming cytolytic protein 
that is secreted by cytotoxic T cells and NK cells upon conjugation between 
effector and target cells. It is known to be sequestered along with granzyme 
serine proteases in secretory cytotoxic vesicles. Perforin can perforate the 
membrane of the target cell and polymerize to form a cell death-inducing pore 
which allows the entry of granzymes that trigger apoptosis. The second gene in 
which autosomal recessive mutations cause HLH is UNC13D.  This encodes 
Munc 13-4 which is important for the fusion of cytolytic granules with the plasma 
membrane and its deficiency results in defective degranulation (Filipovich, 
2009). Syntaxin 11 deficiency similarly leads to defective degranulation 
(Filipovich, 2009).  Other cytotoxic defects that have been associated with life 
threatening episodes of HLH are Chediak-Higashi syndrome (defect in the 
lysosomal trafficking regulator (LYST/ CHS1) gene) (Faitelson and Grunebaum, 
2014), Griscelli type 2 (mutation in the RAB27A gene that is involved in 
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vesicular fusion, trafficking and docking at the plasma membrane) (Faitelson 
and Grunebaum, 2014) and Hermansky Pudlak type 2 (mutations in the AP3B1 
gene that encodes the adaptor protein AP-3 complex, involved in trafficking of 
proteins to lysosomes) (Faitelson and Grunebaum, 2014). The latter disorders 
lead to severe impairment of secretory lysosomes of melanocytes, platelets and 
neutrophils as well as of T and NK cells, with corresponding associated features 
such as oculocutaneous albinism and bleeding diathesis as well as 
susceptibility to HLH. 
HLH arises as a complication of EBV infection in 35% of boys with X-linked 
lymphoproliferative syndrome (XLP1), other outcomes of EBV including 
fulminant infectious mononucleosis, aplastic anaemia and lymphoma (Booth et 
al., 2011). XLP1 is caused by hemizygous mutations in SH2D1A encoding SAP 
(SLAM-associated protein) which results in deficiency of invariant Natural killer 
T (iNKT) cells and impaired T and NK cytotoxic responses towards EBV-
infected B cells (Filipovich, 2009). XLP1 is also characterised by decreased 
activation-induced apoptosis of lymphocytes, which contributes to associated 
lymphoproliferation (Filipovich, 2009). Dysgammaglobulinaemia is prominent 
and may precede the acquisition of EBV.  XLP2 is due to a hemizygous 
mutation in X-linked inhibitor of apoptosis (XIAP) and has been described in 
male patients with EBV-associated HLH (Rigaud et al., 2006).  In contrast to 
XLP1, lymphomatous change does not appear to occur in XIAP deficiency but 
patients often experience splenomegaly and colitis. 
1.4.3.2 Clinical features and diagnostic criteria 
In the absence of a positive family history, it is difficult to distinguish primary 
from secondary HLH on clinical grounds alone as their presentations overlap. 
Most patients with HLH present with prolonged fever and hepatosplenomegaly 
(Henter et al., 2007). Other findings that are associated with HLH are 
neurological symptoms including seizures and/or ataxia, hypo- or hypertonia, 
cranial nerve palsies, meningismus, signs of increased intracranial pressure 
and altered consciousness (Filipovich, 2009). Less common findings in HLH are 
rashes, lymphadenopathy and diarrhoea. Laboratory findings reveal 
hyperferritinaemia, cytopenias (especially anaemia and thrombocytopenia), liver 
dysfunction, hypofibrinogenemia, hypertriglyceridemia, hypoalbuminemia and 
hyponatremia(Filipovich, 2009). Furthermore, other abnormal laboratory 
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findings in HLH are low NK cell cytotoxic activity and elevated soluble IL-2 
receptor (sIL-2r) levels in serum and cerebrospinal fluid (Henter et al., 2007). 
Histological examination of bone marrow or other tissues may demonstrate 
frank haemophagocytosis (ingestion of erythrocytes by macrophages) but this is 
neither sensitive nor specific for HLH.   
Diagnostic guidelines were formed in order to assist the diagnosis of HLH. The 
guidelines had been revised twice and the latest was in 2004. The main five 
guideline criteria that was generated in 1991 is still maintained in 2004 , 
including :1) fever 2) splenomegaly 3) cytopenias affecting at least two or three 
lineages in the peripheral blood 4) hypertriglyceridemia and hyperfibrinoginemia 
and 5) hemophagocytosis in bone marrow, spleen or lymph nodes (Henter et al., 
2007). Three other criteria that are added to the 2004 guidelines are : 6) low or 
absent NK cells activity 7) hyperferritinemia and 8) high levels of sIL-2r (Henter 
et al., 2007). For the diagnosis of HLH, altogether five of the eight criteria must 
be fulfilled , however exception for patients with molecular diagnosis of HLH, 
these diagnostic criteria not need to be fulfilled (Henter et al., 2007). The 
diagnostic criteria are summarised in Table 1.4.  
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Table 1.4: 2004 Diagnostic Guideline for HLH. VLDL- very low density 
lipoprotein, HDL- high density lipoprotein. This table is reproduced from (Henter 
et al., 2007). 
1.4.3.3 Treatments for HLH 
The prognosis of untreated active HLH is extremely poor and it can rapidly 
progress to a fatal disease. Thus, treatment must be started urgently when 
there is a high clinical suspicion of HLH. Treatment consists of combinations of 
chemotherapy and immunosuppressive drugs targeting the abnormal and 
hyperactivated T cells (Filipovich, 2009). The treatment protocol for HLH has 
been revised twice, firstly in 1994 and secondly in 2004 in which the protocol is 
designed for the patients with HLH, with or without evidence of familial or 
genetic disease, regardless of suspected or documented viral infections (Henter 
et al., 2007). The treatment protocol includes initial therapy that covers the first 
8 weeks of treatment involving etoposide, dexamethasone and cyclosporine A 
as well as other supportive medications such as prophylactic antibiotics. This is 
followed by continuation therapy with the same therapy and, if an acceptable 
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donor is available, HSCT should be performed as soon as possible. HSCT is 
the curative treatment for HLH. Through follow up, it was demonstrated that 5 
years after HSCT, up to 66% of HLH patients are still alive, providing a good 
prognosis after receiving HSCT treatment (Trottestam et al., 2011).  
1.5 Approaches to the identification of defective genes of PIDs 
1.5.1 Overview 
As mentioned earlier, in the latest update (2015), PIDs were classified 
according to the basis of the affected immunological compartment (Picard et al., 
2015). In each classification, they were further classified based on their 
diseases and phenotypes and finally the genetic defects that cause the disease. 
Although many genetic defects have been identified, nonetheless , still many 
patients with clinical and laboratory evidence of PID lack a molecular genetic 
diagnosis (Conley and Casanova, 2014). These patients present a challenge in 
providing an appropriate prognosis and therapy. There have been several 
approaches that have been used to identify the disease causing variants in 
some of these patients. The three major approaches that are currently favoured 
are: 1) investigating candidate genes within pathways that are known to be 
important and shown to be dysfunctional, 2) using unbiased genomic 
approaches such as next generation sequencing (NGS) and/or linkage analysis 
and 3) comparative genetics, i.e. similarity of the clinical phenotypes to mouse 
models (Platt et al., 2014). These approaches are discussed below.  
1.5.2 Investigating known signalling pathways 
The phenotypic investigation of known signalling pathways can be helpful in 
candidate gene identification for targeted Sanger sequencing (Platt et al., 2014). 
For instance, previously our own group has successfully identified a novel 
genetic defect associated with increased viral susceptibility via this approach 
(Hambleton et al., 2013). With the knowledge that type I IFN signalling is crucial 
for antiviral immunity, we investigated this pathway in a patient with 
disseminated vaccine strain measles following routine immunization and by 
Sanger sequencing found a homozygous STAT2 mutation to be the cause of 
the disease. This approach was also useful in identifying the Interleukin-17 
receptor (IL-17R) as a novel defect causing impaired Th17 responses in certain 
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patients with chronic mucocutaneous candidiasis (CMC) (Puel et al., 2011). 
Likewise, molecular defects affecting tumor necrosis factor receptor–associated 
factor 3 (TRAF3) were identified by investigating type I IFN induction pathways 
(Pérez de Diego et al., 2010), adding to mutations in TLR3 and UNC93B that 
had already been described in this pathway as causing Herpes simplex 
Encephalitis (HSE) (Dropulic and Cohen, 2011). 
It is easier to use this approach if the disease manifests with specific 
phenotypes as one can concentrate on one rather than multiple signalling 
pathways. However, such a hypothesis-driven approach may be limited by prior 
knowledge and preconceptions. Therefore, to overcome this limitation, other 
methods such as using the advanced genetic approaches can be used to 
broaden the scope of gene discovery. 
1.5.3 Unbiased genetic approaches 
Next Generation sequencing (NGS) is currently widely used and has been 
demonstrably successful in identifying many novel disease genes in PID In 
contrast to Sanger sequencing, NGS enables fast and cost-effective 
sequencing of the whole genome (WGS) or whole exome (WES) within a few 
days (Moshous et al., 2013; Nijman et al., 2014). WES captures the coding 
regions that, while constituting only 1% of the genome, harbour approximately 
85% of deleterious mutations (Botstein and Risch, 2003). Currently, WES is the 
preferred method due to its lower cost and complexity. However, WGS provides 
better coverage of non coding as well as coding exons, intronic sequences, 
promoters and regulatory regions (Conley and Casanova, 2014). There are 
several NGS platforms in widespread use, including Solexa/Illumina (the most 
common method), 454 Sequencing (Roche) and SOLID (Sequencing by 
Oligonucleotide Ligation and Detection, Life Technologies), which differ in their 
sequencing chemistries and technical details (Heather and Chain, 2015).  
Newer platforms continue to enter the market and differ dramatically in read 
length, error rate and cost. 
Briefly, to perform WES involves shearing the patient’s genomic DNA into small 
fragments, followed by ligation of adaptors to the ends of the sheared DNA. 
Next, the coding regions are selected by allowing a labelled “bait’, which consist 
of exons with flanking splice sites, to hybridise to the patient DNA (Conley and 
Casanova, 2014). Finally, the labelled bait and the patient’s coding region are 
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purified, amplified and primers hybridising to adaptors are used for massively 
parallel sequencing (Conley and Casanova, 2014) where the sequencing of 
each patient coding region must be sequenced at least 10 up to 100 times. This 
is to avoid mistaking a sequencing error for a true DNA alteration. To analyse 
the sequencing data, a bioinformatic analysis or pipeline is required and to 
finally identify the pathogenic variants, it involves several filtering processes (will 
be discussed in chapter 4.1). Although, this technique provide a comprehensive 
sequencing data but it is challenging to analyse the data as it requires multistep 
of bioinformatics analysis or pipeline as well as involving several filtering 
processes to finally identify the pathogenic variants.  
Nevertheless, this technique has already been shown to be useful in identifying 
causative genetic defects in PIDs showing both recessive and dominant models 
of inheritance (Casanova et al., 2014; Conley and Casanova, 2014). The first 
successes were in patients from consanguineous families or belonging to 
isolated populations, in which context homozygous disease-causing variants 
are likely (Conley and Casanova, 2014). For example, one young woman was 
found to have inherited a homozygous premature stop codon of exon 6 of 
PI3KR1 which resulted in agammaglobulinaemia and failure of B cell 
development (Conley et al., 2012). WES has also been used successfully to 
investigate groups of unrelated patients who share a distinctive and rare 
phenotype, and are likely to bear mutations in the same gene. One example is 
mutations in GATA2, affecting 4 patients with similar phenotypes of dendritic 
cell, monocyte, B and natural killer lymphoid deficiency (Dickinson et al., 2011). 
The familial occurrence of this phenotype in adjacent generations of outbred 
families strongly suggested an autosomal dominant model of inheritance. 
Heterozygous mutations were found at different sites of the same gene in each 
patient but all mutations were predicted be deleterious, affecting the C-terminal 
zinc finger domain of GATA2 (Dickinson et al., 2011). Some GATA2 mutations 
were de novo and hence sporadic. 
In addition to WES, another available genetic approach is classical linkage 
analysis which uses SNPs flanking a pathogenic mutation to define the disease 
locus shared by the affected subjects (Platt et al., 2014). To identify the 
causative variant, the genes within the linkage region are then sequenced. 
There have been studies that have demonstrated the success of this technique 
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in identifying novel disease-causing variants. One example is in 5 patients 
within 4 consanguineous families who presented with hypogammaglobulinemia, 
decreased B cell numbers and autoimmunity (Lopez-Herrera et al., 2012). 
Initially 81 genes were identified through linkage analysis and Sanger 
sequencing was performed for selected genes. A homozygous mutation in 
LRBA was shown to be causative. This technique is most powerful in large 
families with multiple affected members but often identifies large linkage regions 
within which to spot and analyse the disease gene by Sanger Sequencing.  
Another related and useful genomic approach is homozygosity mapping, a 
special case of linkage analysis (Platt et al., 2014). This approach is helpful in 
the setting of rare disorders in consanguineous families where homozygous 
autosomal recessive mutations are expected. It identifies the genomic regions 
that most likely harbours the pathogenic mutation within a locus containing 
clusters of homozygous SNPs specific to the affected subjects (Platt et al., 
2014). It is commonly combined with WES to assist in filtering candidate 
variants in PID. An example is the identification of a homozygous mutation in 
tripeptidyl peptidase (TPP2) in four patients from two families (two members of 
each family were affected) with combined immunodeficiency, severe 
autoimmunity and developmental delay (Lu et al., 2014). Another example is in 
4 members of an extended consanguineous family who presented with 
biological features of ALPS and susceptibility to viral and bacterial infections. 
Both WES and homozygosity mapping were performed and their intersection 
revealed a homozygous missense mutation of Fas-associated death domain 
(FADD) to be disease-causing (Bolze et al., 2010). These examples 
demonstrate that homozygosity mapping and WES provide a powerful 
combination in identifying the molecular defects in PIDs. 
After candidate pathogenic variants are identified using these genetic 
approaches, extensive functional assays are often required in order to confirm 
that the identified variants are disease-causing. However, in certain cases, such 
functional assays fail to provide a mechanistic link to the clinical phenotype. In 
part this may reflect technical limitations of the experimental system such as the 
use of different cell types and lines in vitro. In addition, additional factors, such 
as the modifying genetic factors, environmental factors or infectious exposures 
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may influence the expression of the disease phenotype in different settings 
(Conley and Casanova, 2014). 
1.5.4 Similarity of the clinical phenotypes to mouse models 
It has been demonstrated by many studies that mouse models are useful in 
enabling the identification of disease causing variants when the phenotypes of 
the knock-out mouse models are similar to the patients’ (Bolze et al., 2010).  
This approach has been used in three patients with Interferon Regulatory Factor 
8(IRF8) deficiency where they displayed disseminated mycobacterial disease 
and absence of dendritic cells including both myeloid and plasmacytoid 
dendritic cells in the blood in which these phenotypes were similar to 
phenotypes observed in IRF8 knock out mice (Hambleton et al., 2011).   
In addition, mouse models can also be used to help prioritize candidate genes 
that were derived from NGS. For example, in a family with congenital asplenia , 
32 candidate genes had been identified  in 3 affected siblings by WES (Koss et 
al., 2012). Among the candidate genes, NKX2-5,stood out as it had already 
been shown to be essential for mouse spleen development (Koss et al., 2012). 
To confirm, in vitro studies demonstrated that the missense mutation of NKX2-5 
results in abolition of its function (Koss et al., 2012) . 
Whilst comparative genetics can be a powerful approach, there is a major 
limitation since not all mouse models recapitulate human disease. A good 
example is provided by a mouse deficient in TANK-binding kinase 1 (Tbk1), the 
susceptibility phenotype of which suggested that this protein is important for 
multiple antiviral and antibacterial pathways (O'Neill, 2008). However, in 
contrast, so far human TBK1 deficiency only results in susceptibility to herpes 
simplex virus (HSV), causing herpes simplex encephalitis (Herman et al., 2012). 
Thus, the mouse model of Tbk1 deficiency did not predict the limited scope of 
human disease. Although only one example, it can still show that in certain 
cases the phenotypes observed in patients may not be similar to the mouse 
models. 
In recent years, many mouse models were generated in order to help providing 
an understanding of the human immune system, but mostly the mouse 
generated from the studies had null mutation, complete loss of function. 
However since the phenotypes of null and hypomorphic mutations can be 
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dramatically different, knock out mice are imperfect models of the many PIDs 
due to hypomorphic mutations. In addition, due to mouse and humans being 
two different species, it is unavoidable to expect that there may be differences 
in the phenotypes and the scope of diseases between them.  
1.5.5 The importance of molecular diagnosis for the patient and family 
members 
The identification of a molecular defect provides a huge impact for the patients 
and family members. Firstly, by knowing the molecular diagnosis, this provides 
a better understanding on how the gene defects lead to the pathogenesis of the 
diseases. Secondly, the mutation analysis help to provide precise diagnosis and 
accurate prognosis for the patient. Since patients with PIDs are associated with 
increased morbidity and mortality, the molecular diagnostics enable the 
appropriate therapy and treatment to be given to the patients which include in 
the development of long term preventive strategies to limit complications and 
irreversible organ damage. In addition, a lifesaving and permanent curative 
interventions such as HSCT can be performed.   
In recent years, Haematopoietic Stem Cell Transplantation (HSCTs) is 
considered to be the treatment of choice for many forms of PID as it offers cure 
and HSCT-associated morbidity and mortality is constantly improving (Cant et 
al., 2013). Although it is not the main criterion in assessing whether the patient 
is suitable for HSCT or not, knowing the genetic defect may influence and help 
to predict the outcome of the HSCT (Ochs et al., 1999).  For most SCID patients, 
the definitive treatment is HSCT, however, different gene mutations have 
different prognosis. For example, patients with Artemis deficiency have a worse 
prognosis of HSCT compared to RAG deficiency due to the associated cellular 
radiosensitivity. Besides SCID, patients with life-limiting combined 
immunodeficiencies such as that caused by mutations in the dedicator of 
cytokinesis 8 (DOCK8) have been successfully transplanted and this results in 
HSCT as the choice of treatment for this molecular diagnosis (Barlogis et al., 
2011). 
The definitive treatment that requires knowledge of the molecular defect is gene 
therapy. This is a technique whereby a functional copy of the defective gene is 
introduced into the patient’s stem cells by means of viral vectors (Cant et al., 
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2013). Although in some cases such as in Adenosine Deaminase deficiency 
that gives rise to severe combined immunodeficiency (SCID) gene therapy was 
demonstrated to be successful (Cavazzana-Calvo et al., 2012), due to the 
evident serious potential complications such as activating oncogenes (Cant et 
al., 2013), this treatment has yet to enter the mainstream. 
Finally, the molecular diagnosis is not only for the patient’s benefits but also for 
other family members as proper genetic counselling can be given to the family 
members. Knowing the genetic diagnosis can help the family members to plan 
and expect the risk of having other children that will be affected with the same 
disease.   
1.6 Aims of the study 
For my study, I have two different Primary Immunodeficiencies where: 
1) Patient 1 demonstrated increased viral susceptibility after receiving 
measles, mumps, rubella (MMR) immunization. 
2) Two patients (siblings) who had viral susceptibility and immune 
dysregulation that results in autoimmune lymphoproliferative syndrome 
(ALPS). 
These patients were diagnosed with PID based on clinical and laboratory 
evidence, but their molecular diagnosis was unknown. Since it is important to 
provide the molecular diagnosis, the aim of my study was to identify the genetic 
defects causing these two novel PIDs using the approaches that have been 
described earlier. In addition, I anticipated that the identification of the genetic 
defects would enable me to elucidate the pathogenesis of their disease, which 
would provide new and better knowledge of the human immune system. 
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Chapter 2: Materials and Methods 
2.1 Study subjects 
Specimens were obtained with signed informed consent from patients and 
healthy volunteers. For samples from children age <16 years old, the informed 
consent was obtained from parents of the children. 
For the novel defect in the IFN signalling study, patient and control fibroblasts 
and parents’ whole blood were provided by the Clinical consultant in charge of 
the patient, Dr Ronan Leahy, Our Lady’s Children Hospital, Crumlin, Dublin. 
For the novel defect of autoimmune lymphoproliferative syndrome study, 
fibroblasts and frozen DNA from patients, family members and controls were 
prepared and collected from Human Genetics Laboratory, Centre for Life, 
Newcastle University. Control DNA was extracted from whole blood from 
healthy volunteers recruited from the Musculoskeletal Research Group, 
Newcastle University. 
2.2 Materials 
Reagents/medium 
 
Company Catalogue number 
Phosphate buffered Saline (PBS) Lonza BE10-543F 
Hanks Buffered Saline Solution 
(HBSS) 
Lonza  BE17-512F 
Dulbecco’s Modified Eagle’s 
Medium 
Gibco 41965-039 
RPMI 1640 medium Sigma R0883 
Fetal Calf Serum (FCS) Lonza 14401F1 
Lymphoprep Axis-Shield Diagnostic NYC1114547 
Trypsin-EDTA Sigma 59418C 
200 mM L-glutamine Solution Sigma G6392 
10x Penicillin-Streptomycin 
Solution (104 units per ml 
penicillin, 10 mg/ml 
streptomycin) 
Sigma P0781 
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Sodium Pyruvate Sigma S8636 
2-mercaptoethanol Gibco 31350-010 
Non essential amino acid Sigma M7145 
FuGENE HD Transfection 
Reagent 
Promega E2311 
CD19 Microbeads, human Miltenyi Biotec 130-050-301   
Whole blood CD19 Microbeads, 
human 
Miltenyi Biotec 130-090-880 
Phytohaemaglutinin (PHA) Sigma L1668 
Table 2.1: Cell culture reagents and medium used for the research. 
Cytokine 
 
Company 
Interferon-α ( Intron A, recombinant) Schering-Plough 
Interferon-γ (Immunikin) Boehringer Ingelheim 
Interferon-β (Avonex) Biogen Idec 
Interleukin-2 (Proleukin) Novartis 
Table 2.2: Cytokines used for the research 
Antibodies 
 
Species Company Catalogue 
number 
Dilution Assay 
Tet2  Mouse Active Motif 61389 1:1000 WB 
IFNAR2 C-terminal Sheep R & D systems AF7014 1:500 WB 
ISG56/IFIT Goat Santa Cruz sc-82946 1:10000 WB 
MxA(Mx1/2/3) Rabbit Santa Cruz sc-34128 1:500 WB 
STAT2 Rabbit Millipore 07-140 1:500 WB 
pSTAT2 (Tyr690) Rabbit Cell Signalling 4441 1:500 WB 
STAT1 Rabbit Cell Signalling 9172 1:500 WB 
pSTAT1(Tyr701) Rabbit Cell Signalling 7649 1:500 WB 
STAT3 Rabbit Cell Signalling 4904 1:500 WB 
pSTAT3(Tyr705) Rabbit Cell Signalling 9131 1:500 WB 
GAPDH Rabbit Cell Signalling 5174 1:2000 WB 
CD20-PE,human  Mouse Miltenyi Biotec 130-098-084 1:100 Flow 
cytometry 
Pacific blue α-mouse CD19 Mouse Biolegend 115526 1:100 Flow 
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cytometry 
5-hydroxymethylcytosine (5-
hmC) 
Rabbit Active Motif 39769 1:1000 IF 
Anti-Flag M2 Mouse Sigma F3165 1:500 IF 
Donkey α-sheep IgG HRP 
conjugated 
Sheep R & D system HAF106 1:500 WB 
Horse α-mouse IgG HRP Mouse Cell Signalling 7076 1:5000 WB 
α-rabbit  IgG HRP Rabbit Cell Signalling 7074S 1:2000 WB 
Alexa Fluor 488 Goat anti-
rabbit IgG 
Rabbit Invitrogen A11070 1:500 IF 
Alexa Fluor 546 Goat anti-
mouse IgG 
Mouse Invitrogen A21237 1:500 IF 
Table 2.3: List of antibodies used in study 
Chemical/reagent Company Catalogue number 
 
Sodium Dodecyl Sulfate(SDS) Sigma 71727 
Sodium Deoxycholate Sigma D6750 
Protease inhibitor cocktail Roche 04693116001 
DL-Dithiothreitol(DTT) Sigma 646563 
NuPAGE LDS Sample Buffer Life Technologies NP0007 
Tris-HCL Sigma T5941 
Sodium chloride Sigma S9888 
Triton-X-100 Sigma T8787 
Trypan blue solution, 0.4% Thermo Fischer Scientific 15250-061 
Sodium Fluoride Sigma 201154 
Sodium Orthovanadate Sigma S6508 
Pierce Protein Assay Reagent Thermo Scientific 22660 
Bovine Serum Albumin Sigma A2058 
4-12% Tris-Glycine polyacrylamide 
gel 
Life Technologies EC60352BOX 
Nu-PAGE Tris Glycine SDS Running 
Buffer 
Life Technologies LC2675 
ImmobilonTM Western Millipore WBKLS0500 
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Chemiluminescent HRP Substrate  
Paraformaldehyde Sigma P6148 
Vectashield® Mounting Media with 
DAPI  
VectorLabs H-1200 
Super Optimal Broth (SOB) medium Invitrogen 15544-034 
NEB 5-alpha Competent E. coli (High 
Efficiency) 
New England Biolab C2987H  
 
Staurosporine Calbiochem 569397 
TaqMan® Gene Expression Master 
Mix 
Life Technologies 4369016 
Tris Base Sigma T1503 
PageRuler Prestained Protein Ladder  Thermo Scientific 26616 
Acetic Acid Sigma 537020 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma E9884 
Tween-20 Sigma P1379 
Glycine Sigma 410225 
LB Broth Powder Sigma L3022 
NP-40 (Tergitol) Sigma S5439 
Table 2.4: Chemical and biochemical reagents used for the research 
Buffer Components Assay 
MACS buffer 0.5% (w/v) Fetal Calf Serum (FCS), 2mM 
EDTA, Phosphate Buffered Saline (PBS) 
B cells isolation using 
Miltenyi Biotec 
FACs buffer  1% (w/v) Bovine Serum Albumin , 
Phosphate Buffered Saline (PBS) 
B cells purity assessment 
by flow cytometry 
50xTAE (Tris-acetate-
EDTA) buffer  
242 g Tris Base, 57.1 mL  Acetic Acid 
100 mL 0.5 M EDTA 
Agarose gel 
electrophoresis 
Tris Buffered-Tween 
Saline Solution (TBS/T)  
100mM Tris Base, 0.15M Sodium Chloride, 
0.1% (v/v) Tween-20 
Western Blotting 
Stripping buffer 15 g glycine, 1 g SDS, 10 ml Tween20, pH 
2.2, dH2O 1L 
 
Tris- HCL Buffer 100mM Tris HCL, distilled H2O Immunofluorescence 
Blocking buffer 1% (w/v) Bovine Serum Albumin(BSA), Immunofluorescence 
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0.05% (v/v) Tween-20, PBS 
LB Broth medium 5.15g mixed LB Broth powder( Tryptone, 
Sodium Chloride, Yeast extract), 250ml  
distilled water 
Plasmid cloning 
RIPA buffer 50mM Tris HCL (pH 7.5), 150mM Sodium 
Chloride, 0.5%(w/v) Sodium Deoxycholate, 
0.1% (w/v) Sodium Dodecyl Cholate (SDS), 
1% (v/v) NP-40, 1x complete protease 
inhibitor 
Extraction of nuclear 
protein lysate 
Whole cell lysis 20 mM Tris-HCL (pH 7.4), 150mM Sodium 
Chloride, 1% (v/v) Triton X-100, 5 mM 
EDTA, 1x complete protease inhibitor, 
phosphatase inhibitor( Sodium Fluoride, 
Sodium Orthovanadate) 
Whole cell lysate 
extraction 
Table 2.5  List of buffers used for assays. 
Gene Sequence (5’-3’) 
IFNAR2 cDNA 1) For -  GGCGAGAGCTGCAAAGTTTA 
Rev – GCTTGCTCATCACTGTGCTC 
2) For – TTCTGGCTGGCCATAGACAT 
Rev – ACATCAACCTCAGGCAGGTC 
3) For – CCATGGATATGGTGGAGGTC 
Rev – TTGGAGAACACTTGCAGACG 
4) For – GCCTCGTGTTTGGTATTTCA 
Rev – GATGGAAATTTCACCATCACA 
5) For -  CCCGAAATAAAAGGAAACATGA 
Rev -  CCATATCCATGGCTTCCAAC 
6) For – CTGACCTGCCTGAGGTTGAT 
Rev -  GGAAAGGTTGGCTGTGTCC 
IFNAR2 gDNA (Exon 5) 1) For -  AAGGCGCCCAAAAATAGACT 
Rev -  GGGACGAAGTGGAGAAACAG 
IFNAR1 cDNA 1) For -  GGGCGGTGTGACTTAGGAC 
Rev -  TGGTGGAGGTAGTTCATTTTCA 
2) For -  AAGCTCAGATTGGTCCTCCA 
Rev – GTGCTCTGGCTTTCACACAA 
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3) For -  GCGTACAAGCATCTGATGGA 
Rev – CAGGGAAACGTCCTCTCTGT 
4) For – GATGACAACTTTATCCTGAGGTG 
Rev -  CACCTGAAGAGTTTTTCCAGA 
5) For -  TGAAAATGAACTACCTCCACCA 
Rev – TTCCAGACTGTTTTGGAGCA 
6) For – TTGGGAAAACACTTCAAATGC 
Rev -  TGTTCCTCAGAAGTTGAAAGCA 
Tyk2 cDNA 1) For – ACTGAGGCCCAGAATTGCTA 
Rev -  AGGGCCAGGGTCTGTAGG 
2) For – CTTCGGCACAGAGCGTGT 
Rev – CCCTCATACACGTTGGTCCT 
3) For -  CCCAGGACACTCAACCTCAG 
Rev – CTCCCTCTGCAGCCACTG 
4) For – CCACAATCTTGCTGACGTCTT 
Rev – CTCCCTCTGCAGCCACTG 
5) For -  CGGCTGTGTACCGTTGTG 
Rev – AGGGCCAGGGTCTGTAGG 
6) For -   ACTGAGGCCCAGAATTGCTA 
Rev -  TTGCCCTGCTCAAAGAGGTA 
7) For -  CTTCGGCACAGAGCGTGT 
Rev -  GGTGCTCCAGTGAATGAGGT 
8) For -  ACTCCAGCCACTACCTGTGC 
Rev – CCCTCATACACGTTGGTCCT 
9) For -  GTAATGTGTGTGGCCGGAAC 
Rev – AAGCTGACCTTGCCGAAGT 
10) For – CCCAGGACACTCAACCTCAG 
Rev – CCAGGGGATCCTCTCCAC 
11) For -  CCACAATCTTGCTGACGTCTT 
Rev -   GGTAGTACTCGTGGCCTTCG 
12) For – CAGCACTACATCCACCGAGA 
Rev - CTCCCTCTGCAGCCACTG 
    
TET2 gDNA 1) For – CTTTCGCATTCACACACACTTT 
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Rev - TGTGCAGGGGAACTC 
TET2 (SDM) 1) For -  TTCTGTGCTCATGCCCGCAGAGACTTGCACAAC 
Rev -  GTTGTGCAAGTCTCTGCGGGCATGAGCACAGAA 
TET2 cDNA 1) For -  TGAACACAGAGCACCAGAGTG 
Rev -  AAAAGTCAGCCCCATCACGT 
Table 2.6: Primers used for standard PCR and Sanger Sequencing. 
Gene Sequence ( 5’-3’) Universal Probe Library 
Probe number 
TET1 For – TCTGTTGTTGTGCCTCTGGA 
Rev -  GCCTTTAAAACTTTGGGCTTC 
57 
TET2 For – AAAGATGAAGGTCCTTTTTATACCC 
Rev - ATAGCTTTACCCTTCTGTCCAAAC  
68 
TET3 For – CACTCCGGAGAAGATCAAGC 
Rev - GGACAATCCACCCTTCAGAG 
1 
TIA1 For – CCCTGTGCTTGTACATCTTCC 
Rev -  TGTCTTTGTACATGCAATCTAGTTCTT 
8 
Smad3 For – GAAGAAGGGCGAGCAGAA 
Rev - TTTCTTGACCAGGCTCTTGAC 
51 
DUSP1 For – TGGGTACATCAAGTCCATCTGA 
Rev - GCAAAAAGAAACCGGATCAC 
29 
CDKN1A For – TCCAGACACAGACATATCCACA 
Rev -  TGCTCTGGTGGCTGTACTGA 
76 
TRAF5 For – TGCTATGCAGAGACCCATACC 
Rev - ATTTCTTTTGTGGACTCTTCATCC 
67 
Table 2.7: Oligonucleotide primers and probes used for Real time PCR. 
Kit Catalogue  
number 
Company Method 
QiAmp DNA Mini  51304 Qiagen DNA extraction 
Quest 5-hmCTMDNA ELISA  D5425 Zymo  
research 
ELISA (quantification  
of global 5hmC) 
ReliaPrep™ RNA Cell Miniprep 
System 
Z6011 Promega RNA extraction 
SuperScript® III Reverse 18080-044 Invitrogen cDNA production 
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Transcriptase 
MyTaq™ HS DNA Polymerase BIO-21111 Bioline PCR DNA  
amplification 
PureYield Plasmid Midiprep 
System  
A2492 Promega Plasmid DNA 
purification 
QuikChange II XL Site-Directed 
Mutagenesis  
200521 Agilent  
technologies 
Site-Directed 
Mutagenesis (SDM) 
QIAprep Spin Miniprep 27104 Qiagen Mutated plasmid  
DNA purification 
FasL, soluble (human) 
(recombinant) set 
ALX-850-014-KI02 Enzo Life  
Sciences 
Fas-mediated  
apoptosis  
FITC Annexin V Apoptosis 
Detection  
556547 BD  
Pharmingen 
Fas-mediated  
apoptosis  
Table 2.8 : List of commercially available kits used for the research. 
2.3 Methods 
2.3.1 Preparation and culture of human cells 
2.3.1.1 Fibroblast culture 
Dermal fibroblasts obtained from patients and controls were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal 
calf serum (FCS), penicillin/streptomycin and L-glutamine. Fibroblasts were 
cultured in T75 flasks and incubated in a 5% CO2 incubator at 370 C until they 
were 80% confluent.  Cells were split, maximum up to passage 14, to maintain 
them in a sub- confluent state. The cells were removed from T75 flasks by 
trypsinisation: cells were washed once with PBS before 1x trypsin EDTA was 
added to detach the cells from the flask over 2 to 3 minutes at room 
temperature. Serum-containing DMEM was added, cells and medium harvested 
and centrifuged at 600g for 5 minutes at RT. The cells were seeded again in 
T75 flasks, containing fresh medium until ready to be used for further 
experiments. 
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2.3.1.2 HEK293T cell culture 
HEK293T is an adherent cell line, originally derived from human embryonic 
kidney cells. I obtained an aliquot from the Musculoskeletal Research Group, 
Institute of Cellular Medicine, Newcastle University. The cells were grown and 
subcultured as described for dermal fibroblasts, except that as this is an 
immortalised cell line it could be grown continuously. 
2.3.1.3 PBMC isolation 
Whole blood samples were collected in heparinized tubes. Blood was mixed 1:1 
with Hanks Buffered Saline Solution( HBSS) (containing 1% FCS). The mixed 
blood was layered on top of Lymphoprep 2:1 and centrifuged at 825g for 30 
minutes at RT. The PBMC were collected from the interface, and washed with 
cold HBSS by centrifugation at 600g for 5 minutes. The PBMC pellet was 
washed with HBSS once and centrifuge at low speed for 5 minutes. The pellet 
was then resuspended in fresh HBSS medium kept on ice for further 
experiments and an aliquot was taken and counted for determination of cell 
numbers. 
2.3.1.4 B cell isolation and purity assessment by flow cytometry 
B cells were isolated using two methods:  
2.3.1.4.1 Positive selection from whole blood for microarray analysis 
For microarray analysis, B cells were isolated from fresh whole blood using 
positive selection and either an autoMacs Pro Separator (patient samples, 
carried out by Dr Dawn Barge, Clinical Immunology Laboratory, Royal Victoria 
Infirmary, Newcastle) or an autoMacs Classic Separator (healthy controls). 
Whole blood (4ml) was collected in EDTA tubes and labelled with 200ul of 
whole blood CD19 Microbeads (Miltenyi Biotec). The blood and beads were 
mixed well and incubated for 15 minutes at 4C. The cells were washed with 
10ml of autoMacs running buffer and centrifuged at 445g for 10 minutes at RT. 
The supernatant was discarded except for a residual volume (approximately 1-
2ml deep) which was left to avoid cell loss. The pelleted cells were resuspended 
in autoMacs running buffer to a total volume of 2ml. B cells were then isolated 
using positive selection by autoMacs Separator. Isolated B cells of both healthy 
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controls and patient were kept on ice for RNA extraction and an aliquot was 
taken for cell counting and assessed for purity by flow cytometry. 
 
2.3.1.4.2 Positive selection of B cells from PBMC for Real Time PCR 
Another method that was used to isolate healthy control B cells was by positive 
selection from PBMCs. This method was used to isolate more B cells from a 
higher volume of blood (60ml). This was performed to investigate the TET1, 
TET2 and TET3 mRNA level in healthy control B cells by qRTPCR. PBMCs 
were centrifuged at 600g for 5 minutes at RT. The cell pellet was resuspended 
in 80ul of MACs buffer and CD19+ cells were labelled with 20ul of CD19 
Microbeads per 107 total cells. The cells were then incubated for 15 minutes at 
40C. The cells were washed with 2ml of MACs buffer per 107 cells and 
centrifuged at 300g for 10 minutes. The supernatant was discarded completely 
and the pelleted cells were resuspended in 500ul of buffer. The suspended cells 
were applied to a prepared LS column attached to a magnet. The column was 
washed three times and was removed from the magnet. The magnetically 
labelled CD19+ cells were retained within the column and eluted as the 
positively selected cell fraction. An aliquot of cells was counted for 
determination of cell number and assessed for purity by flow cytometry. The 
remaining B cells were kept on ice for RNA extraction. 
2.3.1.4.3 Purity assessment 
Following B cell isolation, cells were assessed for purity. 500ul of isolated B cell 
suspension was aliquoted into a FACs tube. The cells were centrifuged at 400g 
for 5 minutes. The supernatant was discarded and pelleted cells were washed 
initially with 1ml PBS, centrifuged then washed again with 1ml FACs buffer and 
centrifuged. Both centrifugations were at 400g for 5 minutes. The pelleted cells 
were resuspended in 100ul of FACs buffer containing 10ul of PE-CD20 antibody 
(Miltenyi Biotec) and incubated on ice for 30 minutes. Then the cells were 
washed with 2 ml of FACs buffer and centrifuged at 400g for 5 minutes. The 
cells were washed again with FACS buffer and finally resuspended in 300ul 
FACs buffer and assessed on the BD FACs Canto II flow cytometer (BD 
Bosciences). The data was then analysed using FlowJo 7.6 (Treestar, USA) 
software. 
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2.3.1.5 Cell counting 
Trypan Blue-exclusion method was used to distinguish between live and dead 
cells. Due to membrane rupture, dead cells absorb the blue dye which stains 
the cytoplasm and were thus visualised under the microscope in blue, whereas 
viable cells were visualised as clear.  
For cell counting, a 20ul aliquot of the cells was diluted at 1:5 with 30ul of 
growth media and 50ul of 0.4% Trypan blue. 10ul of the cell dilution  was 
applied to the surface of a haemocytometer at the edge of the coverslip. The 
number of cells within a 5 x 5 grid was counted under inverted microscope at 
40x magnification. The concentration of cells was calculated as :  
Total number of cells/ml = Number of cells within 5 x 5 grid x 5 (dilution factor) x 
104  
2.3.1.6 Cell transfection 
HEK293T cells that were 80% confluent in T75 flasks were removed by 
trypsinisation (method is similar to splitting the cells). The cells were then 
seeded on chamber slides at 18000 cells/well in 100 ul of DMEM/10% FCS 
(antibiotic free) in the morning. At the end of the day, cells were transfected with 
DNA of the WT TET2 or mutant TET2p.H1382R plasmids. A Fugene HD 
transfection reagent/DNA mixture was prepared by incubating 2ug DNA of 
either construct with 6ul of Fugene HD (at 3:1 Fugene HD:DNA ratio), a non-
liposomal transfection reagent, and 90ul of serum and antibiotic free DMEM 
medium for 15 minutes at room temperature. Then 6ul of each mixture was 
added per well to the HEK 293T cells that were seeded earlier in the morning. 
The cells were incubated in 370C CO2 incubator for 48 hours prior to staining for 
immunofluorescence microscopy.  
In addition, to assess the transfection efficiency by Western blot, 400,000 cells 
per well were seeded in a 6-well plate in 1ml of serum and antibiotic free media. 
The amount and ratio of DNA:Fugene HD were the same as before and 90ul of 
the mixture was added per well to the cells. The cells were left in the 370C CO2 
incubator for 48 hours. The transfection efficiency was assessed by Western 
blot. 
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2.3.1.7 Cell stimulation  
For the novel defect of IFN signalling study, both patient and control fibroblasts 
that were 80% confluent  were removed from T75 flasks as described and 
seeded at 60,000 cells per well in a 24-well plate. The cells were left in 370C 
CO2 incubator overnight. For PBMCs, 2 x106 cells per well were seeded per 
well in a 24-well plate.  Both fibroblasts and PBMCs were left unstimulated or 
stimulated with : 
a) IFNα at 100IU/ml for overnight stimulation. The cells were lysed the next 
day and subjected to Western blotting. This cell stimulation experiment 
was performed  to assess the upregulation of Interferon stimulated genes 
(ISGs).  
b) IFNα and IFNγ at 1000 IU/ml for 15 minutes, 30 minutes and 60 minutes. 
The cells were lysed after the indicated times, and subjected to Western 
Blotting (see below). This experiment was performed to assess the 
expression and phosphorylation of STAT1, STAT2 and STAT3. 
c) IFNα , IFNγ and IFNβ at 1000IU/ml for 10 hours. RNA was extracted 
from the cells and subjected to microarray analysis. 
2.3.2 DNA methods 
2.3.2.1. DNA extraction and quantification 
Total DNA was extracted from patient and control PBMCs or fibroblasts. Cells 
were collected and pelleted in a sterile microcentrifuge tube. DNA extraction 
was performed using QiAmp DNA Mini kit (Qiagen, UK) according to the 
manufacturer’s protocol. Cells were lysed enzymatically by Qiagen protease. 
DNA was isolated with a fast spin column procedure in which the DNA bound 
specifically to the QiAmp silica gel membrane while the contaminants passed 
through. DNA in the spin column was washed in two efficient steps with wash 
buffer. Finally, DNA was eluted in TE buffer provided with the kit. Isolated DNA 
was quantified using a Nanodrop 2,000 Spectrophotometer and stored frozen at 
-200C for further experiments. 
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2.3.2.2 Whole exome sequencing and homozygosity mapping 
Patient genomic DNA was submitted for whole exome sequencing using Sure 
Select Human All Exon 50Mb kit (Agilent Technologies) coupled with massively 
parallel sequencing by Illumina GA II Sequencing system. The DNA sequences 
were mapped to the hg19 human genome by NovoAlign 
(http://novocraft.com/main). Bioinformatic analysis was performed by Dr Helen 
Griffin (Institute of Genetic Medicine, Newcastle University) and Dr Yaobo Xu 
(Institute of Genetic Medicine, Newcastle University) using an in-house 
pipeline.In parallel, homozygosity mapping was also performed using the 
Affymetrix Genome-Wide Human SNP 5.0 microarray. Homozygous regions 
were identified using HomozygosityMapper (http://homozygositymapper.org) 
and further analysed using microsatellite markers. Homozygosity mapping was 
performed by Dr Neil Morgan, Birmingham University. 
 
2.3.2.3 5-hydroxymethylcytosine (5hmC) enzyme-linked Immunosorbent Assay 
(ELISA)  
To quantify the global 5hmC level in patient and control B-cell DNA for the study 
of novel defect of the lymphocyte apoptosis disorder, a Quest 5hmCTMDNA 
ELISA kit (Zymo Research,UK) was used. This kit uses a sandwich-based 
ELISA format in which firstly, the anti-5hmC polyclonal antibody was coated to 
the bottom of the well. Then, DNA was added and single stranded 5hmC-
containing DNA binds to the anti-5hmC antibody. Captured DNA is then 
recognised by an anti-DNA-HRP antibody. Finally, the addition of HRP 
developer produces a greenish colour, due to the enzymatic reaction of the anti-
DNA-HRP antibody to the chemical substance in the HRP developer. A 
summary of this method is shown in Figure 2.1. 
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Figure 2.1 : A sandwich-based ELISA format. Anti-5hmC polyclonal antibody 
is coated onto the bottom of the well. The single stranded 5hmC-containing 
DNA binds to anti-5hmC and this is recognised by an anti-DNA-HRP antibody. 
HRP developer is added which produces a greenish colour. 
Method : This techniques involved five steps : 
1. Coating 
Anti-5hmC polyclonal antibody (4ng/ul) in coating buffer was coated onto the 
96-well ELISA plate and was incubated in an incubator at 370C for 1 hour. 
2. Blocking  
The wells were washed with 1x ELISA buffer three times. 1x ELISA buffer was 
added into the wells and incubated at 370C for 30 minutes. 
3. DNA addition/binding 
Patient and control DNA was denatured at 980C for 5 minutes in a thermal 
cycler. Then, the samples were incubated on ice for 10 minutes, after which 
250ng of each sample was diluted in 1x ELISA buffer to a concentration of 
100ng. The samples were added into the wells and incubated at 370C for 1 hour. 
4. Addition of anti-DNA HRP antibody 
The wells were washed with 1x ELISA buffer three times. Anti-DNA HRP 
antibody in 1x ELISA buffer (1:100) was added into the wells and incubated at 
370C for 30 minutes. 
5. Colour development 
The wells were washed again with 1x ELISA buffer three times. 1X developer 
was added into the wells. The absorbance of each well was measured with an 
ELISA plate reader at 450nm. Readings were taken 30 minutes after the 
developer was added. 
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2.3.3 RNA methods 
2.3.3.1 RNA extraction and quantification 
RNA was extracted from fibroblasts and B cells using the ReliaPrep RNA Cell 
Miniprep System (Promega, US), as per the manufacturer’s instructions. This 
method uses a spin-column purification protocol. Briefly, it requires five 
essential steps : 
1) disruption and lysis of the cells  
2)  denaturation of nucleoprotein complexes, allowing the RNA to be 
released into the solution and isolated free of the protein 
3) After clearing the protein and cellular debris by centrifugation, RNA is 
precipitated with ethanol and loaded onto the spin column, where it binds 
to the silica membrane  
4)  contaminating DNA is removed by adding DNase which is an enzyme 
that digests DNA 
5) Finally, after several washing steps, the purified RNA is eluted in 
nuclease free water. 
Purified RNA was quantified using the Nanodrop 2000 Spectrophotometer, 
aliquoted at 100ng/ul and kept at -800C for further experiments 
2.3.3.2 Complementary DNA (cDNA) production 
cDNA for use in Real Time PCR and Sanger sequencing was synthesised from 
RNA using Superscript III Reverse Transcriptase (Invitrogen, UK) reagents. 
100ng of RNA sample was mixed with 100ng Random Hexamer primers, 1ul 
dNTP Mix and sterile distilled H20 up to 13ul in a microcentrifuge tube. The 
mixture was heated on a thermal cycler at 650C for 5 minutes and then 
incubated on ice for 1 minute. Then, 4ul 5x First strand buffer, 1ul 0.1M DTT , 
1ul SuperScript II RT and 1ul sterile distilled H20 were added to the mixture. 
The tube was incubated at 250C for 5 minutes, followed by 500C for 60 minutes 
on thermal cycler. Finally the reaction was inactivated by heating at 700C for 15 
minutes.  
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2.3.3.3.Microarray analysis 
2.3.3.3.1 Illumina HT-12 labelling: Nugen 
For the study of the novel defect of autoimmune lymphoproliferative disease, a 
microarray analysis was performed on RNA extracted from patient and control B 
cells. Quality control, RNA labelling, hybridization and data extraction for 
microarrays were performed by ServiceXS BV (Leiden, Netherlands). The RNA 
quality and integrity was determined using Lab on-Chip analysis on the Agilent 
2100 Bioanalyzer (Agilent Technologies, US). Biotinylated ss-cDNA was 
prepared from 50ng of total RNA with the WTA system kit using the NuGEN 
Ovation PicoSL. This was a specialised protocol as the total amount of RNA 
used was low. Then 750ng of biotinylated ss-cDNA samples was hybridized 
onto the Illumina HT-12 v4 Expression Bead Chips (Illumina Inc, San Diego, 
USA). Image analysis and extraction of raw expression data was performed 
with Illumina GenomeStudio v2011.1.  
Once the Illumina Human HT12v4 Expression BeadChip data was received 
from ServiceXS BV (Leiden, Netherlands), further bioinformatics analysis was 
performed in conjunction with Andrew Skelton (Bioinformatics Unit, Newcastle 
University). The data was background corrected in Illumina Beadstudio, 
subsequent analysis proceeded using the Lumi and Limma packages in R 
(Bioconductor). Normalization of background corrected data was applied 
through Variance Stabilising Transformations (VST) and Robust Spline 
Normalisation (RST) in Lumi. A technical effect was identified using principal 
component analysis and linked to scanning batches, this effect was corrected 
for using the ComBat function from the SVA package. Differential expression 
was detected using linear models and empirical Bayes statistics in Limma. A list 
of genes for each comparison was generated using a Benjamini Hochberg false 
discovery rate correct p-value of 0.01 and a fold change of 2 as cut-offs. 
 
2.3.3.3.2 Illumina HT-12 labelling: Total Prep 
For the study of the novel defect of IFN signalling, RNA extracted from patient 
and control fibroblasts were subjected to microarray analysis which was 
performed by ServiceXS BV (Leiden, Netherlands). The RNA quality and 
integrity was determined using Lab-on-chip analysis on the Agilent 2100 
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Bioanalyzer (Agilent Technologies, USA). Biotinylated cRNA was prepared 
using Illumina Total prep RNA amplification kit with an input of 200ng total RNA. 
Per sample, 750ng of biotinylated cRNA was hybridized onto the Illumina HT-12 
v4 Expression Bead Chip (Illumina Inc, San Diego, USA). Image analysis and 
extraction of raw expression data was performed with Illumina GenomeStudio 
v2011.1. 
Bioinformatic analysis of the Illumina Human HT12v4 Expression BeadChip 
data was performed in conjunction with Andrew Skelton (Bioinformatics Unit, 
Newcastle University). Data from two Illumina HT-12 v4 Expression Bead Chips 
were background corrected in Illumina Beadstudio with further analysis carried 
out using the Lumi and Limma Bioconductor packages in R. Variance 
Stabilising Transformations (VST) and Robust Spline Normalisation (RSN) in 
Lumi were applied for normalization of the background corrected data. 
Differential expression was detected using linear models and empirical Bayes 
statistics, utilizing a multi-level experiment approach through Limma. A gene list 
for each comparison was generated using a Benjamini Hochberg false 
discovery rate correct p-value of 0.01 and a fold change of 2 as cut-offs.  
2.3.4 PCR based methods 
2.3.4.1 PCR DNA amplification for Sanger Sequencing  
Amplification of genomic DNA for Sanger sequencing was performed by the 
standard Polymerase Chain Reaction (PCR) method. PCR relies on thermal 
cycling, including cycles of repeating heating and cooling of the reaction mixture 
for DNA melting and enzymatic replication of DNA. First, heating to 95°C results 
in denaturation of the DNA template, yielding single stranded DNA molecules.  
This is followed by heating to around 56°C (depending on the melting 
temperatures of the primers), allowing the annealing of two primers, forward 
and reverse primers, which contain sequences complementary to the target 
region, to the single stranded DNA template. Next is the extension step at 72°C, 
where the enzyme DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand. At this step, the amount of DNA is 
doubled, resulting in exponential amplification of the specific DNA fragment. 
These steps will then be repeated usually for 20-40 cycles.  
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PCR : PCR was performed using MyTaq HS DNA polymerase (Bioline) 
reagents. All reagents were added to a 0.2ml centrifuge tube and mixed prior to 
cycling, as per table 2.9 
Reagents One reaction (50ul) 
5x MyTaq reaction buffer (containing dNTPs, MgCl2 and 
enhancers 
 
10ul 
DNA 
 
100ng 
Forward Primer (10uM) 
 
1ul 
Reverse Primer (10uM) 
 
1ul 
MyTaq HS DNA Polymerase 
 
0.25ul 
Water (ddH2O) Up to 50ul 
 
Table 2.9 : Standard PCR reagents 
Reactions were cycled on a thermocycler using the following condition (Table 
2.10) 
Step Temperature Time Cycles 
Initial denaturation 95°C 3 minutes 1 
Denaturation 95°C 15 seconds 35 
Annealing 
 
57°C 15 seconds 
Extension 
 
72°C 1 minute 
Final Extension 
 
72°C 5 minutes 1 
Table 2.10 : PCR cycling condition 
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Forward and reverse primers were designed using NCBI ePCR software 
(www.ncbi.nlm.nih.gov/projects/epcr/reverse.cgi) with DNA target sequences 
including the exon/intron boundaries. Specificity of the primers was confirmed 
using NCBI blast software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
Sequences of the DNA were obtained from human Ensembl website 
(www.ensembl.org/Homo_sapiens). Primers were ordered from Sigma Aldrich. 
A list of primers is shown in the Section 2.2(Table 2.6).   
Agarose gel electrophoresis : To check whether the PCR generated the 
anticipated DNA fragment, agarose gel electrophoresis was employed to 
separate the DNA fragments based on their size.  2% agarose (w/v) gels were 
prepared by dissolving agarose in 1x TAE buffer by heating in the microwave. 
Ethidium bromide was then added to the cooled agarose-TAE solution and the 
solution was poured into a gel form and allowed to set. Once the gel was 
formed, it was placed in the electrophoresis tank and submerged in 1x TAE 
buffer. 20ul of the PCR products were mixed with loading buffer and loaded into 
the gel. A DNA ladder, a molecular weight marker which contains DNA 
fragments of known sizes, was also loaded into the gel, alongside with the PCR 
products. An electric voltage of 100V was applied for 45 -60 minutes. The PCR 
products were visualised using ChemiGenius II BioImager (Syngene, 
Cambridge, UK). 
Sanger sequencing : Once the PCR products were shown to be present and at 
the correct size, the remainder of the PCR products were sent to Geneius 
Laboratories, UK, for Sanger Sequencing using the same primers that were 
used for amplification of the DNA fragments. 
2.3.4.2 PCR cDNA amplification for Sanger Sequencing  
Primer design, amplification of cDNA for Sanger sequencing for the novel defect 
of IFN signalling study by PCR, visualisation of PCR products by gel 
electrophoresis and Sanger sequencing was done as described in Section 
2.3.4.1(above). A list of primers is shown in the Section 2.2(Table 2.6). 
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2.3.4.3  Real time PCR 
Real time PCR was used to test for the expression of TET genes in control B 
cells and to validate the microarray transcriptional analysis of the patient and 
control B cells in the study of novel defect of autoimmune lymphoproliferative 
syndrome. This method measures mRNA expression relative to a housekeeping 
gene and relies on a fluorescent probe that binds to a short target sequence 
between the PCR primers.  The oligonucleotide primers and matching Universal 
Probe Library probe were designed using Universal Probe Library Assay Design 
Centre software (http://lifesciences.roche.com). The oligonucleotide primers 
(Section 2.2 (Table 2.7) ) were purchased from Sigma Aldrich, UK. Each of the 
universal probes incorporates a fluorophore at the 5’ end and a quencher 
molecule the 3’ end. When Taq polymerase encounters the probe bound to its 
target DNA, Taq displaces and degrades the probe, resulting in dissociation of 
the fluorophore from the quencher. The resulting fluorescence is therefore 
directly proportional to the amount of product produced in the PCR reaction.  
Method : Real time PCR was done with cDNA that was synthesised as 
described in Section 2.3.3.2. 4.5ul of cDNA (diluted 1:5 in H2O for all genes 
except 18S, which was diluted 1:100) was added into a Fast optical 96-well 
reaction plate. Then, 5ul/well of Taqman Fast Universal PCR master mix was 
added along with 0.2ul/well of each forward and reverse primers (final 
concentration of 10uM each) and 0.1ul/well of probe (final concentration of 
150nM) making a total volume of 10ul. This was subjected to PCR cycling 
(500C for 2 minutes, 950C for 10 minutes and 40 cycles of 950C for 15 seconds 
and 600C for 1 minute) on ABI 7900HT Fast Real Time PCR system. 
Data analysis: The expression of each gene was normalised to the expression 
of 18s rRNA. Data was expressed in the 2-ΔCt format, where ΔCt = Ct (target ) 
– Ct (18s). Ct (cycle threshold) value is described  as the number of cycles 
required for the fluorescent signal to cross the threshold and Ct levels are 
inversely proportional to the amount of target nucleic acid in the sample. 
Statistic : Statistical analysis and graphing of data was performed with Prism 4.0 
software ( GraphPad Software, USA).  
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2.3.5  Western blot 
Western blotting (also known as Immunoblotting) is a widely used technique for 
detection of specific proteins in a sample. This technique involves three 
elements to complete the task: 1) through gel electrophoresis, proteins 
contained within a sample are separated according to their molecular weight; 2) 
the proteins are transferred onto a solid support such as polyvinylidene fluoride 
(PVDF) membrane; and 3) the targeted proteins are recognised by specific 
primary and secondary antibodies followed by a detection step. 
For the novel defect of IFN signalling study, Western blot was performed for the 
assessment of Interferon stimulated gene (ISG) upregulation and STAT2 
phosphorylation. 
For the novel defect of autoimmune lymphoproliferative study, this method was 
used to investigate TET2 protein expression in patients compared with controls.    
2.3.5.1 Preparation of lysates 
2.3.5.1.1 Extraction of nuclear protein 
Radioimmunoprecipitation (RIPA) buffer was used to extract TET2 as this 
protein is nuclear. RIPA buffer contains Sodium dodecyl sulphate (SDS, Sigma) 
and Sodium Deoxycholate (Sigma), both active constituents that are useful in 
disrupting the nuclear membrane for the preparation of nuclear extracts. Cells in 
T75 flask (80% confluence, roughly at 2 million cells) were removed by 
trypsinisation, as described before. Cells were washed once with cold PBS and 
pelleted by centrifugation at 600g for 5 minutes at 40C. Cell pellets were lysed in 
RIPA buffer (50mM Tris HCL (pH 7.5), 150mM Sodium Chloride, 0.5%(w/v) 
Sodium Deoxycholate, 0.1% (w/v) Sodium Dodecyl Cholate (SDS), 1% (v/v) 
NP-40, 1x complete protease inhibitor ) and left on ice for 45 minutes. The cells 
were then pelleted at 8000g for 3 minutes at 40C. Lysates were removed 
carefully from the cell pellet and transferred into a new Eppendorf tube. 100mM 
dithiothreitol (DTT,Sigma) and 1x NUPAGE loading buffer (Life technologies) 
were added to the lysates. 
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2.3.5.1.2 Extraction of whole cells lysate 
For the novel defect of IFN signalling study, lysis buffer that contains less strong 
denaturing detergents such as Triton X-100 was used to lyse the cells. 
Fibroblasts or PBMCs that were seeded and stimulated with IFNs in a 24-well 
plate were washed once with cold PBS. Cells were lysed on ice with lysis buffer 
( 20 mM Tris-HCL (pH 7.4), 150mM Sodium Chloride, 1% (v/v) Triton X-100, 5 
mM EDTA, 1x complete protease inhibitor, phosphatase inhibitor( Sodium 
Fluoride, Sodium Orthovanadate)) containing 100mM dithiothreitol (DTT,Sigma) 
and 1x NUPAGE loading Buffer (Life technologies). 
2.3.5.2 Protein Quantification 
To measure the concentration of proteins in cell extracts, a Pierce Bicinchoninic 
Acid (BCA) Assay (Pierce, Thermo Scientific) was used. Standards within the 
assay’s working range were prepared by diluting Bovine Serum Albumin (BSA) 
in PBS at concentrations of 0mg/ml, 0.2mg/ml, 0.4mg/ml, 0.6mg/ml, 0.8mg/ml 
and 1.0mg/ml. Standards and extracted samples were prepared in duplicate. 
10ul of each of standards and extracted samples were mixed with 150ul of 
Pierce Protein Assay reagent (Pierce, Thermo Scientific) in a 96-well plate and 
were prepared in duplicate. After 5 minutes of incubation at room temperature, 
absorbances were measured at 660nm using a Tecan sunrise microplate 
absorbance reader. 
A standard curve was generated by plotting the absorbance measurement of 
each BSA standard against its concentration. The standard curve was used to 
determine the protein concentration of the extracted samples.  
2.3.5.3 Immunoblotting 
After the lysates were heated at 900C on hot block for 10 minutes, equal 
amount of lysates were loaded and subjected to 4-12% Tris-Glycine 
Polyacrylamide gel electrophoresis (Novonex, Life Technologies) in 1x Sodium 
Dodecyl Sulphate (SDS) NuPAGE MOPS Running Buffer (Life Technologies) at 
a constant voltage of 160V between 1 ½ and 2 hours. 5ul of pre-stained Ladder 
(Thermo Scientific, Life Technologies) was used as the size marker. After 
electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Thermo Scientific Pierce, Life Technologies) in NuPAGE Tris - 
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Glycine Buffer (Life Technologies). The membrane was then blocked with 5% 
(w/v)  Bovine Serum Albumin or  5% milk in Tris Buffered Saline- 0.1% 
Tween(TBS/T) for 1 hour at room temperature, followed by incubation with anti-
human primary antibodies for overnight at 40C. The blots were then washed 
three times with TBS/T and incubated with appropriate Horseradish Peroxidase 
(HRP)-conjugated secondary antibodies in 5% (w/v) milk in TBS/T for 1 hour at 
room temperature. After washing the blots three times, the blots were 
developed with ImmobilonTM Western Chemiluminescent HRP substrate 
(Millipore) according to the manufacturer’s instruction. The Chemiluminescent 
images were captured on a G:BOX Chemi (Syngene, India) using GeneSnap 
Software (Syngene). A list of primary antibodies and secondary antibodies used 
in WB is available in Section 2.2 (Table 2. 3) 
 
2.3.6 Immunofluorescence Microscopy 
Immunofluorescence is a microscopy based technique that is used to assess 
the localization and endogenous expression levels of the protein of interest. 
This technique utilizes fluorescent-labelled antibodies to detect specific target 
antigens (Odell and Cook, 2013). There are two techniques in 
Immunofluorescence including 1) direct Immunofluorescence which uses a 
single antibody that is conjugated to a fluorescent dye, and 2) indirect 
Immunofluorescence utilizing a two-step technique in which in the first step a 
primary antibody recognizes and binds to the target biomolecules, followed by 
the detection of the primary antibody by a fluorescent-labelled secondary 
antibody. For the assessment of 5hmC level in the recombinant system in the 
novel defect of autoimmune lymphoproliferative study, the indirect 
immunofluorescence technique was used.  
Method : HEK293 T cells were transfected as described in Section 2.3.1.6. After 
48 hours of transfection, cells were fixed with 4% paraformaldehyde in PBS for 
15 minutes and permeabilised with 0.2% of Triton-X in PBS for 15 minutes at 
room temperature (RT). Subsequently, to reveal the epitope, the cells were 
incubated with 2M HCl at RT for 30 minutes and neutralized with 100mM Tris-
HCl buffer (pH 8.0) for 10 minutes. The cells were washed with PBS for 2 times. 
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For blocking, the cells were treated with 1%BSA, 0.05% Tween-20 in PBS for 1 
hour at RT. Then, a rabbit monoclonal anti-5-hmC antibody (1:1000 dilution, 
Active Motif, UK) and a mouse monoclonal anti-Flag antibody (1:500 dilution, 
Sigma Aldrich, UK), were added into the blocking buffer overnight at 40C. The 
cells were washed 3 times with 1% Tween-20-PBS solution, after which an 
Alexa Fluor 488 goat anti-rabbit IgG antibody (1:500 dilution, Invitrogen, UK), 
and an Alexa Fluor 546 goat anti-mouse IgG antibody (1:500 dilution, Invitrogen, 
USA) were added in blocking buffer for 1 hour at RT in the dark. The cells were 
stained with 4’,6-diamidino-2-phenylindole (DAPI) and mounted with 
VectaShield reagent. Images were obtained with Zeiss AscioImager 2 
microscope using Asciovision 4.8 software. 
2.3.7 TET2 wild type plasmid cloning 
For the study of novel defect of the autoimmune lymphoproliferative syndrome, 
a recombinant system was used in which a TET2 WT and mutant construct 
were overexpressed in cell lines such as HEK293 T cells to investigate the 
effect of TET2 mutation on its functional activity. To perform this, TET2 WT 
plasmid was generously given by Dr Skirmantas Kraucionis and his PhD 
student, Melania Zauri from Oxford University, UK. The next step was to 
replicate the WT TET2 plasmid for further experiments.  
2.3.7.1 Preparation of Luria-Bertani (LB) Broth/ Medium 
LB Broth was prepared by dissolving 5.15g of Mixed LB Broth Powder, 
containing Tryptone, NaCl and Yeast Extract (Sigma Aldrich, USA) in 250 ml of 
dH2O. The LB Broth was autoclaved, allowed to cool and stored at room 
temperature prior to use. 
LB plates were prepared by dissolving 5g of Bacto Agar in 250ml LB Broth. 
After autoclaving, the LB agar was left at room temperature to allow it to cool 
and 100ug/ml of ampicillin was added. The LB agar was then poured into petri 
dishes (working around the flame of a penunu bunsen). The LB agar was 
allowed to set and dry. Plates were stored in up-side position at 40C until further 
used.  
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2.3.7.2 Transformation into competent cells 
Transformation is the process of getting the plasmid DNA into the competent 
bacteria cells. Competent cells are cells that have the ability to take up free, 
extracellular genetic material. A common strain of competent bacteria used is 
E.Coli. In order to select transformed cells, plasmids have a selection marker 
such as an antibiotic resistance gene so that only cells containing the plasmid 
will be able to grow in medium containing the respective antibiotic. Furthermore, 
plasmids have an origin of replication allowing for independent replication within 
the bacterial cell. 
Method : The WT TET2 plasmid  was received on filter paper and dissolved in 
sterile dH2O. 1ul of dissolved plasmid DNA was added to 50ul of NEB 5-alpha 
competent E.Coli cells (New England, BioLabs, USA). The mixture was 
incubated on ice for 30 minutes. The mixture was heat shocked at 420C water 
bath for 30 seconds, followed by incubation on ice for 2 minutes. 250ul of Super 
Optimal Broth with Catabolic repression (SOC) medium was added and the 
mixture was placed in a 370C shaker for 60 minutes at 250 rpm. While waiting, 
the LB agar plate was warmed in a 370C incubator.  Following this, the mixture 
was centrifuged at 13000 rpm and the cells were pelleted. 250ul of the 
supernatant was discarded and the pelleted cells were resuspended in the 50ul 
remaining supernatant. The cells were plated on LB-ampicillin agar plates and 
incubated in upside down position in 370C incubator overnight. 
2.3.7.3 Purification of Plasmid DNA 
Next day, several colonies were selected from the LB-ampicillin agar plate and 
each colony was grown in 5ml of LB Broth, containing 100ug/ml of ampicillin. 
The colonies were incubated in 37°C shaker for 5hours. Following this, the 
colonies were then transferred into 100ml of LB Broth with 100ug/ml of 
ampicillin and grown in 370C shaker overnight. Purification of plasmid DNA was 
performed using the PureYieldTM  Plasmid Midiprep system (Promega, USA) 
according to the manufacturer’s protocol. The purified DNA was quantified using 
Nanodrop 2000 Spectrophotometer and kept in -200C. 
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2.3.8 Site Directed Mutagenesis 
To investigate the effect of TET2 mutation on its functional activity in the novel 
defect of autoimmune lymphoproliferative syndrome study, mutant TET2p.H1382R 
plasmid was generated from TET2 WT plasmid, described in Section 2.3.6, by 
QuikChange II XL Site-Directed Mutagenesis (SDM) kit. This method is used to 
introduce a specific point mutation or other intentional changes to a DNA 
sequence. This method is a PCR-based technique that requires synthetic 
primers which contain the desired mutation and are complementary to the 
template DNA around the mutation site to allow it to hybridize to the DNA of the 
gene of interest during PCR reaction. The single stranded primers are extended 
during temperature cycling by Pfu Ultra HF DNA Polymerase, which copies the 
rest of the DNA. Thus, this generates a mutated plasmid containing staggered 
nicks. Following temperature cycling, Dpn 1 endonuclease is added to digest 
the parental DNA. The mutated plasmid is then transformed into ultracompetent 
cells and cloned.  
Method: The detailed procedure of QuikChange II XL Site-Directed 
Mutagenesis (SDM) is as follows : 
1. Mutant strand synthesis 
Firstly, sense and antisense primers were designed using Primer3 Plus 
software (http://primer3plus.com) which incorporated the desired mutation into 
the sequence. 
Sense primer : 5’ – ttctgtgctcatgcccgcagagacttgcacaac - 3’ 
Antisense primer : 5’ – gttgtgcaagtctctgcgggcatgagcacagaa – 3’ 
 
To synthesise the mutant, TET2 WT plasmid (DNA template) was mixed with 
QuikChange II XL Site-Directed Mutagenesis (SDM) reagents listed in Table 
2.11. PCR reactions were performed in a thermal cycler as described in Table 
2.12. 
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Reagents 
 
One reaction (51ul) 
10x Buffer 5 ul 
Sense primer X ul (125ng) 
Antisense primer X ul (125ng) 
dNTP mix 1 ul 
DNA template X ul (200ng) 
QuikSolution 3 ul 
ddH2O To a final volume of 50ul 
Pfu Ultra HF DNA Polymerase 1 ul 
Table 2.11 : SDM reagents.  
 
Segment Cycles Temperature Time 
1 1 950C 1 minute 
2 18 950C 50 seconds 
600C 50 seconds 
680C 13 minutes 19 seconds 
(1 minute/kb of plasmid 
length) 
3 1 680C 7 minutes 
Table 2.12: PCR reactions 
 
2. Dpn 1 Digestion of template 
Following the PCR reaction, the reaction tubes were placed on ice for 2 minutes, 
to cool the reactions to 370C. 1ul of Dpn 1 restriction enzyme was added to the 
reaction tubes and incubated at 370C for 1 hour. 
3. Transformation into Ultracompetent cells 
45 ul XL10-Gold ultracompetent cells were thawed on ice and mixed with 2ul of 
β-ME mix provided with the kit. The mixture was incubated on ice for 10 minutes. 
4ul of Dpn 1-treated DNA sample  was added  the ultracompetent cells and 
incubated on ice. The mixture was heat shocked in 420C water bath for 30 
seconds, followed by incubation on ice for 2 minutes. Then, 250 ul of Super 
Optimal Broth with Catabolic repression (SOC) medium was added to the 
mixture and incubated in a 370C shaker at 225 rpm for 1 hour. Finally the cells 
were plated and cloned on LB-ampicillin agar plate in 370C incubator overnight.  
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4. Purification of mutated plasmid DNA 
Between 5-10 colonies were picked from the LB-ampicillin agar plate and each 
colony was grown in 5ml LB – ampicillin broth overnight in 370C shaker. The 
mutated plasmid DNA was extracted using the QIAprep Spin MiniPrep Kit 
(Qiagen, UK) according to manufacturer’s protocol. The extracted DNA was 
quantified using Nanodrop 2000 Spectrophotometer. 
5. DNA sequencing 
DNA sequencing was performed by Geneius Laboratories, Uk, to confirm that 
the selected DNA contains the desired mutation. The sequencing was 
performed using the following primers : 
Forward primer : 5’ – TGAACACAGAGCACCAGAGTG – 3’ 
Reverse primer : 5’ – ACGTGATGGGGCTGACTTTT – 3’ 
                                                                                                                                                                                                                                                              
2.3.9 Fas-mediated apoptosis assay for mouse B cells 
For the study of novel defect of autoimmune lymphoproliferative syndrome, a 
Fas-mediated apoptosis assay was performed using mouse B cells, to 
investigate the effect of TET2 mutation on Fas-mediated apoptosis pathway. 
2.3.9.1 Cells culture for mouse cells 
Mouse spleen was dissected from the body using aseptic technique. This was 
performed by Dr Consuelo Anzilotti, Oxford University. The splenocytes were 
removed from the spleen by mashing the spleen using the plunger end of the 
syringe through a 100um cell strainer into a 60mm petri dish. The cells were 
removed into a centrifuge tube and centrifuged at 600g for 5 minutes at 40C. 
The cells were washed once and counted (method described in Section 2.3.1.5). 
Splenocytes were seeded at 1x 106cells/ml in 48-well plates in RPMI media 
supplemented with 10% FCS, L-Glutamine, 1x Penicillin/Streptomycin, 50uM β-
ME, Na Pyruvate and 1x non-essential amino acids. 
2.3.9.2 Cells stimulation with soluble Fas Ligand (sFasL) 
The cells were then simulated with a soluble Fas Ligand set (Enzo Lifesciences, 
US) including enhancer ligands, to enhance the apoptosis activity. The cells 
were stimulated with different concentration of sFasL as follow (Table 2.13). 
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Cells were also stimulated with staurosporine (10uM,Sigma Aldrich, UK) as 
positive control. 
sFasL concentration 
 
Enhancer concentration 
100ng/ml 0.5ug/ml 
50ng/ml 0.5ug/ml 
25ng/ml 0.5ug/ml 
0ng/ml 0ug/ml 
Table 2.13: sFasL and enhancer ligands concentration 
The cells were incubated overnight in a 370C incubator. 
2.3.9.3 Annexin V/ PI staining 
For cell death and apoptosis detection, the FITC Annexin V Apoptosis Detection 
Kit I (BD Biosciences, UK) was used according to manufacturer’s protocol. 
Briefly, the cells were collected and pelleted by centrifugation at 600g for 5 
minutes at 40C. The cells were washed twice with cold PBS. The cells were 
stained as described (Table 2.14) in 100 ul of 1x Annexin V Binding buffer for 
15 minutes in the dark at room temperature. 
Antibodies 
 
Volume Detection 
FITC Annexin V  5ul Apoptotic cells 
Propidium Iodide (PI) 5ul Dead cells 
CD19 (Biolegend) 0.5ul B cells 
Table 2.14: Antibodies that were used for apoptosis, cells death and B cell 
detection. 
Then, 400ul of 1x Annexin V Binding buffer was added to the tubes. Data 
acquisition was performed using BD FACs Canto II flow cytometer (BD 
Biosciences) and the output data was analysed by FlowJo 7.0 (Treestar, USA).  
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2.3.9.4 Statistics 
Statistical analysis and graphic data was performed as described in Section 
2.3.4.3. Two way Anova analysis was used to compare the apoptosis 
differences between wild type and knock out mouse B cells. P value less than 
0.05 (< 0.05) was considered as significant.
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Chapter 3: A novel defect in the Type 1 IFN signalling pathway 
3.1 Introduction 
Primary Immunodeficiencies that predispose individuals to severe viral 
infections have been identified and present either as isolated susceptibility to 
specific viruses or susceptibility to multiple viruses in addition to disease with 
other microbes (Dropulic and Cohen, 2011). IFNs are the first line of defence 
against viruses. IFNs achieve their various biological responses by inducing the 
expression of hundreds of IFN-stimulated genes (ISGs) (Platanias, 2005). Type 
I IFN is known to be potent in interfering with viral infection (Perry et al., 2005). 
Type I IFN which consists of  IFNα/β  is induced by the detection of viral 
pathogen associated molecular patterns (PAMPs) by the pattern recognition 
receptors in infected cells. IFNα/β binds to its heterodimeric transmembrane 
receptor which is composed of two subunits, IFNAR1 and IFNAR2. This is 
followed by phosphorylation of JAK1 and TYK2, which in turn activate STAT1 
and STAT2 through phosphorylation (Platanias, 2005). Phosphorylated STAT1 
and STAT2 translocate to the nucleus and form together with IRF9 the 
heterotrimeric complex ISGF3, which binds to IFN-stimulated response 
elements (ISRE) and initiates transcription of the ISGs (Platanias, 2005). In 
addition, IFNAR signaling also leads to limited formation of phosphorylated 
STAT1 homodimers (also known as GAF) (Platanias, 2005).  Type II IFN, IFNγ, 
is the prototypical inducer of GAF; binding of IFNγ to IFNGR results in the 
activation of JAK1 and JAK2, causing STAT1 phosphorylation, and the resulting 
GAF translocates to the nucleus and binds to GAS elements in the regulatory 
region of IFN-γ-induced genes (Platanias, 2005). It should be noted that the 
engagement of IFNα/β to its receptor also causes phosphorylation of another 
STAT, STAT3, which indirectly suppresses pro-inflammatory gene expression, 
another known role of  Type 1 IFNs (Ivashkiv and Donlin, 2014).  
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Figure 3.1 : Type I and Type II IFN signalling pathway. Type I IFN, IFNα/β, 
binds to its receptor, IFNAR1 and IFNAR2, leading to phosphorylation of Tyk2 
and JAK1, which results in STAT1/STAT2 phosphorylation. Phosphorylated 
STAT1 and STAT2, together with IRF9, form ISGF3, in the nucleus and binds to 
ISRE, leading to transcription of ISGs. STAT1-STAT1 homodimers translocate 
into the nucleus and bind to GAS. STAT3 homodimers translocate into the 
nucleus and bind to GAS, which suppresses pro-inflammatory gene expression. 
Type II IFN, IFNγ, binds to IFNGR, leading to JAK1/2 phosphorylation,  resulting 
in phosphorylation of STAT1 and formation of STAT1 homodimers. STAT1 
homodimers then binds to GAS elements in the nucleus. 
 
Many mouse knock out models were generated in order to study the role of 
Type I IFN signalling in antiviral immunity. IFNAR1 (Muller et al., 1994), IFNAR2 
(Muller et al., 1994), STAT1 (Durbin et al., 1996) and STAT2 (Park et al., 2000) 
knock out mouse models were shown to have marked susceptibility to viral 
infection, suggesting the essential and non-redundant role of Type I IFN in 
antiviral defence mechanisms. However, it has been difficult to validate this in 
humans. Primary Immunodeficiency Diseases provide the opportunity to learn 
about the significance of specific genes and pathways in humans. As mentioned 
in chapter 1, deficiencies of STAT1, TYK2 and STAT2 are known PIDs that 
impair Type I IFN signalling. These recognised PIDs provide information for 
understanding the role of IFNα/β in human antiviral immunity. 
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In this chapter, I will describe the identification of a novel defect in the Type I 
IFN signalling pathway in a previously healthy patient who presented with fatal 
illness after receiving the MMR vaccine. MMR vaccine is a live-attenuated 
combined vaccine that is given intramuscularly to protect from illnesses of 
measles, mumps and rubella. MMR is a safe vaccine and is administered widely 
to children around the world. The common mild side effects of MMR vaccine are 
swelling at the injection site, rash and general feeling of being unwell. Rare side 
effects such as seizures can also occur.  However, a severe illness leading to 
death of the patient is vanishingly rare and strongly suggests underlying 
immunodeficiency. Previously, we described a patient with disseminated 
vaccine-strain measles, who had a STAT2 mutation which caused profoundly 
defective Type 1 IFN signalling (Hambleton et al., 2013) (albeit several STAT2-
deficient individuals had mild phenotypes and led a relatively healthy life). By 
analogy, we considered that the current patient’s susceptibility to live attenuated 
vaccine viruses indicated an underlying problem in the Type 1 IFN pathway.  
3.2 Hypothesis 
Enhanced viral susceptibility in a patient with fatal encephalitis following MMR is 
caused by a defect of type 1 IFN signalling. 
3.3 Aims 
To identify the putative disease-causing mutation(s) and associated molecular 
mechanism of viral susceptibility in the patient. 
3.4 Results 
3.4.1 Clinical case 
The proband was well until he received a first dose of a live-attenuated MMR 
vaccine at 13 months old. Six days after his vaccination, he was admitted to 
hospital with a complaint of swelling at the vaccination site, fever, irritability and 
generalized morbilliform skin rash. He was thought to suffer from common 
complications of post-MMR vaccination but was treated with antibiotics for 
possible cellulitis. The patient had received all the routine childhood 
immunizations such as BCG and oral live attenuated rotavirus without 
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complication. His condition improved and he was discharged home, but 
readmitted on day 15 due to fever, misery, prominent purulent tonsillitis and 
widespread erythematous rashes. Investigations showed mild anaemia, 
lymphopenia, hepatitis and small pericardial effusion. He was suspected of 
Kawasaki’s disease which was excluded later after his angiography showed 
normal coronary arteries.  
While in the ward, at day 21 after first presentation, he developed seizure 
activity that was highly refractory to medical management. Brain MRI was 
performed and demonstrated bilateral hippocampal abnormalities, suggestive of 
meningeal inflammation. He was transferred to the paediatric intensive care unit 
for intubation and ventilation, and was treated with intravenous Immunoglobulin 
followed by high dose of corticosteroid for a suspected 
autoimmune/autoinflammatory disorder. Later on, his condition improved 
somewhat and he was extubated at day 30; however, he did not recover 
neurologically, showing persistent encephalopathy and temporal lobe seizure 
activity. His condition appeared to worsen and he became systematically unwell, 
with fever, hepatosplenomegaly, worsening rash and electrolyte disturbances. 
Bone marrow aspirate confirmed the diagnosis of Haemophagocytic 
Lymphohistiocytosis (HLH), a dysregulated immune response to his persistent 
viral infection. At this stage, the patient was supported with palliative care and 
subsequently, he died on day 81.  
Throughout the period, thorough investigations were carried out to establish the 
diagnosis. Standard immunological testing was taken at day 21 and was shown 
to be normal (Table 3.1). 
Parameter Result Normal range 
Immunoglobulins (g/L) 
IgG 5.52 3.1-13.8 
IgA 0.35 0.3-1.2 
IgM 1.86 0.5-2.2 
Leucocytes (109/L): 
Total  7.7  6.0-18.0 
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Lymphocytes 3.6  
Neutrophils 2.0  
Monocytes 1.3  
Eosinophils 0.8  
Basophils 0.0  
Bone marrow trephine: 
Myelopoesis Normal  
Megakaryocytes Normal  
Lymphocytes (cells/L): 
T cells 1683  1200 – 3000 
CD4 1229 850 – 1800 
Naïve CD4+ T cells 56 % N/A 
CD8 436 650 – 1500 
B cells 349 600 – 1300 
NK cells 260 180 – 600 
Table 3.1: Patient immunological parameters.  Standard immunological 
testing was normal in the patient. NK cells = Natural killer cells. N/A= Not 
available 
Human Herpes Virus 6 (HHV6) was detected consistently at similar levels 
throughout the illness in nasopharyngeal aspirate, plasma, oral fluid and CSF 
by PCR (Table 2). Measles (confirmed as genotype A vaccine-strain), rubella 
and mumps viruses were detected by PCR on nasopharyngeal aspirate, oral 
fluid and plasma (Table 2). Mumps virus was also detected in the patient urine 
at day 29 (Table 3.2). 
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Day PCR detection Viral 
culture Measles Mumps Rubella HHV6 
20 NPA NPA NPA NPA ND 
21 Oral fluid, 
plasma  
(Vaccine 
genotype)  
 
Oral fluid, 
plasma  
(Vaccine 
genotype)  
Oral fluid Oral fluid,  
plasma 
NT 
23 ND NT NT CSF NT 
29 NT NT NT NT Mumps 
(urine) 
35 ND Serum, CSF NT Serum NT 
44 ND Plasma Plasma Plasma NT 
50 NPA Plasma,  NPA, swab,  
Plasma,  
NPA, swab,  
Plasma,  
ND 
Table 3.2 : Vaccine strain measles, mumps and rubella and HHV6 were 
detected by PCR or viral culture in the patient. NPA= nasopharyngeal 
aspirate, CSF= Cerebrospinal fluid, NT= Not tested, ND= Not detected. 
This occurred despite an appropriate serological response to MMR, with IgM 
and IgG to both measles and mumps and IgG to rubella (Table 3.3) 
. 
Day Sample Antibody isotype 
Measles Mumps Rubella 
21 Plasma IgM  IgM/IgG IgG 
30 CSF IgM  NT NT 
44 Serum IgG  IgM/IgG NT 
48 CSF IgM NT NT 
Table 3.3: Antibody response to measles, mumps and rubella. NT= not 
tested, ND=not detected 
Interestingly, viruses that commonly cause infection in humans such as EBV, 
VZV, enterovirus and CMV were not identified in any of the samples taken. As 
the patient had persistent encephalopathy and persistent temporal lobe activity, 
91 
 
brain biopsy was done on day 50 and confirmed histological appearances of 
viral encephalitis (Figure 3.2). 
 
Figure 3.2:Brain biopsy showed the histological appearances of  
meningoencephalitis. Cortical inflammatory cell nodular infiltrate (left) with 
marked microglial activation (CD45 staining, middle) and patchy dural 
inflammation (right). This work was performed and provided by Dr Thomas 
Jacques, Department of Histopathology, Great Ormond Street Hospital, London. 
 
In addition, vaccine-strain rubella and HHV6 were detected by PCR in cerebral 
cortex, arachnoid and dura as well as mumps in cerebral cortex; these results 
were confirmed by RNA sequencing carried out in the laboratory of Prof Judith 
Breuer. However, immunostaining for HSV1 and HSV2 were negative in the 
brain. Based on patient history and laboratory findings, it appeared highly likely 
that the fatal illness was due to the vaccine viruses mumps and rubella.   
Recently, the mother gave birth to a second child, P2, who is currently healthy 
with normal growth and development. 
3.4.2 Increased susceptibility to viral infection and lack of protection from 
IFNα in patient fibroblasts 
To investigate the apparently increased susceptibility to viral infection, a viral 
plaque assay was performed on a cell monolayer, comparing the ability of 
patient and control fibroblasts to support viral plaque formation in vitro. Viral 
plaques are localized areas of cells killed by the replication of a viable virus 
(Mocé-Llivina et al., 2004). This work was done by Professor Richard Randall’s 
lab, St. Andrews University. Patient and control fibroblasts were infected with 
highly attenuated recombinant strains of Parainfluenza Virus 5 (PIV5ΔC) and 
Bunyamwera virus (BUNΔNSs). Because these viruses lack defined functional 
IFN antagonists, the IFN system is readily upregulated in normal cells and 
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protects against viral replication. Thus, few viral plaques were formed on control 
fibroblasts. 
 
Figure 3.3 Increased susceptibility to viral infection in patient fibroblasts. 
Patient and control fibroblasts were infected with PIV5ΔC and BUNΔNSs 
viruses. Plaques were visualized by immunostaining. Figure was provided by 
Professor Richard Randall, St. Andrews University. 
 
However, in patient cells, there was formation of large plaques of PIV5ΔC and 
BUNΔNSs, suggesting a complete failure of the type 1 IFN response in the cells 
(Figure 3.3). To investigate whether patient cells were able to develop an 
antiviral state in response to exogenous IFNα, the cells were infected with 
Parainfluenza virus 5 (PIV5) and the viral replication was visualized by 
immunofluorescence. This work was also done by Professor Richard Randall’s 
lab, St. Andrews University. This time, wild type viruses were used for the 
experiment, meaning that the viruses were able to interfere with the IFN 
response. Therefore exogenous IFNα was added so that IFN response is 
induced in the cells and it is anticipated that the cells will be protected against 
viral replication. 
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Figure 3.4: Lack of protection from IFNα in patient fibroblasts. Patient and 
control fibroblasts were untreated or treated with IFNα for 15 hours before 
infection with PIV5. At 48h.p.i, virus-infected cells were visualized by 
immunofluorescence. Figure was provided by Professor Richard Randall, St. 
Andrews University. 
 
Control cells were protected by IFN against viral replication, whereas patient 
cells demonstrated a remarkable lack of protection, being unable to develop an 
antiviral state even in the presence of exogenous IFNα. This result showed that 
the cellular response to IFNα is defective in patient cells (Figure 3.4).  
3.4.3 Failure of ISG upregulation in response to IFNα in patient fibroblasts, 
despite preserved expression of STAT1 and STAT2. 
To understand this impaired IFN response, I next investigated whether antiviral 
ISGs such as MxA and ISG56 were upregulated in response to IFNα in patient 
fibroblasts. Both MxA and ISG56 are members of the viral stress-inducible 
genes which are strongly induced by Type 1 IFN (Haller et al., 2006). In addition, 
I also examined the integrity of STAT1 and STAT2, which are two of the 
components that form the heterotrimeric complex, ISGF3. Patient and control 
fibroblasts were left untreated or treated with IFNα and protein expression was 
examined by Western Blotting. 
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Figure 3.5 : Failure of ISG upregulation in response to IFNα in patient 
fibroblasts despite preserved expression of STAT1 and STAT2 . Patient 
and control fibroblasts were analysed by Western Blotting using antibodies 
directed against the indicated proteins. The cells were left untreated (-) or were 
treated (+) with IFNα at the concentration of 100IU/ml overnight. GAPDH was 
used as loading control. Data are representative of two separate experiments.  
 
In the control cells, MxA and ISG56 proteins were upregulated, in contrast to 
patient cells, which completely failed to upregulate the ISGs (Figure 3.5), 
suggesting a defect within the Type 1 IFN signalling pathway. As for the ISGF3 
complex components, STAT1 and STAT2 were expressed in control and patient 
cells (Figure 3.5).   
3.4.4 Absence of antiviral transcriptional responses to IFNα and IFNβ but 
preserved transcriptional responses to IFNγ in patient cells 
As it was shown  that the antiviral response was impaired in patient cells, whole 
genome microarray analysis by Illumina HT-12 v4 Expression Ebead Chips was 
performed using RNA that was extracted from 3 technical replicates of patient 
and  3 different control fibroblast lines, to further support and determine the 
degree of the impaired antiviral responses. 
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Figure 3.6 : Absence of transcriptional responses to IFNα and IFNβ but 
preserved transcriptional response to IFNγ by microarray. (A) Principle 
Component Analysis (PCA) plot  of patient and control cells untreated 
(unstimulated) or treated with IFNα (Alpha), IFNβ (Beta) and IFNγ (Gamma) (B) 
Volcano plot of patient (right) and control (left) treated with IFNα (I), IFNβ (II) 
and IFNγ (III).  Shown in red are differentially expressed genes (>= 2 fold 
change up or down and p ≤ 0.01) in patient cells, n = 3 technical replicates and 
control cells, n = 3. Data was analysed using Lumi and Limma Bioconductor 
packages in R and performed by Andrew Skelton, Bioinformatics Unit, 
Newcastle University. 
 
All the samples that were used for the array were of high quality where the RNA 
Integrity Number (RIN) value was more than 9. RIN is measured using a 
Bioanalyzer (Agilent Technologies) which evaluates the integrity of the RNA 
samples using software algorithm (Schroeder et al., 2006). To make the 
samples comparable to one another, a normalization step was done through 
Variant Stabilising Transformation (VST) and Robust Spline Normalisation 
(RSN) in Lumi package. After normalization, principle component (PCA) plot 
(Figure 3.6(A)) was generated to summarise and visualise the variance of the 
samples. Principle Component Analysis 1 showed that in control cells that were 
treated with IFNα, IFNβ and IFNγ, the variance was large compared to 
untreated cells (Figure 3.6(A)). In contrast, patient cells that were treated with 
IFNα and IFNβ, were not transcriptionally different from untreated cells whereas 
in cells treated with IFNγ, there were large transcriptional differences compared 
to untreated cells (Figure 3.6(A)).  
To identify differentially expressed genes, a pairwise comparison was 
performed between IFN-treated and untreated cells (either control or patient), 
using a multi-level approach through Limma. The genes with an expression 
level that was changed ≥ 2 fold with p value ≤ 0.01 were considered as 
significantly differentially expressed genes. To visualize the significant 
differentially expressed genes, a volcano plot was generated for each 
comparison (Figure 3.6(B)). There were 157 and 230 upregulated genes in 
IFNα- and IFNβ- treated control cells, respectively, however, no changes in 
gene expression were observed upon IFNα or IFNβ treatment of patient cells 
(Figure 3.6(B)(I) & (II)). This result demonstrated the striking failure of 
transcriptional response to IFNα and IFNβ, consistent with all the results of the 
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impaired antiviral responses that were shown earlier.  Nevertheless, when 
treated with IFNγ, both control and patient showed 250 and 241 upregulated 
genes respectively (Figure 3.6(B)(III), indicating preserved transcriptional 
response to IFNγ in the patient.  
Detailed comparison revealed that both the identity of genes upregulated by 
IFNγ and the magnitude of their induction were similar between patient and 
control cells (Table 3.4).   
Genes 
Fold Change 
Control Patient 
IFNα IFNβ IFNγ IFNγ 
MX1 83.67944 94.74192 38.53125 31.58689 
IFIT1 56.96109 72.63143 7.10684 6.270381 
IFIT2 52.60496 92.00999 31.67814 21.61149 
ISG15 35.94936 39.67155 12.61514 17.57555 
OAS2 35.12103 40.8928 17.82121 19.83077 
IFIT3 32.62033 37.817 24.0788 15.24897 
MX2 28.74235 35.12128 5.080561 3.725809 
HERC6 23.9643 28.6527 6.603215 5.31487 
OAS1 23.94958 28.11519 5.488271 4.314488 
IFI44L 23.88935 27.74313 12.97447 11.0865 
ISG20 23.72714 32.24204 4.512792 4.95057 
IFI6 22.56866 22.86152 8.543254 7.866593 
EPSTI1 19.8517 26.05893 17.12185 15.04604 
HERC5 19.236 27.88745 not upregulated not upregulated 
IFITM1 15.22598 17.27342 10.51996 14.07765 
IFI27 15.07486 16.89267 3.754558 4.442659 
IFI35 13.61686 16.62107 12.7105 10.75185 
IFI44L 12.86096 27.74313 12.97447 11.0865 
HELZ2 12.6438 16.53127 5.220394 5.332532 
TNFSF13B 12.254 19.79534 11.16043 9.546272 
IRF7 10.98105 15.16052 2.663317 2.18853 
TAP1 10.61389 13.20197 21.24851 22.4947 
RSAD2 10.48412 16.02325 3.736038 not upregulated 
OAS3 10.37657 14.21979 3.779401 4.473941 
OASL 9.965741 15.76712 not upregulated not upregulated 
XAF1 9.931357 12.34975 3.314304 2.659994 
IDO1 9.719625 11.37384 120.0388 118.1495 
SLC15A3 9.474831 11.98493 8.499544 8.671811 
GBP1 9.257324 12.26308 33.97603 29.44939 
PARP9 8.784777 9.676822 6.275462 6.554662 
IL18BP 8.631514 10.92923 27.61209 33.65494 
IFIH1 8.276362 12.88486 4.676429 3.856069 
CXCL10 8.160909 17.18051 24.64496 9.302818 
RNF213 7.944793 10.41398 5.935499 5.377577 
TYMP 7.82178 9.435624 2.568863 3.518993 
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DDX58 7.792168 11.37879 2.106979 not upregulated 
WARS 7.618849 9.848175 19.98488 16.02173 
UBE2L6 7.440798 8.243137 6.181831 6.183141 
Table 3.4 : 40 highest upregulated ISGs in IFNα-stimulated control 
fibroblasts  and extent of induction by alternative IFNs or in IFNγ-treated 
patient fibroblasts. The genes were identified from the significant differentially 
expressed genes (>= 2 fold change and p ≤ 0.01) from IFNα, IFNβ and IFNγ - 
treated fibroblasts of controls and patient. 
 
As expected, the most strongly upregulated genes in IFNα- and IFNβ-treated 
control cells were the known classical IFNα/β ISGs such as Mx1, IFIT1, IFIT2, 
ISG15 and OAS2 (Table 3.4) (Liu et al., 2012). Interestingly, it was also shown 
that many ISGs that are upregulated in IFNα- and IFNβ-treated control cells are 
also upregulated in IFNγ-treated control and patient cells. However the extent of 
upregulation was less in IFNγ-treated control and patient cells compared to 
IFNα-treated control cells. This result demonstrated that IFNγ, although partially, 
also activates similar ISGs as IFNα, with likely relevance to its antiviral effects. 
3.4.5 Absent phosphorylation of STAT1, STAT2 and STAT3 in response to 
IFNα but intact STAT1 phosphorylation in response to IFNγ 
To localize the defect of the type 1 IFN signalling pathway, I stimulated patient 
and control cells with IFNα and analysed the phosphorylation of STAT1, STAT2 
and STAT3 by Western blotting. 
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Figure 3.7 : Absence of STAT1, STAT2 and STAT3 phosphorylation in 
response to IFNα in patient fibroblasts. Control and patient cells were 
untreated (0 min) or treated with IFNα (1000IU/ml) for 15, 30, and 60 minutes. 
The cells were analysed by Western blotting using antibodies directed against 
pSTAT1 Tyr701, STAT1, pSTAT2 Tyr689 , STAT2, pSTAT3 Tyr705 and STAT3. GAPDH 
was used as loading control. Data are representative of 3 experiments. Figure 
of STAT1 phosphorylation and total STAT1 shown was by Dr Christopher 
Duncan, Newcastle University. 
  
Upon stimulation with IFNα at different time points, control cells showed 
phosphorylation of STAT1, STAT2 and STAT3 whereas in patient cells, no 
phosphorylation was observed despite similar levels of total STAT1, STAT2 and 
STAT3 (Figure 3.7). The failure of STAT1, STAT2 and STAT3 phosphorylation in 
patient cells indicated a defect upstream of STAT phosphorylation in the IFNα 
signalling pathway, which includes IFNAR (1 and 2), JAK1 and TYK2. JAK1 
phosphorylation can also occur in the IFNγ signalling pathway where it leads to 
STAT1 phosphorylation and results in the transcription of GAS-element 
containing genes in the nucleus (Platanias, 2005).  To investigate whether the 
causative variant is in JAK1, I therefore stimulated control and patient cells with 
IFNγ and observed STAT1 phosphorylation by Western blotting. 
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Figure 3.8 : Preserved STAT1 phosphorylation in response to IFNγ in 
patient fibroblasts. Control and patient cells were left untreated (0) or treated 
with IFNγ for 15, 30 or 60 minutes. The cells were lysed and analysed by 
Western Blotting using antibodies directed against total STAT1 or pSTAT1 Tyr701. 
GAPDH was used as loading control. Data shown are representative of 3 
independent experiments.  
 
In contrast to IFNα, STAT1 phosphorylation was normal in patient fibroblasts 
upon stimulation with IFNγ (Figure 3.8).  This finding appears to exclude JAK1 
as harbouring the causative variant (Figure 3.9). 
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Figure 3.9 : Localization of the causative genetic lesion to IFNAR1, 
IFNAR2 or TYK2. JAK1 phosphorylation occurs through the binding of IFNγ to 
IFNγ receptors and results in the formation of GAF and transcription of GAS 
genes in the nucleus. JAK1 is excluded as the disease causative mutation due 
to preserved STAT1 phosphorylation in response to IFNγ ( ). Failure of 
upregulation of ISGs (     ) and absence of STAT1, STAT2, STAT3 
phosphorylation (      ) in response to IFNα in patient cells suggests the disease 
causing variant that affects the protein is upstream of STATs , excluding JAK1 
in the IFNα signalling pathway. 
 
3.4.6 Homozygous deletion in exon 5 of IFNAR2 
By excluding JAK1, I reasoned that the putative genetic lesion(s) must affect 
IFNAR1, IFNAR2 or possibly TYK2, which encode the molecules upstream of 
the STATs in the IFNα signalling pathway.  To investigate this I performed 
Sanger sequencing of IFNAR1, IFNAR2 and TYK2 using PCR-amplified patient 
cDNA as template.  
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Figure 3.10: Deletion of A311 (c.A311del) in exon 5 in IFNAR2 gene using 
patient cDNA. (A) Amplification of IFNAR2 gene using three pairs of primers 
(1- pair 1, 2- pair 2, 3-pair 3) by PCR in control (C) and patient cDNA (P) and 
visualisation by agarose gel electrophoresis. (B) Sequences of patient cDNA 
compared to control revealed A311del of IFNAR2, resulting in frameshift 
mutation, p.E104fs110x. 
 
By comparing and aligning patient sequences to healthy controls from public 
databases of genomic variation such as dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and Ensembl release 78 
(http://www.ensembl.org), no variants were observed in IFNAR1 or TYK2. 
However, there was a rare single nucleotide deletion identified in patient cDNA 
that was amplified and sequenced using primer pair 2 of IFNAR2 (Figure 3.10). 
This single base deletion is in exon 5 at position c.A311. To confirm the deletion, 
I sequenced the same region in patient genomic DNA. 
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Figure 3.11 :  Homozygous deletion of A311 in exon 5 of IFNAR2 gene in 
patient and heterozygous deletion of A311 in both father and mother 
genomic DNA (gDNA). (A) Amplification of IFNAR2 gene, targeted in exon 5 by 
PCR in control (C), patient (P), father (F), mother (M) and visualisation by gel 
electrophoresis. (B) Sequences of patient, father, mother gDNA. 
 
By sequencing of IFNAR2 exon 5, I confirmed that the deletion was 
homozygous in patient genomic DNA (Figure 3.9). To investigate whether both 
parents are carriers for the deletion, I sequenced both mother’s and father’s 
genomic DNA. The sequencing confirmed that both parents were heterozygous 
for the deletion (Figure 3.11). The homozygous c.A311del caused a frameshift 
mutation of glutamic acid to glycine at position 104 in the predicted protein 
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product, resulting in a premature stop codon, six amino acids after the mutation 
(p.E104Gfsx6). This variant was therefore predicted to be disease-causing.  
3.4.7 Absence of IFNAR2 protein expression in patient fibroblasts 
The human IFNAR2 gene is spliced into three isoforms (short, soluble and long) 
by exon skipping, alternative splicing and differential usage of polyadenylation 
sites (de Weerd et al., 2007). The position of the premature stop codon created 
by c.A311del, p.E104Gfsx6 is predicted to affect all three isoforms of IFNAR2, 
with loss of the transmembrane and cytoplasmic domains as well as much of 
the extracellular domain (figure 3.12(A)). To confirm the expected loss of 
IFNAR2 protein expression, Western blotting was performed using an antibody 
directed against the C-terminus of IFNAR2.   
 
 
Figure 3.12: Absence of IFNAR2 protein expression in patient fibroblasts. 
(A) c.A311del results in truncated IFNAR2 protein affecting all three isoforms of 
IFNAR2. (B) Control and patient fibroblasts were left untreated (-) or treated (+) 
with IFNα (100IU/ml) overnight. IFNAR2 protein expression was analysed by 
Western blotting using an antibody directed against the C-terminus of IFNAR2. 
GAPDH was used as loading control. This experiment was performed by Dr. 
Christopher Duncan, Newcastle University. Data is representative of three 
independent experiments. 
 
In keeping with the loss of the full length protein, by immunoblotting against C-
terminus of IFNAR2, it was shown that IFNAR2 was completely absent in 
patient, in contrast to control fibroblasts where IFNAR2 protein expression was 
normal irrespective of IFNα treatment (Figure 3.12(B)). The absence of IFNAR2 
protein in patient cells was consistent with the observed failure of IFN signalling 
and antiviral response.  
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3.4.8 Reconstitution of IFNAR2 into patient fibroblasts restores IFNα/β 
responses 
From the sequencing, it is suggested that the disease causing variant is in 
IFNAR2. To prove that the loss of function of IFNAR2 was responsible for the 
impaired IFNα/β responses, patient fibroblasts were transduced with wild type 
IFNAR2 by lentiviral transduction (Figure 3.13(A)) and assessed for STAT1 
phosphorylation as well as the upregulation of ISGs, ISG56 and MxA in 
response to IFNα. The commercially obtained lentiviral particles encoded the 
full length open reading frame of human IFNAR2 transcript variant 1 
(NM_207585) under the control of the constitutive promoter EF1a, with a GFP-
Puromycin selection marker under an RSV promoter. Particles containing the 
vector backbone but which lacked the IFNAR2 insert were used as a negative 
control (denoted Null). 
 
Figure 3.13 : Complementation of IFNAR2 in patient fibroblasts restores 
responsiveness to IFNα. (A) IFNAR2 expression; (B) STAT1 phosphorylation 
in response to IFNα; (C) Upregulation of ISGs, ISG56 and MxA in response to 
IFNα. Patient cells were either untransduced (“patient”, transduced with null 
control (“patient/null”) or transduced with lentivirus encoding IFNAR2 
(“patient/IFNAR2”). This experiment was performed by Dr Christopher Duncan, 
Newcastle University. Data are representative of three experiments. 
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Immunoblotting showed that STAT1 phosphorylation in response to IFNα was 
restored in patient fibroblasts expressing IFNAR2 (Figure 3.13(B)). The ISGs, 
ISG56 and MxA were also upregulated by IFNα in patient cells expressing 
IFNAR2 whereas in patient cells expressing null control, there was no 
upregulation of ISGs (Figure 3.13(C)). These results demonstrated that 
reconstitution of wild type IFNAR2 expression in patient cells restores the IFNα 
response. 
Our collaborator, Prof Richard Randall, St. Andrews University, repeated the 
earlier described tests of viral susceptibility in IFNAR2-reconstituted patient 
cells. 
 
Figure 3.14: Complementation of IFNAR2 protects patient fibroblasts 
against viral infection. (A) Plaque assays of control, patient expressing null 
control and patient expressing IFNAR2. (B) Patient expressing null control and 
patient expressing IFNAR2 fibroblasts were not treated (-) or pre-treated with 
IFNα (+) overnight and were later infected with Enders mumps vaccine (MuV), 
Parainfluenza virus 3 (PIV3) and Parainfluenza virus 5 (PIV5). At 24 h p.i., the 
virus infected cells were visualised by Immunofluorescence staining. Figure was 
provided by Prof Richard Randall, St.Andrew’s University. 
 
In patient cells expressing IFNAR2, no plaque formation was observed which is 
similar to control cells, whereas in patient cells expressing null control, there 
was formation of plaques (Figure 3.14(A)). It was also shown by 
immunofluorescence staining that there was less replication of viruses in patient 
cells expressing IFNAR2 (Figure 3.14(B)). Both results demonstrated that 
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IFNAR2 complementation reinstated the ability of the patient cells to control 
viral infection. 
3.4.9 Homozygous deletion in IFNAR2 in exon 5 in newborn sibling of the 
index patient 
Recently, the mother gave birth to a newborn baby. To investigate whether the 
baby also has the deletion in IFNAR2, I have extracted the DNA from the baby 
cord blood, performed a PCR to amplify the relevant region and sent for Sanger 
sequencing. 
 
 
Figure 3.15: Homozygous deletion in IFNAR2 in exon 5 in newborn baby. 
(A) Pedigree of the family, Father : I:1 , Mother : I:2, Patient : II:1. Newborn : II:2 
(B) Sequences of healthy control and newborn baby gDNA. 
 
Sequencing of the newborn gDNA showed that she has the same homozygous 
variant c.A311del as her deceased brother (Figure 3.1). To confirm this result, 
Western blotting was performed to investigate IFNAR2 expression and IFNα 
induction of MxA in PBMCs. 
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Figure 3.16 : Absence of IFNAR2 expression and MxA induction in 
newborn PBMCs.  Control and patient PBMCs were untreated (-) or stimulated 
with IFNα (+) at 100IU/ml overnight. Western blotting was performed using 
antibody directed against IFNAR2 or MxA. GAPDH was used as loading control.  
 
Upon stimulation with IFNα, there was upregulation of MxA in control cells, 
however, in contrast, absence of upregulation of MxA in the baby PBMCs. In 
addition, IFNAR2 expression was also absent from baby PBMCs. Both findings 
supported the sequencing result and confirmed that the baby also has the same 
defect as the patient. 
3.5 Discussion 
We clearly demonstrated that the c.A311del, p.E104Gfsx6 frameshift mutation 
in IFNAR2 leads to absence of IFNAR2 protein, resulting in a profoundly 
impaired response to Type I IFN in patient cells. This proves beyond reasonable 
doubt that the mutation in IFNAR2 is the cause of the viral susceptibility 
phenotype observed in the proband. IFNAR2 deficiency has never before been 
reported in humans and represents a novel Primary Immunodeficiency Disease. 
Mouse knock out models provide information and understanding on the 
importance of IFNα/β response against viral infection. Mice lacking the IFNα 
receptor were shown to be very susceptible to a wide variety of  viruses  such 
as vesicular stomatitis virus (VSV, member of rhabdoviridae family (Roche et al., 
2008)), vaccinia virus (member of poxviridae family (Walsh and Dolin, 2011)), 
Semliki Forest virus (SFV, member of arbovirus family (Willems et al., 1979)), 
Influenza virus (member of orthomyxoviridae family (Jeffery and David, 2008)) 
and Lymphocytic choriomeningitis virus (LCMV, member of arenaviridae family 
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(Buchmeier et al., 1980)) in vivo and in vitro (Muller et al., 1994; Van Den Broek 
et al., 1995; Goodman et al., 2010), implying that  type I IFN signalling is crucial 
for antiviral immunity. By contrast, the IFNAR2-deficient patient did not develop 
any unusual illnesses until he was given MMR vaccine, despite the profound 
defect of IFNα/β signalling and inevitable contact with a variety of viruses during 
the previous 13 months of life.  
Apart from the measles, mumps and rubella viruses, HHV6 was also detected in 
the patient CNS and other tissues at low level but its significance was unclear. 
HHV6 is a member of the herpesviridae along with other herpesviruses that are 
well known to infect humans such as Herpes Simplex Virus Type 1 (HSV1), 
Herpes Simplex Virus Type 2 (HSV2), Varicella Zoster virus (VZV), Epstein-Barr 
Virus (EBV) and Cytomegalovirus (CMV) (Yoshikawa and Asano, 2000). HSV1 
has been identified to cause encephalitis in humans that had mutations which 
specifically impaired the viral IFN Type I induction (Casrouge et al., 2006; 
Zhang et al., 2007). These data and the fact that our IFNAR2-deficient patient 
also developed encephalitis, supports other studies (Paul et al., 2007)  that 
emphasise the importance of IFNα/β pathway in CNS antiviral immunity. Our 
patient showed serologic evidence of prior CMV infection, which he had 
controlled, but had not yet encountered EBV or VZV (data not shown).  
However susceptibility to herpesviruses might not be expected based on the 
experience in STAT2 deficiency, in which patients appeared to handle VZV, HSV, 
CMV and EBV relatively normally. In contrast to inbred mouse models (Muller et 
al., 1994; Park et al., 2000), these data suggest overall a redundant role for 
human IFNα/β-mediated antiviral immunity in the natural environment. 
Many live attenuated viruses including measles, mumps, small pox and polio 
are created by passaging the virus in nonhuman cell lines, making the virus less 
virulent and thereby preventing the occurrence of disease (Lauring et al., 2010). 
Such attenuation often includes loss of IFN evasion genes, with the result that 
the live attenuated viruses are efficient IFN inducers, compared to wild type 
virus strains (Shingai et al., 2007). However, the defect of the IFNα/β response 
in the patient cells led to widespread dissemination and revealed the underlying 
pathogenicity of the viruses, which had also been observed in  mice with 
targeted mutation inactivating the α/β interferon receptor (Mrkic et al., 1998). 
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Similarly, susceptibility to another live attenuated vaccine prepared from 
attenuated strain of Mycobacterium bovis was observed in patients with a defect 
of IFNγ receptors who presented with susceptibility to mycobacterial disease 
(Altare et al., 1998).  Thus the occurrence of disseminated disease caused by 
live attenuated vaccines should be considered to indicate underlying 
immunodeficiency until proved otherwise. 
Type II IFN, IFNγ, also displays an antiviral effect through the induction of ISGs   
(Liu et al., 2012). To understand the antiviral activity of Type I and type II IFN in 
vitro, control and patient cells were stimulated with IFNα, IFNβ and IFNγ and 
expression of the ISGs was assessed by microarray. A study done by Liu et al. 
demonstrated that both IFNα and IFNγ upregulate a similar set of ISGs, 
however, IFNα is thought to be a stronger inducer of antiviral ISGs than IFNγ as 
the number of ISGs that were upregulated by IFNα was higher than IFNγ (Liu et 
al., 2012). From the microarray analysis, our finding is consistent with Liu et al. 
showing that both IFNα/β- and IFNγ-stimulated control cells activate a similar 
set of ISGs. However, genes such as Mx1, IFIT and OAS2 were upregulated to 
much higher levels in IFNα- than in IFNγ-treated control cells, supporting the 
notion that they are the classical IFNα/IFNβ-specific genes (Liu et al., 2012), 
whereas IRF1 was  upregulated higher in IFNγ- than IFNα-treated cells, 
supporting as IFNγ-specific gene (Kimura et al., 1994). Previous studies 
suggested that IFNγ mediated its antiviral effect via an IFN amplification loop 
which it is thought to be dependent on IFNAR activity (Park et al., 2000; 
Takaoka et al., 2000). Therefore, we expected that the upregulation of ISGs in 
IFNγ-treated patient cells would be lesser compared to control.  However, from 
the microarray result, we found that in the IFNγ-treated patient cells, the 
upregulation of ISGs was similar to IFNγ-treated control cells. One possible 
explanation could be that as the cells were stimulated with IFNγ for 10 hours, 
we think that at this time point the upregulation of ISGs such as Mx1, IFIT and 
OAS is a truly IFNγ-mediated antiviral effect which is not dependent on the IFNα 
signalling. Type 1 IFN-mediated amplification of the IFN response may only 
occur later; to prove this, a longer time of IFNγ stimulation would be required to 
observe a difference in ISG upregulation between control and patient cells.  
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Furthermore, proteomic studies would be required to establish whether 
transcriptional upregulation is matched by equivalent induction at protein level. 
Another type of IFNs are Type III IFNs which consist of IFNλ 1,2 and 3 (Gough 
et al., 2012). Type I and type III IFNs were shown to exhibit similar properties in 
that both were triggered by viral infection and TLR ligands, used similar signal 
transduction pathways and induced similar sets of ISGs (Onoguchi et al., 2007). 
However, type III IFN is recognised by a different heterodimeric cell surface 
receptor consisting of IL-10Rβ  and IL28Rα (Sommereyns et al., 2008). A study 
done by Sommeryns et al. demonstrated that the key difference between type I 
and type III IFNs is the cell specificity of IFNλ where its receptor is primarily 
expressed by cells of epithelial origin whereas IFNAR is widely expressed in 
nucleated cells (the production of IFNλ also contributing somewhat to this 
tissue-specificity) (Sommereyns et al., 2008). Since epithelial surfaces are the 
primary site of replication for many viruses, intact IFNλ activity could explain the 
absence of a more general viral susceptibility in the patient. By contrast, the 
systemic route of vaccine administration for MMR bypasses the IFNλ system at 
mucosal surfaces, and evidently allowed viral dissemination in the patient. 
Besides their role in antiviral defence, type I IFNs have been implicated in 
regulating adaptive immunity by modulating the behaviour of T cells and antigen 
presenting cells (Hambleton et al., 2013; Jennings et al., 2014). For example, a 
study by Montoya et al. demonstrated that IFNα receptor KO mice show 
reduced expression of co-stimulatory molecules or MHC Class I and Class II on 
GM-CSF-derived dendritic cells, together with impaired  T cell proliferation 
(Montoya et al., 2002). Other studies also reported impaired myelopoeisis or 
defective thymic T cell development in the same KO mice (de Weerd et al., 
2007). However, our IFNAR2-deficient patient showed no clinical or laboratory 
evidence of impaired adaptive immunity, implying evolutionary divergence 
between species or mouse strains with respect to this interplay between innate 
and adaptive immunity (Parekh and Crooks, 2013).  
As mentioned in the history, recently the mother gave birth to another child.  
Genomic DNA sequencing showed that she bears the same homozygous 
IFNAR2 mutation with absence of IFNAR2 protein and no IFNα-inducible MxA 
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expression by western blotting. It is extremely important to know that the 
newborn has heightened viral susceptibility so as to be able to manage and 
treat her. For instance, she must not receive live attenuated vaccines, in order 
to prevent the occurrence of a similar fatal illness. As our analysis demonstrated 
that IFNγ can induce an antiviral state in patient cells, it could be considered as 
a potential therapeutic in the event of overwhelming viral infection.  In future 
work, it would be interesting to assess the surviving patient’s adaptive immunity 
in more detail, for example by examining T cell effector polarisation and 
responses in vitro.  Unfortunately we cannot currently study serologic antiviral 
responses because the child is receiving immunoglobulin replacement therapy 
as a means to prevent potentially fatal viral infection. 
Haematopoietic stem cell transplantation (HSCT) has been a choice of 
treatment for many PIDs (Dvorak and Cowan, 2007). The goal of treating PID 
patients with HSCT is to provide normal cells of haematopoietic origin to replace 
the genetically defective immune system (Buckley et al., 2013). However, in this 
case transplantation would appear to be unhelpful as the IFNAR2 defect is 
intrinsic to all cells and hence correction of the haematopoietic compartment 
would most likely fail to cure the viral susceptibility phenotype. In addition, the 
inevitable period of intense iatrogenic immunosuppression would likely be 
hazardous for the baby, compounding her intrinsic viral susceptibility by 
transiently removing both adaptive and innate immune cells. 
My data clearly show that the Type I IFN signalling pathway is essential for host 
defence against certain viral pathogens in humans, in agreement with my earlier 
findings in STAT2 deficiency. This novel PID, IFNAR2 deficiency, helps us in 
understanding the role of this receptor and the importance of IFNα/β signalling 
in human antiviral immunity. The recognition of this phenotype provides an 
important model in defining the significant role of innate IFN and its interaction 
with viral pathogenesis in humans.
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Chapter 4: A novel autoimmune lymphoproliferative disorder 
This chapter is structured into three sub chapters : 
4.1 Identification of disease causing variant 
4.2 Effect of TET2 p. H1382R variant on its functional activity 
4.3 Effect of TET2 p. H1382R variant on lymphocyte apoptosis 
4.1 Identification of the disease causing variant 
4.1.1 Introduction 
4.1.1.1 Whole exome sequencing  
Whole exome sequencing is a genetic technique that is currently widely used to 
identify gene defects responsible for Mendelian disorders. Most primary 
immunodeficiency diseases are Mendelian, meaning that the disease is caused 
by a DNA mutation in single genes inherited from parents by their offspring 
(Ochs et al., 1999). Whole exome sequencing uses the approach of targeted 
sequencing of the protein coding regions known as exons within the human 
genome (Bamshad et al., 2011). The exome constitutes only 1% (30MB) of the 
human genome but it is estimated to contain approximately 85% of deleterious 
variants (Rabbani et al., 2014). Therefore, sequencing these coding regions of 
the genome provides a high chance of identifying the cause of genetic disorders 
(Rabbani et al., 2014). Depending on the sequencing platform used, whole 
exome sequencing is able to identify 20,000 – 35,000 single nucleotide variants 
per exome by comparison with the reference human genome sequence (Platt et 
al., 2014). It should be noted that some proportions of the variations is at the 
level of common polymorphisms whereas smaller proportion is ‘private’ or rare 
to the individual which provide the risk of developing certain diseases. 
In order to discover the putative disease-causing variant(s) among the many 
variants identified by whole exome sequencing, several filtering steps are 
applied including elimination of variants that are synonymous as they will only 
alter the DNA but not the amino acid sequence (Platt et al., 2014); as such 
these are very rarely pathogenic. Since by definition in rare diseases the 
causative variant is novel or rare, common variants (polymorphisms with an 
allele frequency of more than 1% in public single nucleotide polymorphism 
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(SNP) databases such as dbSNP and 1000 genome projects or in house 
exomes) are also eliminated (Bamshad et al., 2011; Platt et al., 2014). Polyphen 
2, SIFT, Mutation Taster and MAPP are bioinformatic algorithms that are used 
to predict whether the variants are benign or deleterious e.g. on the basis of 
evolutionary conservation and amino acid similarity, and benign variants will be 
removed from further analysis (Platt et al., 2014). Similar software can be 
applied to understand the effect of mutations within splice sites. Another filtering 
step is by removing variants that do not fit with the expected mode of 
inheritance (Singleton, 2011). For example, in autosomal recessive disorders,  
two mutated alleles are present in the offspring, resulting in a homozygous 
mutation due to one of the mutated allele is generally inherited from the mother 
and the other from the father of a consanguineous couple who are both likely to 
inherit from one ancestor. Both parents are unaffected as they only carry one 
mutated allele and one normal allele.  
4.1.1.2 Homozygosity mapping 
Homozygosity mapping is often applied in parallel with whole exome 
sequencing in consanguineous families where autosomal recessive inheritance 
is suspected (Platt et al., 2014). Homozygosity mapping is applied to determine 
the genomic region linked to the disease, commonly by means of SNP arrays 
and/or microsatellite markers (Alkuraya, 2010). In autosomal recessive 
disorders, the affected children are likely to be homozygous at the markers 
linked to the disease locus because of co-inheritance from a recent common 
ancestor on both maternal and paternal sides. Homozygosity mapping identifies 
the chromosomal homozygous regions that are shared by affected family 
members but are heterozygous or not shared at all in healthy family members. 
By combining both whole exome sequencing and homozygosity mapping data, 
attention can be focused on a shorter list of candidate variants that lie within 
shared regions of homozygosity. 
4.1.1.3 Novel autoimmune lymphoproliferative syndrome 
In this chapter, I will describe the investigation of two siblings from a 
consanguineous family who were diagnosed clinically with autoimmune 
lymphoproliferative syndrome (ALPS) but lacked known molecular defects. 
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ALPS is a disease that results from failure of the apoptotic mechanisms in 
maintaining lymphocyte homeostasis (Rao and Oliveira, 2011). Several 
mutations within the Fas-mediated apoptosis pathway have been described 
which lead to this clinical syndrome (Rieux-Laucat et al., 1995; Wang et al., 
1999; Chun et al., 2002; Del-Rey et al., 2006; Oliveira et al., 2007; Takagi et al., 
2011). However, one third of ALPS patients still lack a genetic diagnosis 
(Oliveira et al., 2010), like our two brothers. The fact that they were born to 
consanguineous parents increased our suspicion for a novel form of autosomal 
recessive ALPS, caused by a homozygous disease-causing mutation. 
Accordingly, whole exome sequencing was applied together with homozygosity 
mapping to identify the genetic defect.  
4.1.2 Hypothesis 
The patients’ phenotype is caused by a homozygous mutation in a novel 
disease gene. 
4.1.3 Aims 
To identify the disease-causing variant in both patients by whole exome 
sequencing and homozygosity mapping. 
4.1.4 Results 
4.1.4.1 Patients’ history 
We investigated two siblings from a consanguineous marriage who were 
clinically diagnosed with ALPS but lacked a known molecular defect. Patient 1 
(P1, the elder brother) presented to hospital at 4 weeks of age due to 
pneumonia which was caused by Respiratory Syncytial Virus (RSV) and 
Cytomegalovirus (CMV) infection. He was treated with Ganciclovir and 
discharged home. Subsequently, P1 showed failure to thrive and developmental 
delay, and had frequent admissions due to recurrent lower respiratory tract 
infections. From 18 months old, he developed hepatosplenomegaly, chronic 
lymphadenopathy and persistent EBV infection. He developed autoimmune 
phenomena such as immune thrombocytopenia and autoimmune haemolytic 
anaemia, requiring frequent transfusions. Autoantibodies were present as 
confirmed by direct antiglobulin test (DAT), and assays for anti-nuclear antibody 
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(ANA) and Rheumatoid Factor (RF). Since he displayed both 
lymphoproliferative disease and autoimmunity, he was investigated for ALPS at 
the age of 3 years.  Analysis by the laboratory of Dr Frederic Rieux-Laucat 
confirmed the diagnosis of ALPS on the basis of defective Fas-mediated 
apoptosis (Figure 4.1.1), raised double negative (CD4-CD8-) TCRαβ T cells 
(20%) and a raised level of soluble Fas Ligand (0.9ng/ml) (Table 4.1.1). 
Throughout this illness, standard lymphocyte subsets were grossly normal.  His 
IgM and IgA levels were normal, but IgG and IgG1 were high for one episode 
(Table 4.1.2).  
P1 was treated with high dose (2g/kg) intravenous immunoglobulin, Rituximab 
(anti-CD20 antibody) and corticosteroid.  His overall condition and 
lymphadenopathy initially appeared to be responding to this immunomodulatory 
therapy. However, when he was 4 years old, P1’s condition deteriorated 
markedly, with the development of massive hepatosplenomegaly and evolution 
of his lymphadenopathy to become hard and ‘knobbly’.  Further investigations 
including lymph node biopsy showed lymphoma of a nodular sclerosing, 
Hodgkin’s type (Table 4.1.1). He was started on low intensity chemotherapy but 
developed the life-threatening complication of tumour lysis syndrome with acute 
renal failure, requiring prolonged intensive care.  
Since the formulation was that his lymphoma had occurred as a complication of 
an inherited immune defect, P1 was prepared for haematopoietic stem cell 
transplant (HSCT) as a potentially lifesaving procedure.  Because of his gross 
hepatosplenomegaly, he required a splenectomy prior to transplant; histological 
examination of the explanted spleen as well as liver biopsy showed clearance of 
the lymphoma. At 4 years 4 months old, he received a matched sibling donor 
HSCT after reduced intensity conditioning. One month after BMT, he was at risk 
of rejecting the graft with evidence of a large population of recipient T cells. 
However, after receiving alemtuzumab (anti-CD52 antibody) and an 
unconditioned stem cell top-up, the proportion of donor cells improved to reach 
96% T cells but only 14% B cells (mixed chimerism).  
P1 was monitored frequently and his condition was clinically stable over the 
following two years. An important and interesting finding was that starting from 3 
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months after transplant, P1 developed leucocytosis, monocytosis, neutrophilia 
and lymphocytosis (Figure 4.1.2). In addition, all his lymphocyte subset absolute 
counts including CD3, CD4, CD8, CD19, NK cells and HLA-DR+ % were 
consistently at high levels post-transplant (Figure 4.1.3).  
At 26 months post-transplant (6 years 6 months old), he was noted to have 
recurrent lymphadenopathy, hepatomegaly and hypercalcemia of unknown 
cause.  Lymph node biopsy and bone marrow trephine showed non-caseating 
granulomata but no evidence of malignancy. In keeping with granuloma 
formation, an increased serum level of angiotensin converting enzyme (ACE) 
was detected.  At 36 months post-transplant (7 years 4 months old), he 
developed thrombocytopenia with positive ANA and ongoing widespread 
lymphadenopathy. During this time, his IgG level, which had been normal 
throughout the post-transplant period, was noted to be high (29.7g/L), whereas 
IgM and IgA remained normal. His β2-microglobulin, a tumour marker for blood 
cell cancer, was also increased (14.6mg/ml, normal range <2.7mg/ml). Based 
on the recurrent lymphadenopathy, hepatomegaly and autoimmune phenomena, 
he was diagnosed with recurrent ALPS. The Fas-mediated apoptosis assay was 
repeated, however, it was shown to be normal (Figure 4.1.1). As the test was 
performed post-transplant and the patient had 78% donor T cells, it was not 
surprising that the repeated apoptosis assay was normal. P1 then received a 
course of rituximab, following which his IgG and β2-microglobulin levels 
normalised.  The CD19 absolute count dropped to 0, indicating that Rituximab 
was clearing B cells and the CD3 absolute counts were also reduced at the 
same time.  
At 48 months post-transplant (8 years 4 months old), P1 was admitted to 
hospital with central cyanosis and poor lung function secondary to severe 
bronchiectasis. The lymphadenopathy and hepatomegaly were reduced in size 
but new lumps were noted in his scrotum and tongue. Excision biopsy of these 
lesions demonstrated two granular cell tumours that were completely excised. 
Subsequently, he developed severe immune thrombocytopenia at 60 months (9 
years 4 months old) and anaemia at 62 months (9 years 6 months old) post-
transplant, requiring blood product support and a further course of rituximab for 
presumed autoimmune aetiology. During this time, he also presented with 
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headache and hypertension and later had a seizure, with brain CT showing a 
small right frontal bleed. In addition, he developed pleural effusions and ascites 
of unknown cause which were managed with fluid restriction and diuretics and 
gradually resolved.  
At 82 months post-transplant (11 years 2 months old), another lump was noted 
at his left upper arm and excision biopsy showed another granular cell tumour. 
At 84 months post-transplant (11 years 4 months old), he developed another 
episode of thrombocytopenia and increased lymphadenopathy. So far his last 
admission to the hospital was at 98 months post-transplant (12 years 6 months 
old), which was due to respiratory and gut failure secondary to E.coli sepsis 
complicating a severe febrile diarrheal illness acquired in Pakistan. His stool 
was positive for cryptosporidium, norovirus and sapovirus. He also had blood 
transfusion due to thrombocytopenia and anaemia. Care was shifted to a 
palliative footing as he was severely debilitated and not expected to survive, 
however he showed a remarkable recovery in the home environment and has 
since recovered to his usual level of function.  
Currently, the patient is 13 years old and 9 years post transplantation. His 
condition is stable and he attends school 2-3 days per week, where a statement 
of special educational needs is in place.  He has supplemental oxygen at night 
and his exercise capacity is severely limited.  He was recently evaluated for 
short stature and failure of pubertal development. His history is summarised in 
Table 4.1.1.  
Patient 2 (P2) is the younger brother of P1. His problems started when he 
developed haematuria (blood in the urine) and proteinuria (protein in the urine) 
at 4 weeks of age. Renal biopsy was performed and showed granulomatous 
nephritis which was treated as congenital nephrotic syndrome. He was also 
noted to have hypothyroidism that was attributed to loss of thyroxine (T4)-
binding globulin (TBG) in the urine and was treated with thyroxine. Later on, he 
was admitted to Paediatric Intensive Care Unit (PICU) due to CMV pneumonitis 
complicated by pneumothorax. He was started on immunoglobulin 
supplementation. Subsequently, he developed hepatosplenomegaly and 
lymphadenopathy at 4 months of age. His lymph node biopsy showed a diffuse 
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proliferation of T lymphocytes, suggestive of T cell lymphoma (Table 4.1.1). He 
demonstrated features of autoimmunity such as several episodes of 
thrombocytopenia but no autoantibody tests were documented. His 
neurodevelopment was also noted to be delayed for age.  
 
Based on the presence of lymphadenopathy, lymphoma, hepatosplenomegaly 
and autoimmunity, P2 was clinically diagnosed with ALPS, and diagnosis was 
confirmed by defective Fas-mediated apoptosis (Figure 4.1.1), increased DN 
TCRαβ T cells (1.96) (Table 4.1.1) and raised soluble Fas ligand 
0.96ng/ml(Table 4.1.1). His lymphocyte subsets and Immunoglobulin levels 
were within the normal range for age. He was started with cyclophosphamide 
and methylprednisolone for his lymphoma; however, it was stopped due to 
deranged liver function. A T cell-depleted paternal haploidentical HSCT was 
performed at 9 months of age, following modified intensity conditioning. The 
HSCT was unsuccessful as he developed graft rejection with evidence of 100% 
of T cells being recipient in origin. Subsequently, 3 months post-transplant, his 
condition deteriorated when he developed respiratory failure and required 
intubation for presumed sepsis. The patient died at the age of 13 months, 4 
months post-transplant. Patient history is summarised in Table 4.1.1.  
 
 Patient 1 
Pre-transplant 
Patient 1 
Post-transplant 
Patient 2 
Age of onset 18 months  4 weeks 
CLINICAL SYMPTOMS    
Immunodeficiency Recurrent lower 
respiratory infections 
 with established 
bronchiectasis 
 Recurrent lower  
infections 
Viral infections RSV, CMV, persistent 
 EBV 
Norovirus, sapovirus* CMV 
Bacterial infections  E.coli, cryptosporidium*  
Autoimmunity 
(cytopenias)  
Thrombocytopenia, 
anaemia 
Thrombocytopenia, 
anaemia 
Thrombocytopenia 
Early onset nephrotic 
syndrome 
Yes  Yes 
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Lymphadenopathy  Yes Yes Yes 
Hepatomegaly Yes, massive Yes Yes 
Splenomegaly Yes  Yes 
Malignancy Nodular sclerosing 
Hodgkin type  
lymphoma 
Granular cell tumour 
(Scrotum, tongue and 
liver) 
T-cell lymphoma 
Bone marrow aspirate Marrow is hypercellular 
with expansion of 
myelopoeisis 
 Lymphocytosis not 
 more than 10% 
Developmental delay Yes  Yes 
Failure to thrive Yes  - 
Others - Seizure due to small 
right frontal bleed 
Congenital nephrotic 
syndrome, 
hypothyroidism  
secondary to nephrotic 
syndrome 
LABORATORY VALUES    
Apoptosis Impaired Normal Impaired 
Soluble Fas Ligand Increased (900pg/ml)  Increased (960pg/ml) 
DNT cells Increased (20%)  Increased (1.96%) 
Blood results thrombocytopenia, 
anemia 
Leucocytosis, 
lymphocytosis, 
monocytosis, 
thrombocytopenia, 
anemia 
Thrombocytopenia 
Autoantibodies DAT +ve, ANA +ve,  
RF +ve 
 Not available 
TREATMENT    
Transplant Matched sibling donor 
HSCT 
 T cell-depleted paternal 
haploidentical HSCT 
Outcome Mixed chimerism  
Alive 
 Graft rejection, Died 4 
months post transplant 
Table 4.1.1: Clinical features of patient 1 (pre and post transplant) and 
patient 2.DAT- direct antiglobulin test, ANA-anti nucleic antibody, RF-
Rheumatoid factor, +ve – positive, RSV-respiratory syncytial virus, CMV- 
cytomegalovirus, EBV- Epstein Barr Virus, HSCT- haematopoietic stem cell 
transplant. * respiratory and gut failure 
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Figure 4.1.1 : Fas-mediated apoptosis patient 1 and patient 2. Fas-mediated 
apoptosis assay pre- and post-transplant of patient 1, and pre-transplant of 
patient 2. Patients’ T cells were left untreated (medium) or treated with 100ng, 
30ng, 10ng and 1ng of CD95L (soluble Fas ligand). The % of surviving cells vs 
CD95L concentration were plotted. Patient 1 Fas-mediated apoptosis assay 
(pre-transplant) was performed in the laboratory of Frederic Rieux Laucat, Paris, 
France. Patient 1 (post-transplant) and patient 2 (pre-transplant) Fas-mediated 
apoptosis assay was done in the laboratory of Stephan Ehl in Freiburg, 
Germany. 
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Figure 4.1.2 : Haemoglobin, platelets, total lymphocytes, total white cells, 
monocytes and neutrophil absolute counts in peripheral blood of patient 1 
and patient 2 For haemoglobin and platelets, the hatched areas indicate sub-
normal range. Grey areas in total lymphocytes, total white cells, monocytes and 
neutrophils indicate normal ranges.  indicates post rituximab. Patient 1 pre 
transplant ( ), Patient 1 post transplant ( ), Patient 2 pre transplant ( ), Patient 
2 post transplant ( ). 
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Figure 4.1.3 : Absolute numbers of indicated lymphocyte subsets (CD4, 
CD3, CD8, CD19 and CD16+56+) and percentages of activated T cells. Grey 
area indicates normal ranges of the lymphocyte subsets.   indicates post 
rituximab. Patient 1 pre transplant ( ), Patient 1 post transplant ( )  Patient 2 
pre transplant ( ), Patient 2 post transplant (  ). 
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 Patient 1 Patient 2 
 Pre-transplant (age 
3.5 years) 
Post-transplant  
(age 7 years)* 
Pre-transplant  
(age 5 months) 
Post-transplant     
(age 12 months)* 
 Values 
(g/l) 
Reference 
range 
Values 
(g/l) 
Reference 
range 
Values 
(g/l) 
Reference 
range 
Values 
(g/l) 
Reference 
range 
IgG 22.4 3.6-15.2 29.7 4.9-16.1 12.9 Normal 20.4 High 
IgA 1.16 0.43-1.90 0.79 0.5-2.4 0.98 Normal 0.86 Normal 
IgM 1.24 0.4-2.18 0.72 0.5-2.0 0.22 Normal 0.89 Normal 
IgG1 20.78 2.5-6.9 NA    NA  
IgG2 2.47 0.7-4.8 NA    NA  
IgG3 2.76 0.1-1.1 NA    NA  
Table 4.1.2 : Immunoglobulin levels of patient 1 and patient 2 pre- and 
post-transplant. For patient 1, the values were taken from one episode of high 
IgG level for pre- and post-transplant. * on Iv Ig replacement. 
 
To summarise, both patients presented with clinical features of ALPS including 
lymphadenopathy, hepatosplenomegaly, lymphoma and autoimmune 
phenomena such as thrombocytopenia and anaemia. In further support of this 
diagnosis, both patients demonstrated laboratory features of ALPS including 
defective Fas-mediated apoptosis, increased DN TCRαβ T cells and increased 
soluble Fas ligand. In addition, they demonstrated susceptibility to infection 
including CMV and EBV, which is a less commonly associated feature of ALPS. 
Since neither patient bore mutations in genes already associated with ALPS, a 
novel disease causing variant was suspected. 
4.1.4.2  Identification of candidate disease causing variants 
As we hypothesised that the disease was inherited in an autosomal recessive 
manner, combinations of two approaches were used to identify the disease-
causing variants in both patients: 1) whole exome sequencing, and 2) genome 
wide linkage analysis by homozygosity mapping to search for homozygous 
regions shared by both patients.  
Whole exome sequencing was performed using both patients’ genomic DNA 
which was extracted from the early passage primary dermal fibroblasts. The 
genomic DNA was sheared and size-fractionated prior to exonic enrichment 
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using SureSelect Human All Exon kit (Agilent Technologies) and was subjected 
to next generation sequencing on an Illumina GA II sequencing platform. The 
sequences were aligned to the hg19 human genome by NovoAlign. 
Bioinformatic analysis was performed using an in house pipeline by Dr Helen 
Griffin and Yaobo Xu (Institute of Genetic Medicine, Newcastle University).  
A 
 
 
B  
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Figure 4.1.4 : Whole exome sequencing and homozygosity mapping of 
patient 1 and patient 2. A) Whole exome sequencing of both patients showing 
the numbers of variants as indicated after each filtering step. Possibly 
homozygous variants are variants that are homozygous in patient 1 but not 
available in patient 2 or vice versa. This disparity arose because of a change in 
the exon enrichment kit between sequencing of P1 and P2. B) Homozygosity 
mapper showing the genome wide homozygosity bar charts; homozygous 
regions of interest are indicated by red bars. Numbers labelled in green indicate 
the chromosomes. The homozygosity mapping analysis was performed by Dr 
Neil Morgan, Birmingham University. 
 
By whole exome sequencing, a total number of 12528 variants was identified in 
patient 1 and 9182 in patient 2 (Figure 4.1.4(A)). As many variants were 
identified in both patients, the next step was to identify the variants that cause 
an alteration to the amino acid sequence. Patient 1 had 10716 and patient 2 
had 8324 such non synonymous variants (Figure 4.1.4(A)). These non 
synonymous variants were further filtered using computational algorithms such 
as Polyphen-2, Mutation Taster, SIFT and MAPP which predict whether 
associated amino acid changes are benign or deleterious with respect to protein 
function. We identified 220 variants in patient 1 and 161 in patient 2 that were 
predicted to be deleterious. As we hypothesised that the candidate disease 
causing variant is a homozygous mutation, a further filtering step included 
eliminating predicted deleterious variants that were heterozygous. We identified 
20 homozygous and possibly homozygous variants in patient 1 and 55 
homozygous and possibly homozygous variants in patient 2. We then further 
identified 8 variants that were predicted deleterious homozygous and shared or 
possibly shared by both patients, (Figure 4.1.4(A)). Of note, owing to a change 
in exon capture method, coverage was quite uneven between the two siblings. 
We did not exclude homozygous variants in genes for which analysis was only 
available in one patient as shared homozygosity could not be ruled out. As we 
were focusing on rare and novel disease causing variants, it should be noted 
that variants that are common (more than 0.05% frequency in the population) in 
dbSNP (http://www.ncbi.nlm.nih.gov/ projects/SNP), 1000 genome project and 
our in house database were eliminated from further consideration.   
In parallel, homozygosity mapping was carried out for this kindred using 
Affymetrix Genome-Wide Human SNP 5.0 microarrays. The homozygosity 
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mapping analysis was performed by Dr Neil Morgan, Birmingham University. 
Therefore, this method was applied to search for the homozygous chromosomal 
regions that were shared by both patients but not by their unaffected relatives. 
To analyse and map these homozygous regions, SNP array data were 
uploaded into a programme called Homozygosity mapper (http://www. 
Homozygositymapper.org/) (Seelow et al., 2009). For data visualisation, the 
homozygosity mapper plots genome wide homozygosity as bar charts and 
highlights in red the homozygous regions that are shared by both patients but 
are heterozygous or not shared at all by the healthy family members. The 
homozygosity mapper identified three such regions on chromosomes 4, 9 and 
12 (Figure 4.1.4(B) and Table 4.1.3. Microsatellite markers were further used to 
confirm and refine the borders of these regions. The homozygosity mapping 
analysis was performed by Dr Neil Morgan, Birmingham University. 
 
Table 4.1.3 : Shared homozygous regions that were detected by 
homozygosity mapper in patient 1 and patient 2. Six regions were 
homozygous on chromosome 4, one region on chromosome 9 and 
chromosome 12. The position, from bp to bp, is indicated for each region.  bp = 
base pairs. 
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When we cross-referenced the results of WES with the output from the 
homozygosity mapping, 639 variants lay within the three homozygous regions. 
However, we narrowed down the candidate variants to only 1 predicted 
deleterious variant which mapped to a region of homozygosity, on chromosome 
4. This variant, which was among the 8 deleterious variants identified by WES, 
is a homozygous missense mutation (c.4115A>G) changing the amino acid 
histidine to arginine at position 1382 (p.H1382R) in exon 9 of the gene Ten 
Eleven Translocation 2 (TET2) localized on chromosome 4  
Aligned reads covering the candidate variant of patient 1 in TET2 were 
visualised with the Integrated Genome Viewer (IGV), a computational tool which 
aligns the sequence reads to the reference genome, in this case hg19 (Figure 
4.1.5).  IGV confirmed that the TET2 variant is a homozygous missense 
mutation, substituting A>G (bp:g. 106190867) in exon 9. 
 
Figure 4.1.5: Homozygous TET2 mutation in Patient 1. Overlapping 
sequencing reads of exon 9 of TET2 show the homozygous A>G base pair 
substitution on Integrated Genome Viewer (IGV). The nucleotides and amino 
acids were indicated at the bottom. 
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For patient 2, whole exome sequencing data for exon 9 of TET2 were not 
available because this region was poorly covered among sequence reads. 
4.1.4.3 Segregation of TET2 mutation in both patients and family members 
To validate this putative disease causing variant, the next step was to perform 
dideoxy sequencing of PCR amplicons, (1) to confirm that the mutation is 
present in both patients and was not a false- positive result of whole exome 
sequencing, and (2) to investigate the segregation of the TET2 mutation with 
disease within the family. 
Genomic DNA was extracted from patients’ fibroblasts and family members’ 
peripheral blood. Exon 9 of TET2 was amplified by PCR using specific forward 
and reverse primers (see method chapters), which were designed using the 
NCBI/Primer blast tools (http://www.ncbi.nlm. gov/tools/primerblasts/). Agarose 
gel electrophoresis confirmed a PCR product of the correct size, 386bp (Figure 
4.1.6(A)), which was submitted for Sanger sequencing by a commercial 
provider. 
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Figure 4.1.6 : PCR gel electrophoresis, pedigree of the family and 
sequencing of patients and family members. (A) Amplification of TET2 gene, 
targeting exon 9 by PCR in patient 1 (P1), patient 2 (P2), father (F), mother (M), 
healthy brothers (HB), healthy sister (HS) and control and visualised by gel 
electrophoresis. (B) Pedigree of the family. Patient 1 (IV.2), patient 2 (IV.5). (C) 
Sequencing of the patients, patient 1 (patient IV.2), patient 2 (patient IV.5) and 
family members. 
 
The sequencing results confirmed that both patients are homozygous for the 
TET2 mutation (Figure 4.1.6(C)). They also confirmed that the mutation 
segregates as expected with disease; both parents and one healthy sibling are 
heterozygous for the mutation whereas two other healthy siblings are wild type 
(Figure 4.1.6(B)). This is compatible with autosomal recessive inheritance.
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Chapter 4: A novel autoimmune lymphoproliferative disorder 
4.2 : Effect of TET2 p.H1382 variant on its functional activity 
4.2.1 Introduction 
The genetic data presented in chapter 4.1 suggested TET2 c.4115A>G, 
p.H1382R as the disease-causing variant in the two siblings with ALPS. 
However, to confirm this, an exploration of the functional role of TET2 in 
humans is required. TET2 turns out to be a key enzyme for DNA 
hydroxymethylation, one of the important mechanisms in epigenetic regulation 
of gene expression (Nakajima and Kunimoto, 2014). 
4.2.1.1 Epigenetics 
Epigenetics, in general, is understood  as a study of the heritable changes of  
gene expression or cellular phenotypes that occur without changing the 
underlying DNA sequence (Goldberg et al., 2007). Epigenetic mechanisms are 
fundamental in many cellular processes such as differentiation, genomic 
imprinting, X inactivation, and embryogenesis (Portela and Esteller, 2010). 
Epigenetic studies have been useful and helpful in understanding how 
genetically identical cells can generate different cell types and phenotypes as 
well as maintaining alternative cellular states (Esteller, 2008). In recent years, 
the mechanistic study of epigenetics has increased tremendously. Disruption of 
the balance of epigenetic networks can lead to inappropriate expression or 
silencing of genes which can contribute to the development of human diseases 
including cancer, syndromes involving chromosomal instability and mental 
retardation (Egger et al., 2004). Two major mechanisms of epigenetic regulation 
are 1) histone modification and 2) DNA methylation and demethylation. 
Significant crosstalk occurs between these two mechanisms in which they 
interact and stabilize each other in regulating the cellular processes (Egger et 
al., 2004). 
4.2.1.1.1 Histone modification 
Nucleosomes are formed by the packaging of DNA around a protein core which 
consists of a tetramer of histone 3 (H3), histone 4 (H4) and two dimers of 
histone 2, H2A and H2B (Sakabe et al., 2010; MacRae, 2011). The core 
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histones are tightly packed in a globular formation and protruding from the 
nucleosomes are the N-terminal histone tails (Sakabe et al., 2010). The N-
terminal histone tails are subject to majority of the post-translational 
modifications including phosphorylation, methylation, acetylation, sumoylation 
and GlcNAcylation. These modifications  regulate their ability  to remodel the 
chromatin structure for DNA-related processes such as transcription, DNA 
replication and repair, recombination and chromosomal organization (Sakabe et 
al., 2010). Specific enzymes such as histone acetylases (HATs) and 
deacetylases (HDACs) are known to catalyse the histone post-translational 
modification such as acetylation and deacetylation at the lysine residue of the N 
terminus of histones tails (Ruthenburg et al., 2007). Unmodified lysine residues 
are positively charged and tightly bind to the negative charge of the DNA, 
forming condensed nucleosomes. Conversely, acetylation reduces the binding 
affinity between histone and DNA, resulting  in open-chromatin structure, 
allowing access of transcription factors (Handy et al., 2011). Many studies 
report that HATs are mainly linked to transcriptional activation whereas HDACs, 
in contrast, are involved in transcriptional co-repressor complexes (Portela and 
Esteller, 2010). Another common post -translational modification is histone 
methylation where one, two or three methyl groups are added to a different site 
of the lysine residue catalysed by the enzyme histone methyltransferase 
(Kouzarides, 2007). Histone methylation has different effects on gene activity, 
including transcriptional activation, inactivation or silencing of the genomic 
regions, depending on the specific lysine residue and the degree of methylation. 
For example, enrichment of histone methylation at H3K4me,H3K36me or 
H3K79me is associated with transcriptional activation (Kouzarides, 2007), 
whereas enrichment of histone methylation at a different site, H3K9me, 
H3K27me or H4K20me is implicated in gene inactivation or silencing 
(Kouzarides, 2007). 
4.2.1.1.2 DNA methylation 
Another well-characterised epigenetic modification that has a profound impact 
on genome stability, gene expression and normal development is DNA 
methylation (Wu and Zhang, 2014). DNA methylation occurs in a cell type-
specific manner that is established during mammalian development and 
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maintained in adult somatic cells (Chen and Riggs, 2011). It is a process by 
which a methyl group is added at the 5’position of cytosine to create 5-
methylcytosine (5mC). In human somatic cells, 70-80% of 5mC occurs at CpG 
sites (Chen and Riggs, 2011). In addition, methylation also occurs in non CpG 
context in cells such as oocytes, pluripotent embryonic stem cells and mature 
neurons (Lister et al., 2009; Wu and Zhang, 2011). By using a methylated DNA 
immunoprecipitation (MeDIP) method combined with high throughput 
sequencing, it was demonstrated  that cytosine methylation occurs throughout 
the genome, including genes, transposons and intergenic DNA(Suzuki and Bird, 
2008). The addition of the methyl group is mediated by a family of enzymes 
known as DNA Methyltransferases (DNMT) including DNMT1, DNMT2 and 
DNMT3 which are required for the establishment and maintenance of DNA 
methylation. Aberrant methylation is associated with silencing of tumour 
suppressor  genes as observed in cancers (Esteller, 2005). 
4.2.1.1.3 DNA demethylation 
DNA methylation is a dynamic process in equilibrium with demethylation. DNA 
demethylation is essential in regulating gene expression during mammalian 
development and differentiation. It occurs either actively or passively. Active 
demethylation refers to the enzymatic process that removes or modifies the 
methyl group from 5mC.  In passive demethylation, the methylation is omitted 
from newly synthesised DNA strands during replication. For example, it is 
known to occur in the absence of the functional DNA methylation maintenance 
machinery in the maternal genome during preimplantation growth (Chen and 
Riggs, 2011; Wu and Zhang, 2011; Kohli and Zhang, 2013). Ten Eleven 
Translocation 2, TET2, along with other family members of TET proteins, TET1 
and TET3, have been discovered as the enzymes that mediated the active 
demethylation. 
4.2.1.2 TET2 protein structure and enzymatic function in promoting DNA 
demethylation 
TET1 is highly expressed in embryonic stem cells whereas TET2 and TET3 are 
more ubiquitously expressed (Solary et al., 2013). TET2 expression 
predominates in a variety of differentiated tissues, particularly in haematopoietic 
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and neuronal lineages (Solary et al., 2013). The human TET2 gene is found on 
chromosome 4q24 and contains 11 exons. Three isoforms are produced from 
the TET2 gene by alternative splicing. The enzymatic role of TET2 ( as well as 
TET1 and TET3) was discovered to catalyse oxidation of 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC) (Tahiliani et al., 2009). The global 
5hmC level was found to be the highest in the brain (Kriaucionis and Heintz, 
2009) and embryonic stem cells (Tahiliani et al., 2009). Different 5hmC 
distribution in the genome among cell types may be due to the differences in the 
underlying distribution of 5mC and TET proteins (Tsagaratou et al., 2014). By 
genome wide mapping, several groups identified the presence of 5hmC in gene 
bodies which correlates with gene expression in mouse and human embryonic 
stem cells (Ficz et al., 2011; Pastor et al., 2011) and human T cells (Tsagaratou 
et al., 2014). Their findings implied that TET2 was responsible for depositing 
5hmC in the gene bodies in these cells, whereas other groups demonstrated 
that TET1 regulated 5hmC levels at the promoter and transcription start sites 
(Huang et al., 2014). Later on, several studies identified that TET2 can also 
further oxidize 5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in 
DNA at low levels (Ito et al., 2011). As one of the enzymes that converts 5mC to 
5hmC, 5fC and 5caC, thus TET2 is important in tuning the epigenetic status of 
the cells. 
The catalytic domain of TET2 comprises cysteine rich and double stranded beta 
helix (DSBH) regions. Structural analysis shows that the DSBH domain consists 
of antiparallel β strands that face each other and coordinate sequestering of a 
central Fe(II) ion and N-oxalylglycine (NOG, a 2-OG analogue) molecule (Figure 
4.2.1.(B)). If oxidation occurs, NOG is converted to 2-OG under physiological 
conditions (Hu et al., 2013). The Fe(II) is coordinated by three highly conserved 
amino acid residues, also known as the signature HxD motif (Ko et al., 2010), 
H1382, D1384 and H1881 whereas NOG is coordinated by four highly 
conserved residues, R1261, H1416, R1896 and S1891 of TET2 (Hu et al., 
2013). Interestingly, the highly conserved residue H1382 is mutated in our two 
patients with ALPS. 
All TET proteins possess a catalytic domain, however only TET1 appears to 
contain the CXXC domain, which has been predicted maybe responsible for the 
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DNA binding activity (Pastor et al., 2013). It is suggested that TET2 had the 
CXXC domain but due to the chromosomal inversion during the vertebrate 
evolution split the TET2  gene into distinct segments encoding the catalytic 
domain of TET2 and CXXC domain which is now separately encoded by a 
neighbouring gene named CXXC4 (also known as IDAX4) (Ko et al., 2013; 
Pastor et al., 2013; Solary et al., 2013) Figure 4.2.1(A)) . 
 
Figure 4.2.1 : Structure of TET2 protein and DSBH Core. A) The TET2 
protein consists of the core catalytic region including the cysteine rich insert and 
DSBH domain. A chromosomal inversion detached the TET2 catalytic domain 
from its CXXC domain, which became a separate gene, IDAX. The number of 
amino acid is indicated. B) Ribbon presentation of the DSBH core. The highly 
conserved residues that coordinates both Fe(II) and NOG are indicated as 
dashed line. Figure (A) is reproduced from Pastor et al. (Pastor et al., 2013) and 
Figure (B) is reproduced from Hu et al.(Hu et al., 2013). 
 
4.2.1.3 Active demethylation mechanism 
It was suggested that TET proteins including TET2 mediate active DNA 
demethylation through DNA repair of which three mechanisms were proposed 
(Pastor et al., 2013). In the first mechanism, TET proteins oxidize 5mC to 5hmC 
and then further oxidize 5hmC to generate 5fC and 5caC. 5fC and 5caC will 
then be excised by thymine DNA glycosylase (TDG) (He et al., 2011; Maiti and 
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Drohat, 2011) via base excision repair, and their replacement with cytosine 
results in demethylation (Figure 4.2.2). An alternative mechanism was proposed 
where 5hmC is deaminated to 5-hydroxyuracil (5hmU) by AID (activation 
induced cytidine deaminase ) and APOBEC (apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide) family enzymes (Guo et al., 2011a) then targeted 
by SMUG1 (single-strand selective monofunctional uracil DNA glycosylase 1) 
and TDG glycosylases via base excision repair and ultimately replaced by 
cytosine (Figure 4.2.2) (Pastor et al., 2013) Another proposed mechanism is the 
decarboxylation of 5caC to cytosine, however until now the factors that catalyse 
this decarboxylation reaction are still unknown (Pastor et al., 2013) (Figure 
4.2.2). Although some studies provided evidence to support a role for many of 
these DNA modifying pathways, how effectively these pathways occur in vivo in 
mammalian cells is still unclear and controversial. Part of this controversy was 
due to the fact that the active demethylation that uses 5hmC as an intermediate 
involves several different enzymes and pathways, and it is unclear whether all 
of them contribute to gene regulation in different stages of development or 
different cell types (Pastor et al., 2013). However, newly developed technology 
enabling the mapping of oxidised methylcytosine at a single base resolution in 
small numbers of differentiating cells (Pastor et al., 2013) could provide better 
understanding on active demethylation mechanisms. 
 
Figure 4.2.2 : Mechanisms of DNA demethylation involving TET proteins: 
DNMT add a methyl group to the 5’ position of cytosine and produce 5mC. TET 
proteins then oxidize 5mC to 5hmC, 5fC and 5caC. 5fC and 5caC will be 
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removed by TDG via base excision repair and replaced by cytosine. 5caC can 
also be removed by decarboxylation. 5hmC is deaminated by AID/APOBEC 
family of enzymes, to 5hmU, which will then be converted to cytosine by 
SMUG1 or TDG via the base excision repair pathway (Pastor et al., 2013). 
4.2.1.4 TET2 mutations in haematological malignancies 
As mentioned earlier, TET2 is highly expressed in haematopoietic cells 
including lymphocytes, monocytes, NK cells and particularly granulocytes 
(Langemeijer et al., 2009). The high expression of TET2 in haematopoietic cells 
reflects its role in regulating haematopoiesis, including stem cell self-renewal, 
lineage commitment and terminal differentiation of specific lineages (Solary et 
al., 2013). It is well documented that somatic TET2 mutations are frequent in 
haematological malignancies (Ko et al., 2015). This relationship was first 
observed in Myelodysplastic syndrome (MDS) and Myeloproliferative 
neoplasms (MPN) with chromosome 4q24 abnormalities, which includes the 
TET2 locus (Delhommeau et al., 2009; Langemeijer et al., 2009). Both MDS 
and MPN are clonal disorders that arise in haematopoietic stem cells and the 
main features are ineffective haematopoiesis that affects one or several 
lineages and an increased risk of transformation to Acute Myeloid Leukemia 
(AML) (Delhommeau et al., 2009). Following these findings, several other 
studies identified somatic TET2 mutations in other MDS and MPN patients as 
well as other myeloid malignancies such as chronic myelomonocytic leukemia 
(CMML), and AML (Abdel-Wahab et al., 2009; Jankowska et al., 2009; 
Kosmider et al., 2009; Mullighan, 2009; Tefferi et al., 2009; Weissmann et al., 
2012).  All these studies have established TET2 as one of the common mutated 
genes in myeloid malignancies. TET2 mutations were distributed between exon 
3 and exon 11 (Weissmann et al., 2012). Studies done by Weissmann et al. 
showed that various types of somatic TET2 mutations including missense, 
nonsense, deletion, insertion and splice site mutations were observed in acute 
myeloid cancer patients (Figure 4.2.3). Interestingly, all the missense mutations 
occurred within either of two conserved domains of TET2, spanning from amino 
acid 1104 to 1478 (first conserved domain, CD1) and amino acids 1845-2002 
(second conserved domain, CD2) (Weissmann et al., 2012).  
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Figure 4.2.3: The localization and types of TET2 mutations that had been 
discovered in acute myeloid cancers patients by Weissmann et 
al.(Weissmann et al., 2012). The complete region of TET2, the conserved 
domains (CD1 and CD2) and the amino acid positions are indicated. Figure 
reproduced from Weissmann et al.(Weissmann et al., 2012). 
 
Recently, an observation in Tet2-deficient mice led to the identification of TET2 
mutations in human lymphoid malignancies. A study by Quivoron et al. in Tet2-
deficient mice demonstrated altered T and B lineage development, prompting a 
further investigation in patients with lymphoma. Sequencing of TET2 confirmed 
the presence of somatic mutations in B and T lymphomas (Quivoron et al., 
2011). Subsequently, more TET2 mutations were identified in other types of 
lymphoma such as angioimmunoblastic T cell lymphoma (Odejide et al., 2014), 
peripheral T cell lymphoma (Lemonnier et al., 2012), and more recently mantle 
cell lymphoma (Meissner et al., 2013) and diffuse large B cell lymphoma (Asmar 
et al., 2013). 
A study conducted by Ko et al. demonstrated that the genomic level of 5hmC 
was significantly reduced in patients with myeloid malignancies who had TET2 
mutations, consistent with loss of TET2 enzymatic activity in these patients (Ko 
et al., 2010). The same group also performed a study in which they transfected 
leukaemia-associated mutations, R1896S and R18996S, as well as 
substitutions in the HxD motif such as H1802Y in mouse (similar to human 
H1382 residue), which coordinates the Fe(II) in the highly conserved CD 
domain, into HEK293 T cells and the results also confirmed that these 
mutations result in impaired catalytic activity (Ko et al., 2010). It was expected 
that the TET2 mutations would lead to an accumulation of 5mC in the genome. 
However, this idea still remains controversial as two studies demonstrated two 
different results. In agreement, the first study done by Figueroa et al. showed 
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global hypermethylation at the CpG methylated sites in patients with AML 
(Figueroa et al., 2010). However, in contrast, Ko et al. demonstrated that TET2 
mutations were associated with global hypomethylation at differentially-
methylated site in patients with various myeloid malignancies (Ko et al., 2010) 
The possible differences in these results might be due to cancer subtypes 
examined and the tools used for 5mC quantification and statistical analysis (Ko 
and Rao, 2011).   
Interestingly, other common genetic mutations in haematological malignancies 
were discovered in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes 
(Figueroa et al., 2010). IDH1 and IDH2 form a key enzymes in the tricarboxylic 
acid (TCA) cycle which catalyses the conversion of isocitrate to alpha-
ketoglutarate, an essential cofactor for TET2 (Nakajima and Kunimoto, 2014). 
The absence of IDH1 and IDH2 results in the formation of 2-hydroxyglutarate 
(2-HG), which inhibits α-KG-dependant enzymes such as TET2 by competing 
with α-KG (Figueroa et al., 2010; Nakajima and Kunimoto, 2014). Therefore, in 
AML with IDH1/IDH2 mutation, the increase of 2-HG results in loss of TET2 
function (Figueroa et al., 2010; Ward et al., 2010). Collectively, all these findings 
emphasise the critical role of TET2 in preventing aberrant haematopoiesis and 
leukemogenesis. 
4.2.1.5 TET2 mutations in non-haematological malignancies 
TET2 loss of function has also been discovered to contribute to the 
development of a small number of solid tumours (Solary et al., 2013). It was 
recently proposed that TET2 plays a role in defining the subset of metastatic 
tumours in castration-resistant prostate cancers (Nickerson et al., 2013). 
Interestingly, it was demonstrated that the levels of 5hmC were dramatically 
reduced in human breast, liver, lung, pancreatic and prostate cancers compared 
with the matched surrounding normal tissue and the decreased 5hmC is 
associated with the downregulation of TET2 and other TET proteins (Yang et al., 
2013). The decrease of 5hmC in these solid tumours indicates that 5hmC could 
be an epigenetic hallmark of tumour development. In agreement, loss of 5hmC 
has also been observed in melanoma (Lian et al., 2012). Reintroduction of 
TET2 or IDH2 in melanoma cells increased the 5hmC levels and suppressed 
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melanoma growth as well as increasing the survival in the animal model, 
suggesting the function of 5hmC in melanoma development and linking the TET 
enzymatic pathway to 5hmC–mediated suppression of melanoma (Lian et al., 
2012). 
4.2.1.6 Disruption of Tet2 in mouse models 
In order to understand the role of TET2 in regulating haematopoietic 
development and cellular transformation, in vivo studies using TET2-disrupted 
mice were generated. Li et al. generated a gene-trap mouse strain in which a β-
galactosidase-GFP cassette was inserted into exon 3 of the TET2 locus, 
disrupting the endogenous start codon and inducing premature termination of 
transcription (Ko and Rao, 2011; Li et al., 2011). The TET2-/-mice were viable, 
fertile, developed grossly normally and did not show any lethality. However, as 
they aged, they developed diverse myeloid malignancies: 1) 57%  were found to 
have MDS with erythroid predominance and depletion of haematopoietic 
stem/progenitor, LSK ( Lin-c-Kit+Sca-1+) ; 2) 20% had  myeloproliferative 
disorder (MPD) or CMML-like phenotypes with increased LSK and 
granulocyte/macrophage precursor (GMP) populations, as assessed by 
increased monocytosis, leucocytosis, bone marrow hypercellularity and 
extramedullary haematopoiesis with evidence of hepatomegaly and 
splenomegaly (Ko and Rao, 2011; Li et al., 2011). TET2 deficiency also 
conferred a significant advantage on these cells in repopulating heterogenous 
hematopoietic lineages in a cell-autonomous manner. The TET2-/- LSK cells 
were highly proliferative and they displayed an enhanced capacity for clonal 
expansion.  In addition, the TET2-/-  mice demonstrated that the level of genomic 
5hmC was diminished in bone marrow cells, in agreement that loss of TET2 
function compromised its enzymatic activity as shown previously in patients with 
myeloid cancers and in vitro studies by Ko et al. (Ko et al., 2010).  
Several other groups generated alternative Tet2 knock out mouse models (Ko 
et al., 2011; Moran-Crusio et al., 2011a; Quivoron et al., 2011). Their Tet2-/- 
mouse phenotypes were consistent with the phenotypes described by Li et al. 
(Li et al., 2011). Moran Crusio et al. (Moran-Crusio et al., 2011b) generated 
conditional Tet2-deficient mice targeting exon 3 containing the start codons in 
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the Tet2 locus, whereas Ko et al. (Ko et al., 2011) generated conditional Tet2-
disrupted mice targeting exons 8-11. Another group, Quivoron et al. (Quivoron 
et al., 2011), generated two different strains of Tet2-deficient mice; in the first 
strain, a β-galactosidase –neomycin was inserted into exon 9 and in the other 
strain, exon 11 was conditionally deleted. Of note, exons 7-11 in the Tet2 gene 
encode the double stranded β-helix domain, meaning that their deletion disrupts 
the core region of the catalytic domain. All these Tet2-/- mice showed 
phenotypes consistent with that described by Li et al. They had normal growth 
and organ development in their early life. Later on, they developed CMML-like 
disease. The Tet2-/- LSK cells demonstrated enhanced self-renewal and 
replating capacity in vitro. The deletion of Tet2 resulted in an increase of HSCs 
in a cell intrinsic manner and increased HSCs’ self-renewal capacity. In addition, 
Quivoron et al. demonstrated that lymphoid lineage development was also 
affected with an expansion of an aberrant (CD19+B220low) lymphoid population, 
decrease in B cell lineages in the bone marrow and an increase in CD4-CD8- 
double negative T cells (DNT) progenitors in thymus (Quivoron et al., 2011; 
Solary et al., 2013). The Tet2-deficient mice phenotypes are summarised in 
Table 4.2.1. 
 Quivoron et al. Moran-Crusio  
et al. 
Ko et al. Li et al. 
Models Exon 9 (gene trap) 
Exons 10-11 
(conditional  
deletion) 
Exon 3 
(conditional 
deletion) 
Exons 8-10 
(conditional 
deletion) 
Tet2 disruption 
 6bp upstream of 
the transcription  
start 
Development  Normal development and growth 
5-hmC levels Decreased 
Lin-c-Kit+Sca-1- 
(LSK ) 
 
Increased and increased serial replating 
Bone marrow 
progenitors 
Increased CMP,  
MEP 
Increased 
CMP 
Increased CMP Increased GMP 
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Phenotypes Hepatomegaly, 
splenomegaly, 
leucocytosis,  
anaemia, 
thrombocytopenia  
Splenomegaly, 
leukocytosis 
Splenomegaly, 
monocytosis 
Hepatomegaly, 
splenomegaly, 
leucocytosis, 
Monocytosis 
Lymphoid 
lineages 
Expansion of an  
aberrant (CD19+B220 
low) lymphoid  
population, decrease in B 
cell lineages in the bone 
marrow and an increase 
in CD4-CD8- double 
negative T  
cells (DNT) progenitors 
in thymus 
unchanged unchanged Unchanged 
Diseases CMML-like  CMML-like CMML-like CMML-like, MDS , 
MPD 
Table 4.2.1 : Animal models and phenotypes of TET2-deficient mice. 
CMML - chronic myelomonocytic leukemia, CMP- Common Myeloid progenitors, 
MEP- Megakaryocyte-erythroid progenitors 
 
These Tet2-deficient mouse models are consistent with a pathogenic role for 
TET2 loss of function mutations in myeloid and lymphoid malignancies. Indeed, 
TET2 function is required to restrict the function and expansion of HSCs by 
regulating the gene transcription in HSCs (Solary et al., 2013). Aberrant 
methylation at CpG islands in specific gene promoters is often observed to lead 
to silencing of the tumour suppresser genes and development of cancer 
(Herman and Baylin, 2003). As TET2 function is to oxidise 5-methylcytosine, it 
is appealing to assume that the loss of TET2 contributes to gene-specific 
hypermethylation and results in silencing or activation of genes involved in 
HSCs development. However, based on the conflicting results of previous 
studies Ko et al. (Ko et al., 2010) and Figueroa et al. (Figueroa et al., 2010), 
mentioned earlier in Section 4.2.1.1.6, this assumption requires to be tested. 
Thus, more in vivo and in vitro studies of the epigenetic landscape in TET2 
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mutated patients with haematological malignancies are needed in order to 
advance our understanding on how loss of TET2 activity leads to disease 
development.   
4.2.1.7 Role of TET2 in embryonic stem cells and induced pluripotent stem cells 
TET1 and TET2 play an important role in maintaining the pluripotency, self-
renewal capacity and lineage specification of embryonic stem cells. Embryonic 
stem cells are derived from the inner cell mass of the developing blastocyst and 
they are pluripotent and self-renewing (Koh et al., 2011). Both TET1 and TET2 
are upregulated in mouse embryonic stem cells and downregulated after the 
cells differentiate; similarly the 5hmC level is increased in embryonic stem cells 
and downregulated during development. The binding of TET2 to the 
pluripotency factor Oct4 links TET2 to the pluripotency machinery (Koh et al., 
2011). In addition, it has been shown that TET2 interacts with pluripotency loci 
such as Esrrb and Nanog, where it creates 5hmC, suggesting the involvement 
of both TET2 and 5hmC in the pluripotency mechanism in mouse embryonic 
stem cells (Koh et al., 2011). Similar findings have also been observed in 
studies of reprogramming of somatic cells into induced pluripotent stem cells 
(iPSCs) using pluripotency factors. Doege et al. showed that TET2 is involved in 
somatic cell reprogramming by demonstrating that both Parp1 and TET2 were 
recruited to the loci of Nanog and Esrrb in iPSCs (Doege et al., 2012). In 
addition, Mikkelsen et al. showed that TET2 was upregulated at early 
reprogramming stages and in iPSCs formed from somatic cells that were 
transformed with pluripotency factors (Mikkelsen et al., 2008). Moreover, it was 
also reported that upon downregulation of TET2 in iPSCs, 5hmC was reduced 
while methylation changes varied at the pluripotency loci. This suggests that 
TET2 was needed for inducing 5hmC for pluripotency as well as showing that 
5hmC potentially serves as a distinct epigenetic mark from 5mC (Doege et al., 
2012). Although many studies demonstrate the involvement of TET2 in 
promoting pluripotency in mouse embryonic stem cells and iPSCS, 
nevertheless, how TET2 regulates the pluripotency in human embryonic stem 
cells remains confusing and controversial (Solary et al., 2013) and requires 
further exploration.  
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4.2.1.8 Role of TET2 in histone modification 
Besides DNA demethylation, it has been shown that TET2 is associated with 
histone modifications. TET2 recruits O-GlcNAc transferase (OGT) to chromatin, 
promoting histone GlcNAcylation which influences gene transcription (Chen et 
al., 2013). OGT is an enzyme that catalyses the addition of O-GlcNAc to Ser 
and Thr residues of proteins (Sakabe et al., 2010). It was also demonstrated 
that the TET-OGT complex occupies the CpG islands at transcriptional start 
sites where high levels of O-GlcNAc modified histones but low levels of 5mC 
and 5hmC exist, further supporting that TETs are not only involved in DNA 
hydroxylation but also in mediating the recruitment of OGT to genomic loci to 
modify histones (Deplus et al., 2013). Furthermore, TET2 also recruits OGT 
together with HCF1 (Host Cell Factor 1), a component that is required for the 
recruitment of SET1/COMPASS and H3K4 methylation (Deplus et al., 2013). 
However, the TET2-OGT interaction is independent of TET2’s enzymatic 
activity (Chen et al., 2013) and was preserved in the enzymatically dead HxD 
mutant. The involvement of TET2 with histone modification via OGT suggests 
another role of TET2 in regulating gene transcription. 
4.2.1.9 TET2 regulates cytokine expression in T cells 
Most previous work on TET2 addresses its function in regulating 
haematopoiesis and cellular transformation specifically in myeloid cells. So far, 
few studies address TET2’s functions in lymphocytes and the immune system. 
However, very recently, Ichiyama et al. demonstrated the important role of 
TET2 in T cell function, particularly in cytokine expression (Ichiyama et al., 
2015). The recruitment of TET2 promotes DNA demethylation of regulatory 
elements of cytokine genes and is dependent on the expression of key 
transcriptions factors such as Tbet, RorγT and STAT3 (Ichiyama et al., 2015; 
Zhong and Zhu, 2015). The interaction between TET2 and these transcription 
factors influences the expression of cytokine genes which are important for T 
cell differentiation, such as ifng for Th1, and IL17 and IL10 for Th17 cells.  
In addition, this group demonstrated that TET2 regulates autoimmune 
responses by controlling the production of IL-10 in vivo. They found that the 
development of Type 1 regulatory T (Tr1) cells, which express IFNγ and IL-10, 
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were inhibited in the absence of TET2. Furthermore, they also demonstrated 
that in TET2-deficient mice, IL-10 production was reduced which leads to 
exacerbation of symptoms of autoimmune encephalomyelitis (EAE), a prototype 
for T cell-mediated automimune disease. From this finding, it is believed that 
TET2 plays an important role in regulating IL-10 expression and in regulating 
the T cell-mediated autoimmune response. This study by Ichiyama et al. 
suggests another role of TET2 in the immune system.   
4.2.2 Summary 
Based on previous literature, TET2 plays an important role in DNA 
demethylation as well as histone modification. As mentioned earlier, TET2 has 
been identified as the disease-causing gene in the two patients described in 
Chapter 4.1, who have a homozygous missense mutation, c.4115A>G, 
p.H1382R, in TET2. The residue H1382 is within the catalytic domain and is a 
highly conserved residue that coordinates Fe(II). For this reason, its mutation is 
predicted to disrupt TET2 enzymatic activity which we hypothesise is 
responsible for the disease phenotype. In order to test this hypothesis, I set out 
to investigate the enzymatic function of TET2 using patient material and a 
recombinant system. 
4.2.3 Hypothesis 
A homozygous missense mutation, c.4115A>G, p.H1382R, in TET2 leads to 
impairment of TET2 enzymatic activity and thereby perturbs epigenetic 
regulation. 
4.2.4 Aims  
To investigate the effect of the TET2 missense mutation, c.4115A>G, p.H1382R, 
on 
- TET2 protein expression 
- Hydroxymethylating activity towards DNA (patient cells and recombinant system) 
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4.2.5 Results 
4.2.5.1 TET2 protein is expressed in both patients fibroblasts 
The first experiment that I did was to investigate the effect of TET2 missense 
mutation on the protein expression in the patients. As TET2 is ubiquitously 
expressed in various cells and tissues (Solary et al., 2013) and we had access 
to patients fibroblasts, therefore these cells were used to look at the protein 
expression. Both patients and control fibroblasts were lysed with RIPA 
(radioimmunoprecipitation assay) buffer. RIPA buffer was used in lysing the 
cells because TET2 is a nuclear protein and this buffer contains the ionic 
detergent SDS and sodium deoxycholate as active constituents which are 
useful for disruption of nuclear membranes. 
 
Figure 4.2.4 : TET2 protein expression in patients and control fibroblasts. 
Patient (P1, P2) and control (C) fibroblasts were analysed by Western Blotting 
using a mouse monoclonal antibody directed against TET2 and an anti-GAPDH 
antibody as loading control.  The bands were quantitated from the Western Blot 
using densitometry and the signals were standardized to GAPDH. The result is 
representative of three separate experiments. 
 
By Western Blotting it was shown that TET2 protein was expressed in both 
patients’ fibroblasts at a level similar to control fibroblasts (Figure 4.2.4). This 
finding is consistent with a study done by Ko et al. showing that the homologous 
HxD variant, H1302Y, was stable when expressed in a recombinant system (Ko 
et al., 2010).  
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4.2.5.2 TET2 p.H1382R mutation impairs the enzymatic activity of TET2 
Ko et al. found a significant decrease of 5hmC levels in cells that were 
transfected with mutant TET2 (H1302Y) compared to wild type, demonstrating 
that the catalytic activity of TET2 was impaired (Ko et al., 2010). Interestingly, 
the mutant TET2 in the study, H1302Y, in mouse, is similar to the mutation in 
our patients, H1382R. Therefore, the next experiment to perform is to 
investigate the effect of the H1382R mutation on the enzymatic activity. It is 
predicted that the TET2 enzymatic activity will be impaired as H1382R is in a 
highly conserved CD domain, disrupting the Fe(II) binding motif. 
To investigate the effect of TET2 p.H1382R mutation on the enzymatic function, 
my first approach was to use a recombinant system similar to Ko et al. (Ko et al., 
2010). HEK293T cells were transfected with an expression plasmid encoding 
wild type or mutant TET2. HEK293T cells were chosen because firstly, they had 
been used to assess the enzymatic activity of TET2 in the study by Ko et al. (Ko 
et al., 2010), and secondly, they are known to be easily transfected. 
Three TET2 expression plasmids were provided by our collaborator, Dr 
Skirmantas Kraucionis and Melania Zauri, Oxford University, UK (Figure 4.2.5). 
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Figure 4.2.5 : Three TET2 plasmids for the recombinant system. A) pCMV 
TET2 plasmid; B) pCAG TET2 plasmid; C) pLenti TET2 plasmid. All plasmids 
are flag-tagged and carry an ampicillin-resistance gene. The plasmids were 
generously given by Dr Skirmantas Kraucionis and Melania Zauri, Oxford 
University. 
 
To generate the mutant TET2 plasmid, a Site-Directed Mutagenesis 
QuickChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, USA) 
was used where histidine (H) 1382 was substituted with arginine (R) by 
introducing the A>G mutation into the specific plasmid DNA sequence at 
position c.4115 in TET2 wild type plasmids using a PCR-based technique. This 
technique was unsuccessful for pCAG TET2 but successful for pCMV TET2. 
Unfortunately however, no TET2 expression was achieved with the wt and 
mutant pCMV TET2 plasmids.  A subcloning technique was thus attempted, 
where wild type TET2 in the pCAG plasmid was replaced with mutant TET2 
from the pCMV plasmid. Unfortunately this method also failed. We then 
received the pLent TET2 plasmid and used it for successful site directed 
mutagenesis. The A>G mutation in pLent mutant TET2 was confirmed by 
Sanger sequencing (Geneius Laboratories, UK) (Figure 4.2.6(A)). 
To investigate the effect of the TET2 p.H1382R mutation on enzymatic function, 
HEK293 T cells were transfected with either wild type TET2 or mutant TET2 
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pLent plasmid using Fugene HD transfection reagent. After 48 hours, the 
transfected cells were fixed with 4 % paraformaldehyde. Subsequently, DNA 
was denatured with acid hydrochloric (HCL) and neutralised with Tris-HCl buffer. 
The DNA denaturing step is required for the 5hmC epitopes to be exposed. 
Then the cells were co-stained with anti-Flag and anti-5hmc antibodies and 
analysed by Immunofluorescence.  
 
 
Figure 4.2.6 : The catalytic activity of TET2 is compromised by TET2 
p.H1382R mutation. A) Sequences of successful mutant TET2 that was 
generated using the pLent TET2 plasmid. The A>G mutation was successfully 
introduced into the DNA and confirmed by Sanger sequencing. B) The catalytic 
activity is assessed by Immunofluorescence. HEK293 T cells transfected with 
empty vector (empty), Flag-tagged wild type TET2 (TET2 WT) and mutant TET2 
151 
 
(TET2 H1382R) pLent and were stained with antibodies against 5hmC (red) and 
the Flag epitope (green). DAPI (blue) indicates nuclear staining. Result is 
representative of three independent experiments. 
 
Immunofluorescence results showed that in HEK293T cells expressing wild type 
TET2, 5hmC staining was significantly increased whereas in cells expressing 
TET2 mutant H1382R, the 5hmC staining was absent (Figure 4.2.6(B)). This 
result indicates the role of this residue, H1382, in the catalytic activity and 
confirms that mutation of this residue results in impaired enzymatic activity. 
As mentioned earlier, TET2 and conversion of 5mC to 5hmC were shown to 
play an important role in pluripotency and differentiation of embryonic stem cells 
and iPSCs. To investigate the effect of our patients’ TET2 p.H1382R mutation 
on the pluripotency and differentiation mechanisms, a pilot study was performed 
by my colleague, Dr Katarzyna Tilgner at Institute of Genetic Medicine, 
Newcastle University, using iPSCs that were generated from patients’ 
fibroblasts. Briefly, to generate iPSCs, patient fibroblasts were transduced with 
Sendai virus vectors that carry the pluripotency factors Oct4, Sox2, Klf4 and c-
Myc for 7 days and later transferred onto mouse embryonic fibroblasts (MEFs). 
After 14 - 21 days the transduced cells produced well-formed colonies. Several 
of these colonies were picked and transferred onto new feeder plates for 
expansion. The cells were passaged several times to remove the Sendai virus 
and by this time the cells were established undifferentiated iPSCs that express 
all the pluripotency markers. These undifferentiated iPSCs could further be 
differentiated into specific cell types as required. For the pilot study, our 
hypothesis was that TET2 is important in maintaining the 5hmC level in 
undifferentiated iPSCs and in early differentiation stages. Therefore, to confirm 
our hypothesis, Dr Katarzyna Tilgner assessed the 5hmC level in the 
established undifferentiated, early differentiated, late differentiated iPSCs and 
fully differentiated somatic cells, fibroblasts of both patients and controls as well 
as human embryonic stem cells as positive control by Immunofluorescence. 
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Figure 4.2.7 : 5hmC level in a human embryonic stem cell line (H9), in 
iPSCS from healthy control and in patient iPSCs analysed by 
Immunofluorescence. 5hmC (brown) and 5mC (green) levels in H9, control 
(C1) and patients (P1, P2) A) undifferentiated iPSCs  B) early undifferentiated 
iPSCS (less than 10 days) C) late undifferentiated iPSCS (more than 10 days) 
D) fibroblasts. DAPI is used for nuclear staining. This experiment was 
performed by Dr Katarzyna Tilgner. Result of one experiment. 
 
Figure 4.2.7 shows that 5hmC levels were decreased in both undifferentiated 
and early differentiated patient iPSCs compared to controls and hESC. At later 
time points, when cells had fully differentiated, the 5hmC levels were similar in 
both patient and control.These results demonstrate that TET2 p.H1382R 
mutation does affect the level of 5hmC, consistent with an active role for TET2 
in maintaining the 5hmC level in undifferentiated and early differentiated cells. 
By contrast, in the late and fully  differentiated somatic cells (for example 
fibroblasts) the 5hmC level is similar in patients cells to the controls, suggesting 
that maybe other TETs such as TET3 play a role in normalising the global 
5hmC level in the cells. So far, the recombinant system and iPSCs were 
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consistent with our hypothesis that the TET2 p.H1382R mutation impairs its 
enzymatic activity. To investigate further the effect of TET2 p.H1382R, the next 
experiment was to assess the global 5hmC level in patient material.  
4.2.5.3 : Normal 5hmC level in patient B cells 
To further explore the effect of TET2 p.H1382R mutation in the patients, patient 
B-cell DNA was chosen to assess the 5hmC level in vivo. As mentioned in the 
patients’ history, P2 died after transplantation whereas P1 underwent 
haematopoietic stem cell transplantation and survived. After transplantation, the 
P1 developed split chimerism with donor T cells and recipient B cells. Therefore, 
his B cells represent a source of freshly available patient DNA, suitable in 
assessing the 5hmC level. Unfortunately, we do not have any fresh material 
from P2.   
The first method that was chosen to assess the global 5hmC level in the patient 
B cells was dot blot assay as it was widely used in previous studies to evaluate 
the global 5hmc level in mammalian cells (Ko et al., 2010; Quivoron et al., 2011; 
Kunimoto et al., 2012; Hu et al., 2013; Ko et al., 2013; Yang et al., 2013; Huang 
et al., 2014). In summary, dot blot is an assay where denatured DNA is blotted 
onto a nylon membrane using dot blot apparatus, air-dried and immobilised on 
the membrane by UV cross linking. The membrane is then probed with an anti-
5hmC antibody and later with a secondary antibody. Washing steps are 
required after probing with the anti-5hmC antibody overnight, before and after 
probing with secondary antibody.  Finally, 5hmC in DNA is detected by an 
enhanced chemiluminescence system. The 5hmC level was quantitated directly 
by analysing the density of single dots on the membrane.  Although many 
optimisations including  
1) titrating the amount of DNA using control DNA or different control DNA 
(Figure 4.2.8(A) &(B)) 
2) same amount of DNA were blotted onto the membrane into several wells, 
to make sure that the dots were equal in each well (Figure 4.2.8 (C) 
3) using different antibodies 
4) optimising the dot blot technique such as different times of air drying the 
membrane and UV cross linking exposure 
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were performed using control DNA, this method was shown to be unreliable as 
each optimisation experiment showed variabilities in detecting the 5hmC level. 
Furthermore, by performing two-fold serial dilutions of the amount of DNA, no 
dots were detected on the membrane for both control and patients B cells DNA, 
further suggesting that this method was not working successfully. 
 
 
 
Figure 4.2.8 : Optimisation of the dot blot assay for measuring the 5hmC 
level in control DNA. 5hmC level in control DNA was detected using anti-
5hmC antibody and quantified by dot blot. A) Different amounts of control DNA 
(C1) (1ug, 500ng, 250ng) were spotted onto the membrane B) Two-fold serial 
dilutions of different control DNA (C1, C2) (400ng, 200ng, 100ng, 50ng, 25ng) 
were loaded into each well. C) Equal amount of control DNA (C1) was loaded 
into each well (16 wells). 
 
Therefore, another method, the ELISA 5hmC kit by Zymo Research was chosen 
to assess the 5hmC level in vivo. This method was chosen because it requires 
a small quantity of DNA to perform this experiment as the patient DNA was very 
limited.  However, this method was not commonly used. This ELISA 5hmC kit 
uses a sandwich-based ELISA format where firstly, the anti-5hmC antibody is 
coated at the bottom of the well. Then, sheared DNA is added and the single 
stranded 5hmC-containing DNA binds to anti-5hmC which is then recognised by 
anti-DNA HRP Antibody. Finally the addition of HRP developer will produce a 
greenish colour in the wells containing 5hmC DNA, due to the enzymatic 
reaction of the anti-DNA HRP antibody to the chemical substances in the HRP 
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developer. The intensity of the colour change is analysed by plate reader. 
Included with the kit is a control DNA set that is needed to generate a standard 
curve to calculate the percentage of 5hmC in the DNA samples using the 
absorbance reading by the plate reader.  
To confirm that this method is reliable and sensitive in detecting the 5hmC in 
DNA, several optimisation experiments were performed such as : 
1) Titrating the amount of DNA, expecting to observe an increased amount 
of 5hmC, correlating with the increased amount of DNA 
2)  Reading the absorbance with a plate reader at later time points (20 and 
60 minutes) to allow more time for generation of the colour signal 
3) Titrating the concentration of anti-5hmC antibody. 
After ensuring that the assay was working within its dynamic range, aliquots of 
DNA extracted from the iPSCs that were previously examined by 
Immunofluorescence (Figure 4.2.7) were used to validate the results obtained 
by ELISA. 
 
 
Figure 4.2.9 : Percentage of 5hmC in patients and controls iPScs/hESCs 
quantified by ELISA. The percentage of 5hmC was measured in human 
embryonic stem cells line (C1) as well as in undifferentiated iPSCs, 
differentiated iPSCs and fibroblasts from control (C2) and patients (P1, P2). 
Result is representative of one experiment. 
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The result (Figure 4.2.9) showed a reduction in 5hmC levels in both 
undifferentiated and early differentiated patients iPSCs compared to hESC (C1). 
When the iPSCS were fully differentiated, the 5hmC levels were similar in both 
patients and controls iPSCs, while late differentiated cells showed an 
intermediate pattern. This result correlates with the Immunofluorescence 
findings, thus this method was thought to be reliable and sensitive to detect 
5hmC in DNA. 
Further ELISA experiment was performed, to investigate the 5hmC level in 
patient compared to control B cell DNA.  
 
Figure 4.2.10 : Percentages of global 5hmC in DNA from patient and 
control B cells quantified by ELISA. A) Percentage of 5hmC in controls (C1, 
C2, C3) and patient (P) were calculated using the equation determined by the 
standard curve (B). (B) A standard curve was generated from the control DNA 
set, provided by the manufacturer. C) (i) Aliquots of controls (C1, C2, C3) and 
patient (P) from the experiment (A) were loaded and run on an agarose gel ii) 
Densitometry of the bands that were shown in (C(i)), to quantify the amount of 
each DNA. Result (A) is a representative of two independent experiments. 
Result (B) and (C) shown is one of the result from experiment (A). 
 
The percentage of global 5hmC in controls and patient is shown in Figure 
4.2.10 (A). The 5hmC percentage was calculated using the standard curve 
(Figure 4.2.10(B)) that was generated from the control DNA set that was 
provided by the manufacturer. From the ELISA experiment, it was demonstrated 
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that the percentage of 5hmC in patient B-cell DNA was similar to that of controls 
(Figure 4.2.10(A)). To check that the same total amount of DNA was used for 
each sample in the experiment, aliquots of each DNA sample were loaded and 
run on an agarose gel (Figure 4.2.10(C)(i)). To quantify the amount of DNA, 
densitometry (Figure 4.2.10(C)(ii)) was generated from Figure 4.2.10(C)(i)). 
Densitometry showed that similar amounts of DNA were present in each sample 
used in the ELISA experiment. Hence, this result indicates that the global 5hmC 
level is normal in patient B cells. 
4.2.5.4 TET1, TET2 and TET3 are expressed in healthy control B cells 
Since the TET family members consist of TET1, TET2 and TET3, and all are 
involved in conversion of 5mC to 5hmC, we hypothesised that the normalised 
global 5hmC level in the patient B cells was due to compensation by other TETs. 
To explore this possibility, qRTPCR was performed, to measure TET1, TET2 
and TET3 mRNA expression in normal B cells. H9, a human embyronic stem 
cells line was used as a positive control as it was shown in previous studies that 
TET1 expression was the highest there, followed by TET2 and very low 
expression of TET3 in mouse embryonic stem cells (Koh et al., 
2011),suggesting that the 5hmC levels in embryonic stem cells is oxidised 
mainly by TET1 and TET2.  
 
Figure 4.2.11 : TET1, TET2 and TET3 expression levels in control B cells. 
H9 was used as positive control. The TET1, TET2 and TET3 expression in both 
cells were relative to 18S. Result is representative of three independent 
experiments.  
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The results showed that expression of all three TETs was detectable in control 
B cells (Figure 4.2.11). This result raises the possibility that TET3 or TET1 
might compensate for TET2 in the global 5hmC level in patient B cells which 
was shown before (Figure 4.2.10(A)). To explain the disease phenotypes, we 
can postulate epigenetic differences other than crude changes in global 
hydroxymethylation. While global 5hmC levels might be normal, patients might 
show reduced 5hmC modifications at transcription start sites or other specific 
genomic loci that could results in the disease phenotypes observed in the 
patients. Furthermore the mutant TET2 may behave aberrantly with respect to 
other mechanisms of transcriptional regulation such as its interaction with 
transcription factors. 
4.2.6 Discussion 
Based on the molecular data described in chapter 4.1, the TET2 missense 
mutation c.A4115A>G, p.H1382R was identified as a candidate disease-
causing variant in both patients. Several findings from previous literature 
support this hypothesis. First, TET2 is highly expressed in the haematopoietic 
compartment compared to other tissues. Second, somatic TET2 mutations are 
commonly observed in haematological malignancies including myeloid and 
lymphoid malignancies, consistent with the occurrence of lymphoma in both 
patients. It is interesting to highlight that all TET2 missense mutations in acute 
myeloid leukaemia, reported by Weissman et al. (Weissmann et al., 2012), 
occurred within the core catalytic region (amino acid 1104 to 2002) with both 
patients’ mutation also being in the same region at amino acid position 1382.   
The most striking evidence comes from the Tet2-/- mouse models (Ko et al., 
2011; Li et al., 2011; Moran-Crusio et al., 2011a; Quivoron et al., 2011). All 
Tet2-deficient mice presented with hepatomegaly and splenomegaly which was 
also one of the features observed in both patients. In addition, before transplant, 
P1’s bone marrow aspirate showed increased myelopoeisis which was also 
observed in the Tet2-deficient mice. Other shared features were leucocytosis 
and monocytosis, observed in P1 after transplant and also in Tet2-deficient 
mice.  
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As has been mentioned earlier, Quivoron et al. identified altered B and T cell 
differentiation in the Tet2 knock-out mice (Quivoron et al., 2011). TET2 loss 
affects development of the lymphoid lineage with increased double negative 
(DN) CD4-CD8 T cell progenitors in the thymus and increased lymphoid 
population. Furthermore, apart from the lymphoid malignant transformation, 
there were other non-malignant phenotypes that were observed such as 
massive hepatosplenomegaly, anaemia and thrombocytopenia which also 
resemble those in our two patients. These phenotypes are observed in ALPS 
patients and are believed to be related to an apoptotic defect through the 
development of autoimmune cytopenias. However, neither autoimmunity nor 
apoptosis have been investigated before in the Tet2-deficient mice and remain 
yet to be explored. The similar phenotypes observed in both patients and all 
Tet2-deficient mice are compared in Table 4.2.2. 
Phenotypes Patients TET2-deficient mice 
Hepatomegaly, splenomegaly Yes Yes 
Increased myelopoiesis BMA showed increased 
myelopoiesis in P1 before 
transplant 
Yes 
Leucocytosis and monocytosis Developed in P1 after 
transplant associated with 
relapse of ALPS 
Yes 
Lymphoid malignant 
transformation 
P1 – EBV-positive  nodular 
sclerosing Hodgkin’s  
lymphoma 
P2  – T lymphoma 
Quivoron et al. demonstrated in 
Tet2-deficient mice – increased 
population of B lymphoid  
cells  
Anaemia, thrombocytopenia Yes- autoimmune Yes in Tet2-deficient mice 
generated by Quivoron et al. 
 
Table 4.2.2: Similar phenotypes in both patients and TET2-deficient mice. 
BMA- Bone marrow aspirate, EBV- Epstein-Barr virus 
 
A missense mutation is a point mutation in which substitution of a single base 
pair results in the translation of a different amino acid at that position. Our 
patients’ missense mutation is a single substitution of nucleotide A to G, 
resulting in changing the amino acid histidine to arginine. By Western blotting, it 
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was demonstrated that the TET2 protein was expressed in both patients. 
Although the protein was expressed in patients similarly to control, we show that 
the mutation results in loss of enzymatic function which results in the disease 
phenotypes observed in the patients.  
TET2 promotes DNA demethylation and regulates gene transcription by 
converting 5mC to 5hmC (Ko et al., 2010; Hu et al., 2013). Mounting evidence 
demonstrate that mutations within the catalytic domains or reduced expression 
of TET2 results in loss of  global 5hmC in patients bone marrow cells (Ko et al., 
2010) and these were found in patients with haematological malignancies 
including myeloid and lymphoid malignancies (Solary et al., 2013) as well as in 
non-haematological malignancies such as prostate cancers, melanoma breast 
and lung cancers (Solary et al., 2013). In our patient, the mutation is at H1382, 
a highly conserved residue involved in Fe(II) coordination which is important for 
its enzymatic activity. Therefore, it was predicted that the TET2 missense 
mutation affects the TET2 enzymatic function, perturbs the epigenetic regulation 
and results in the disease phenotypes. By overexpressing wild type and mutant 
p.H1382R TET2 gene in HEK293 T cells and analysing by Immunofluorescence, 
I confirmed that the p.H1382R mutation results in impaired enzymatic activity of 
TET2. In addition, Immunofluorescence also confirmed that this mutation leads 
to decreased 5hmC staining in patient iPSCs.  However, in contrast, by ELISA, 
patient B cells showed similar global 5hmC levels compared to control, 
indicating that the global 5hmC level was normal. This result is not in 
conformance with the loss of global 5hmC observed in patients with myeloid 
and lymphoid malignancies who have TET2 loss of function. In these patients, 
bone marrow cells were used for the analysis, whereas here I used B cells. The 
different results suggest that whereas TET2’s essential role in regulating HSCs 
function and differentiation is reflected by global 5hmC levels, in peripheral B 
cells, which are differentiated cells, global 5hmC levels don’t embody the 
importance of TET2 function. In addition, as mentioned earlier, it could be that 
the normalised 5hmC level in B cells is compensated by other TET family 
members. By qRT-PCR it was shown that TET1 and TET3 are also expressed 
in normal B cells, suggesting the possibility that 5mC is converted to 5hmC by 
TET1 and TET3, hence the normal global 5hmC level in patient B cells.   
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Another possibility is that maybe the ELISA technique is not that accurate in 
detecting the global 5hmC level, despite performing many optimisation 
experiments. At the time the experiment was performed, the method was not 
being described in any previous studies before. Recently, one study had used 
this method where they quantified the 5hmC level in patients with renal cell 
carcinoma and demonstrated a significant difference of 5hmC level in patients 
compared to control (Shim et al., 2014). However, the 5hmC level was also 
being confirmed by dot blot assay, implying that an established method is 
required to validate the 5hmC result by ELISA. As shown in this chapter’s 
results section, the optimisation of the dot blot assay using the 5hmC antibody 
was unsuccessful; therefore this method was not being done to quantify the 
5hmC level in patient B cells. Apart from dot blot, there are other established  
methods that had been shown to quantify the global 5hmC level including thin-
layer chromatography (TLC) (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009) 
and high performance liquid chromatography (HPLC) (Kriaucionis and Heintz, 
2009; Liutkeviciute et al., 2009). Both TLC and HPLC are chemical techniques 
that involve separation of the sample components by chromatography which is 
described as a mass transfer process involving adsorption. These techniques 
were shown to be a reliable and sensitive technique but their disadvantage is 
that they require a high amount of DNA, a minimum of 1ug. As the patient is a 
child, on rituximab, a drug that is used to suppress the B cells and his condition 
was unwell during the time the blood was taken, therefore the number of B cells 
that were isolated from the patient was very few, resulting in a small amount of 
DNA extracted from the cells. The amount of extracted DNA was very limited 
and not enough to use for these techniques.  
Since the 5hmC level was shown to be normal in patient B cells, it does not 
explain the development of lymphoma, apoptosis defect and autoimmunity that 
was observed in the patient. As the ELISA method measured the global 5hmC 
level, another approach is required such as mapping the 5hmC distribution in 
the genome of patient and control, to provide an explanation on the phenotypes 
observed in the patient. With new and advanced technologies emerging, more 
specific and sensitive techniques can be used to map the 5hmC distribution in 
the genome including hydroxymethylcytosine-DNA immunoprecipitation 
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(hMEDIP) followed by next generation sequencing, DNA Array or PCR (Ficz et 
al., 2011; Stroud et al., 2011; Wu et al., 2011; Kinney and Pradhan, 2013). 
Another technique that can be used is single molecule real-time (SMRT) 
sequencing which can discriminate between unmodified cytosine, 5mC and 
5hmC due to variations in polymerase kinetics during the sequence reaction 
(Kinney and Pradhan, 2013). The hMEDIP coupled with deep sequencing 
approach had been used in a study by Lian et al. who identified a reduction in 
the 5hmC level at promoters and gene bodies of patients with melanomas (a 
type of aggressive cancer of the skin) compared to patients with benign nevus 
(which is  a type of benign tumour of the skin) (Lian et al., 2012).  So far, no 
mapping of 5hmC distribution is done in human or mouse B cells. This method, 
hMeDIP with deep sequencing was thought to be one of the approaches that 
can be used to elucidate the differences between patient and control at the level 
of specific genomic loci. However, due to limited fresh patient material, this 
method could not be performed using patient B cells. 
Besides DNA demethylation, TET2 is also involved in recruiting OGT to 
chromatin and promotes histone GlcNAcylation which influences gene 
transcription (Chen et al., 2013). Since the only other material that was 
available from the patients were fibroblasts, therefore I used these cells to 
explore the TET2-OGT interaction mechanism. Immunoprecipitation technique 
was chosen to investigate the interaction as this technique was used in a 
previous study by Chen et al. (Chen et al., 2013). Before using patient cells, I 
used control cells to optimise the experiments. However, I could not 
demonstrate any TET2-OGT interaction in control fibroblasts. This was 
confirmed by three independent experiments. In previous studies, the TET2-
OGT interaction was observed in human embryonic stem cells (Chen et al., 
2013) and a recombinant system where TET2 was overexpressed in HEK293 T 
cells (Chen et al., 2013; Deplus et al., 2013). Apart from the cell type, another 
possibility is the technique itself and the buffer that was used in the experiment. 
Although the protocol and the buffer preparation were referred from a previous 
study (Chen et al., 2013) it still results in failure to observe the TET2-OGT 
interaction. It should be noted that in the study by Chen et al., they 
demonstrated that by overexpressing the TET2 enzymatic dead mutant, 
163 
 
H1382Y, in HEK293 T cells, the histone GlcNAcylation was also increased, 
implying that the enzymatic activity of TET2 is not required for histone 
GlcNAcylation. Due to the possibility that TET2-OGT interaction is reduced in 
fibroblasts, difficulties in optimising the immunoprecipitation methods and 
furthermore with the findings by Chen et al., I abandoned attempts to study 
TET2-OGT interaction. 
So far, we concluded that the p.H1382R mutation affects the TET2 enzymatic 
activity, as it was shown by the recombinant system experiment and patient 
iPSCs. In contrast, by using patient B cells the 5hmC level was normal. 
Nonetheless, we believe that impaired enzymatic activity results in the 
development of lymphoma, defective apoptosis and resultant autoimmunity in 
our patient and that mapping the 5hmC in the genome by investigating local 
changes of 5hmc, e.g. in promoter regions, rather than global levels, will explain 
this. Previous studies had demonstrated that impaired TET2 enzymatic activity 
results in the development of lymphoma (Couronne et al., 2012; Lemonnier et 
al., 2012) and very recently in mouse studies, it was demonstrated that TET2 
plays an important role in controlling autoimmunity (Ichiyama et al., 2015).  
However, until now no study has shown the effect of TET2 mutations on 
apoptosis in lymphocytes, although features such as massive 
hepatosplenomegaly, anaemia and thrombocytopenia that were thought to be 
related to apoptotic defects were observed in TET2 knock out mice (Quivoron et 
al., 2011). The subsequent chapter will discuss the effect of the TET2 
p.H1382R mutation on the lymphocyte apoptosis in our patients.
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Chapter 4: A novel autoimmune lymphoproliferative disorder 
4.3 Effect of TET2 p.H1382R variant on lymphocyte apoptosis  
4.3.1 Introduction 
Apoptosis is a mode of ‘programmed’ cell death which plays a critical role at 
several checkpoints in lymphocyte development and homeostasis (Opferman 
and Korsmeyer, 2003), (Rathmell and Thompson, 2002), as has been described 
in Chapter 1. Increased lymphocyte apoptosis can lead to immunodeficiency 
through cell loss whereas failure of apoptosis can be associated with 
lymphoproliferative disease and autoimmunity, classically in patients with ALPS 
(Rathmell and Thompson, 2002). Two major pathways of lymphocyte apoptosis 
in humans are the extrinsic pathway, which is controlled by death receptor 
signalling, and the intrinsic pathway, controlled by the Bcl-2 family of pro-and 
anti-apoptotic proteins. 
4.3.1.1 Extrinsic cell death pathway 
The extrinsic cell death pathway is initiated when an otherwise healthy cell 
receives an extrinsic signal that instructs it to enter apoptosis (Rathmell and 
Thompson, 2002). This signal is provided by death ligands that interact with 
specific death receptors on the target cell surface.  Death receptors form a 
subset of the Tumor Necrosis Factor Superfamily Receptor (TNFSR) group of 
proteins (Locksley et al., 2001), and are distinguished by possession of a death 
domain (DD) in their cytoplasmic tail.  Three major death ligand-receptor pairs 
that have been described are: 1) Fas Ligand, which binds to Fas; 2) TNF-
related apoptosis inducing ligand (TRAIL), which binds death receptors DR4 
and DR5 and 3) TNF, which binds the TNFα receptor (TNFR1) (Xu and Shi, 
2007).  
The apoptotic pathway involving Fas and FasL is the most extensively studied 
in the immune system (Zhang et al., 2005). The binding of Fas to FasL causes 
Fas trimerisation and leads to the recruitment of Fas-associated death domain 
(FADD) protein and procaspase 8 (inactive), together forming the death 
inducing signal complex (DISC). This subsequently activates the self-cleavage 
of procaspase-8 and -10 to active caspase-8 and -10, followed by the cleavage 
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of procaspase-3, -6 and -7 to form active effector caspases. Following this, 
caspase-mediated cleavage of structural proteins and “destruction” enzymes, 
such as the DNA-fragmenting caspase-activated DNase (CAD) (Strasser, 2005), 
result in the destruction of the cells. Ligation of DR4 or DR5 by TRAIL leads to a 
similar chain of events. Binding of TNF to TNFRI initiates a more complex set of 
downstream signals including activation of the caspases 8 and 10 through a 
TRADD-containing DISC (Rathmell and Thompson, 2002).  
The extrinsic cell death pathway is negatively regulated by several inhibitors, 
including the cellular - FLICE-inhibitory protein (c-FLIP) and the X-linked 
inhibitor of apoptosis (XIAP) protein. C-FLIP is a homologue of caspase 8 and 
acts by inhibiting the recruitment of caspase 8 to the DISC complex (Rathmell 
and Thompson, 2002). XIAP contains the baculovirus IAP repeat (BIR) domains; 
through these domains, it binds directly to and inhibits the activity of caspase-3 
and -7 (Yang and Li, 2000). The extrinsic signalling pathway is shown in Figure 
4.3.1. 
4.3.1.2 Intrinsic cell death pathway 
In the immune system, the intrinsic pathway is controlled by BCL-2 family 
members and triggered by various stimuli such as cytokine withdrawal and 
genomic toxicity (Lenardo et al., 1999; Zhang et al., 2005). The key event of 
intrinsic signalling is mitochondrial outer membrane permeabilization (MOMP), 
in which the release of certain proteins from the mitochondrial intermembrane 
space triggers the activation of caspases and results in cell apoptosis (Zhang et 
al., 2005). The MOMP is regulated by pro- and anti-apoptotic proteins of the 
BCL-2 family. Pro-apoptotic BCL-2 family members can be further subdivided 
into BAX/BAK-like and BH3-only proteins (Strasser, 2005). To date, 25 
members of the BCL-2 family have been described (Elmore, 2007); among the 
pro-apoptotic proteins are BAX, BAK and BAD, whereas anti-apoptotic proteins 
include Bcl-2 and MCL-1  (Chao and Korsmeyer, 1998; Elmore, 2007).  
In healthy cells, BH3-only molecules are in an inactive form and get activated by 
death stimuli, such as cytokine withdrawal, developmental cues or intracellular 
signals, to initiate apoptosis (Rathmell and Thompson, 2002; Strasser, 2005). 
The pro-apoptotic proteins of the BCL-2 family such as BAX and BAK then 
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permeabilize the outer membrane of mitochondria, resulting in the release of 
pro-apoptotic factors such as cytochrome C and second mitochondria-derived 
activator of caspase (SMAC, also known as Diablo) and high temperature 
requirement serine peptidase 2 (HTRA2, also known as OMI) from the 
intermembrane space into the cytosol (Elmore, 2007). Cytochrome C binds to 
and activates apoptotic protease activating factor-1 (APAF-1) and pro-caspase 
9, forming a complex known as the apoptosome (Chinnaiyan, 1999). This result 
in the auto-cleavage of pro-caspase 9, giving rise to active caspase 9 which 
then cleaves the effector caspases such as caspase 3 and caspase 7, leading 
to their activation (Xu and Shi, 2007).  
Anti-apoptotic proteins of the BCL-2 family inhibit the activation of BAX and BAK 
by sequestering these proteins, resulting in inhibition of cytochrome C release 
into the cytosol. Similarly, in the extrinsic pathway, XIAP proteins act as anti-
apoptotic proteins by inhibiting the activation of caspase-3 and -7. However, the 
release of SMAC/Diablo into the cytosol upon activation antagonizes the XIAP 
activity, leading to caspase 3 activation, allowing cell death to occur (Xu and Shi, 
2007).   
Amplification and cross talk between the extrinsic and intrinsic pathways occur 
through the activation of caspase 8, which cleaves the BH3-only protein BH3-
interacting domain death agonist (BID). This results in the pro-apoptotic 
truncated BID (tBID) fragment that induces the release of cytochrome C into the 
cytosol, leading to activation of caspase 9 (Luo et al., 1998). The intrinsic cell 
death pathway is shown in Figure 4.3.1. 
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Figure 4.3.1 : The intrinsic and extrinsic pathways of apoptosis. a) Intrinsic 
pathway.  Intracellular signals such as DNA damage and Endoplasmic 
Reticulum (ER) stress lead to the activation of the pro-apoptotic proteins BAX or 
BAK. In addition, cytokine withdrawal and antigen receptors such as BCR and 
TCR can also activate the intrinsic pathway. These trigger the MOMP, resulting 
in the release of cytochrome C and SMAC/Diablo from the mitochondrial 
intermembrane space into the cytosol. The activation of BAX and BAK is 
controlled by the anti-apoptotic protein BCL-2. Once released into the cytosol, 
cytochrome C binds to and activates APAF1 and pro-caspase 9, forming the 
apoptosome complex. This results in activation of caspase 9 and subsequently 
caspase-3 and -7, finally leading to cell apoptosis. The activation of caspase 3 
and caspase 7 can be inhibited by XIAP. However, XIAP activity is antagonised 
by SMAC and OMI. b) Extrinsic pathway. The binding of death ligand to death 
receptors results in the recruitment of FADD and pro-caspase 8 to FAS, forming 
a DISC. This leads to the activation of caspase-8 and -10, followed by caspase-
3 and -7 which trigger apoptosis. Crosstalk between extrinsic and intrinsic 
pathway occurs through the activation of caspase 8 which then cleaves BID, 
producing the active fragment tBID. This leads to activation of BAX or BAK and 
finally apoptosis. This figure is reproduced from Tait et al (Tait and Green, 2010) 
4.3.1.3 Other genes and pathways involved in cell death and survival 
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In addition to the well-studied pathways described above (Xu and Shi, 2007), 
several other pathways have also been linked to apoptosis and survival. For 
example, the interaction of Ras superfamily GTPases NRAS and KRAS with 
RAS effectors , the Raf family of serine/threonine kinases which include A-Raf, 
B-Raf, and Raf-1 leads to the activation of the mitogen activated protein kinase 
kinase (MEKK)/ MAP kinase extracellular signal-regulated (ERK)-signalling 
cascade, resulting in phosphorylation of downstream targets that either 
negatively or positively regulate apoptosis (Kang and Pervaiz, 2013). 
Furthermore, the p53 –mediated pathway leads to cell cycle arrest and finally 
apoptosis via p21, a protein encoded by the cyclin-dependant kinase inhibitor 
1A (CDKN1A) gene (Gartel and Tyner, 2002). In contrast, TNF family ligands 
such as B cell activating factor (BAFF) and activated TRAF family members 
including TRAF1,TRAF2 and TRAF5 deliver a pro-survival signal via NFκB 
(Kern et al., 2004). Other mechanisms, such as regulation of apoptotic gene 
expression, have also been described to influence cell apoptosis. One example 
is the protein known as T cell-restricted-intracellular Antigen 1 (TIA1) which acts 
as pro-apoptotic factor by  regulating pre-mRNA splicing of the Fas gene (Förch 
et al., 2000). TGF-β-mediated signalling can induce apoptosis through the 
activation of SMAD3-regulated pro-apoptotic genes (Jang et al., 2002). Similarly, 
transcription factors of the Forkhead Box O family exert pro-apoptotic effects by 
various mechanisms including upregulation of pro-apoptotic BCL-2 family 
members and death ligands such as TRAIL (Fu and Tindall, 0000).  
4.3.1.4 Autoimmune lymphoproliferative syndrome in P1 and P2 
ALPS is a disorder characterized by immune dysregulation due to disrupted 
lymphocyte homeostasis and it is caused by defects in the Fas-induced 
apoptotic pathway (Li et al., 2015). Fas surface expression is high on activated 
T and B lymphocytes (Rao and Oliveira, 2011). The role of Fas in maintaining 
lymphocyte homeostasis was initially observed in Fas-deficient MRL/lpr-/- mice. 
These mice demonstrated hypergammaglobulinemia,  glomerulonephritis, 
lymphadenopathy and expansion of DNT cells (Watanabe-Fukunaga et al., 
1992). Later, two groups, Rieux-Laucat et al. (Rieux-Laucat et al., 1995) and 
Fisher et al. (Fisher et al., 1995) identified heterozygous germline Fas mutations 
in patients who presented with autoimmunity and lymphoproliferative disease. 
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Subsequently, more somatic or germline mutations of Fas were identified and 
shown to account for the majority of ALPS cases (Rao and Oliveira, 2011). In 
addition, other proteins within the Fas-mediated apoptosis pathway such as Fas 
ligand (Del-Rey et al., 2006), caspase 8 (Chun et al., 2002) and caspase 10 
(Wang et al., 1999) were found to harbour mutations in patients with ALPS.  
Other genetic aetiologies have been described in patients with ALPS-like 
disorders which include germline mutation of NRAS (Oliveira et al., 2007) and 
somatic mutation of KRAS (Takagi et al., 2011). Nevertheless, there are still 20-
30% of patients with ALPS who have an unidentified defect (Li et al., 2015). 
Mutations within TET2, such as the p.H1382R variant that we identified in our 
patients, have never previously been linked to any apoptotic defect, despite 
their association with haematopoietic malignancy. Functional assays of patient 
T cell blasts, as well as their clinical phenotype, indicated an apoptotic defect in 
both affected patients.  Several features observed in Tet2-deficient mice, 
including thrombocytopenia, anaemia and increased double negative T cells, 
recall the clinical phenotype of ALPS and would be compatible with an apoptotic 
defect but this disease mechanism had not been considered. I hypothesised 
that impaired TET2 function led to epigenetically dysregulated expression of 
genes relevant to apoptosis, providing a mechanistic link to the occurrence of 
autoimmunity and lymphoproliferation in both humans and mice. Therefore I set 
out to investigate the effect of the TET2 missense mutation on the lymphocyte 
apoptosis pathway, using two approaches: 1) transcriptional microarray to 
investigate the expression of genes relevant to apoptosis in patient cells; and 2) 
a Tet2-deficient mouse model to investigate the integrity of Fas- mediated 
apoptosis in lymphocytes.  
4.3.3 Aims 
1) To investigate the effect of TET2 mutation on expression of genes involved in 
apoptosis 
2) To investigate whether lymphocytes from a Tet2 knock out mouse are 
defective for Fas-mediated apoptosis 
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4.3.2 Hypothesis 
TET2 mutation leads to dysregulated expression of genes relevant to 
apoptosis/survival.  
4.3.4 Results 
4.3.4.1 Upregulation and downregulation of pro- and anti-apoptotic gene 
expression by microarray 
To investigate the expression of genes relevant to apoptosis and survival, 
microarray analysis was performed using patient and control B-cell RNA. As 
mentioned before, the surviving patient P1 developed mixed chimerism post-
transplant in which the T cells were donor and B cells were recipient, therefore 
B cells were the only source of patient lymphocytes available for this experiment.  
Furthermore we knew that P1 developed recurrent ALPS after bone marrow 
transplant in the context of mixed chimerism, with T cells being donor and B 
cells being recipient. Therefore it was plausible that the disease phenotype 
could be driven by apoptotically defective B cells, as has been shown in a 
mouse model of B-cell-specific Fas deficiency (Hao et al., 2008).  
Two biological replicates of RNA were extracted from P1’s B cells, which were 
taken at two different time points. For comparison, 10 samples of RNA were 
extracted from B cells of 10 different healthy controls. Both patient and control B 
cells were isolated using the whole blood B cell isolation kit (Miltenyi) and an 
autoMacs separation machine, described in Chapter 2: Materials and methods. 
The B cell purity for each sample ranged between 80-98% measured by flow 
cytometry. Patient and control RNA was extracted using the ReliaPrep RNA 
Cell MiniPrep System (Promega) and quantified using NanoDrop 2000 
Spectrophotometer.  
The quality and RIN of patient and healthy control samples were analysed by 
ServiceXS (Netherlands) using Agilent BioAnalyzer.  For the two replicate 
samples of the patient, the RIN were 6.10 and 6.30, whereas for healthy 
controls, all 10 samples, the RIN were above 7. As the total amount of RNA per 
sample was low (less than 200ng), a specialised protocol, NuGEN Ovation 
PicoSL, was used for preparing biotinylated single stranded cDNA (ss-cDNA). 
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The biotinylated ss-cDNA was hybridized onto the Illumina Human HT-12 v4 
Expression Bead Chip (Illumina Inc, San Diego, USA). The Illumina Human 
HT12v4 Expression BeadChip data were background corrected in Illumina 
Beadstudio. Subsequent analysis was undertaken using the Lumi and Limma 
Bioconductor packages in R.  
The first analysis performed using the Lumi package was Variant Stabilising 
Transformation (VST) which  takes advantage of technical replicates per probe 
on the array when transforming the data and outperforms log2 based 
transformation (Lin et al., 2008). Using VST improves the detection of 
differentially  expressed genes and reduces false-positive identifications (Lin et 
al., 2008). The next step was to normalise the samples using Robust Spline 
Normalisation (RSN), included in the Lumi package. This step was performed to 
ensure that the values of intensity across the different samples have the same 
distribution.  
A Principle component analysis (PCA) plot was generated using Lumi package 
to show the variance in the data on a two dimensional graph. This was 
performed by Andrew Skelton, Bioinformatics Unit, Newcastle University. It is a 
useful plot in spotting the samples that may have gone awry and need to be 
removed from further analysis. The main concept behind PCA plot is that 
samples whose gene expression is similar will be clustered together in space.  
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Figure 4.3.2 : Principal Component Analysis (PCA) plot. A) All 12 samples 
were included in the plot. B) 11 samples were included in the plot as healthy 
control 9 was removed due to being an outlier as shown in (A). C) Only 10 
samples were included in the plot as healthy control 9 and 4 were removed. 
Patient_R1- Patient replicate 1 sample, Patient_R2 – Patient replicate 2 
sample . This analysis is performed by Andrew Skelton, Bioinformatics Unit, 
Newcastle University. 
 
When all 12 samples were plotted in the PCA plot, it was demonstrated that 
healthy control 9 was an outlier as it was not in the two groups that were 
clustered together (Figure 4.3.2 (A)). As healthy control 9 was not responding 
like other samples and may have a problem, it was removed from further 
analysis. This is similar to healthy control 4, as it was also shown to be an 
outlier when PCA was re-plotted without healthy control 9 (Figure 4.3.2 (B)). By 
removing both healthy control 9 and 4, PCA was re-plotted and demonstrated 
that control 1, 2 and 10 were clustered together and control 3, 5, 6, 7 and 8 
were in the same group, whereas patient R1 and R2 were at the top of the plot 
(Figure 4.3.2 (C)). There were several clustered groups because the arrays 
were performed in two batches at different times; batch 1 consists of control 3, 5, 
6, 7 and 8, and batch 2 consists of control 1, 2, 10, patient replicate 1 and 
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replicate 2. However, these differences can be corrected using a batch 
correction, the ComBat function from the SVA package.  
 
Figure 4.3.3 Principal Component Analysis (PCA) plot after batch 
correction. After correction, all the controls samples are clustered together 
whereas patient replicates ( 2 samples) were not clustered together with the 
controls. 1 indicates batch 1 and 2 indicates batch 2.  
 
After batch correction, it was demonstrated that all controls were clustered 
together whereas patient replicates samples were not clustered together with 
the controls (Figure 4.3.3), implying that patient samples were different and the 
gene expression was not similar to controls. Patient replicate 1 and replicate 2 
were not clustered together most probably because the B cell RNAs were 
extracted at different times.  
To identify the differentially expressed genes between patient and control, 
Limma Bioconductor package in R was used. The genes with an expression 
level that was ≥ 2-fold different and had an adjusted P-value less than 0.01 
were considered as significant differentially expressed genes. 
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Figure 4.3.4 : Volcano plot of differentially expressed genes in patient vs 
control. Red dots represent the differentially expressed genes that are≥ 2-fold 
up- (238 genes) or downregulated (207 genes), adjusted P < 0.01. 
 
A volcano plot was generated to visualise an overview of the differentially 
expressed genes (Figure 4.3.4). 445 genes were identified as differentially 
expressed in patient compared to controls (red dots in Figure 4.3.4); 238 genes 
were upregulated and 207 gene were downregulated.  Gene Ontology (GO) 
Terms (http://geneontology.org/) were assigned to differentially expressed 
genes to identify those that are involved in apoptosis/ survival pathways.   
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Figure 4.3.5: 15 dysregulated genes from the microarray analysis that 
regulate apoptosis identified by Gene Ontology (GO) Terms. (-) indicates 
pro-apoptosis genes and (-) indicates anti-apoptosis genes. (↑) indicates gene 
upregulation and (↓) indicates gene downregulation. 
 
A total of 34 genes were identified that influence the apoptosis pathway; 16 
genes were pro-apoptotic and 18 gene were anti-apoptotic (Table 4.3.1).  Some 
of these are mapped into a diagram illustrating pertinent signalling pathways in 
Figure 4.3.5.   
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Table 4.3.1 : Pro- and anti-apoptotic genes that were identified to be 
differentially expressed in patient B cells compared to controls. The genes 
expressed with above 2-fold change were considered to be either upregulate or 
downregulated in patient compared to controls. 
 
These results suggested that TET2 mutation leads to dysregulation of certain 
pro-and anti-apoptotic genes. However, before deriving any conclusion, qRT-
PCR needs to be performed to validate these data. 
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4.3.4.2 qRT-PCR confirmation of the microarray data 
To confirm the microarray data, a qRT-PCR using the universal probe library 
was performed to measure the mRNA expression of the differentially expressed 
genes. 5 genes were chosen  from the differentially expressed apoptosis genes 
which are CDKN1A, DUSP1, Smad3, TIA1 and TRAF5. cDNA was derived from 
an aliquot of  patient and controls B cell RNA. Two patient replicates and four 
healthy control RNAs were subjected to qRT-PCR. The primers and probes for 
each target transcript were designed using the Universal Probe Library Assay 
Design Centre software (http://lifesciences.roche.com).  
 
Figure 4.3.6 : Validation of the microarray data by qRT-PCR. The mRNA 
expression of each gene was expressed as normalised fold change relative to 
18S. The data and graph were plotted using Prism 4.0 software and the centre 
line represents the mean value for patient and controls replicates. Patient 
replicates (n =2), controls replicates (n=4). The data is representative of one 
experiment and this experiment was performed twice. 
 
Figure 4.3.6 demonstrated that only one gene, DUSP1, was upregulated in 
patient compared to control, which corresponded to the microarray data. 
Expression of genes such as CDKN1A and SMAD3 was shown to be similar to 
controls. Although patient replicates were shown to be separated far away and 
not clustered together for TIA1 and TRAF5 genes, the results were still 
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considered to be in contrast to the microarray data where both genes were 
shown to be upregulated in the patient. Based on these results, frustratingly, I 
concluded that the microarray data were unreliable and invalid as the 
dysregulation of the apoptosis genes that were chosen could not be validated 
by qRT-PCR. 
4.3.4.3 Knock out mouse model 
To investigate a possible conserved effect of TET2 deficiency on Fas-mediated 
apoptosis, Tet2 knock out mice were studied. This work was performed through 
collaboration with Prof Richard Cornall and Dr Consuelo Anzilotti, Oxford 
University, where a colony of Tet2 knock out mice was established and I 
performed the Fas-mediated apoptosis assay. 
Briefly, Tet2 floxed allele mice (which possess loxP sites flanking exon 3 of the 
Tet2 gene) were purchased from Jacksons laboratory, USA. To obtain the full 
Tet2 knock out mice, the Tet2 floxed allele mice were crossed to mice carrying 
the Cre-recombinase under the Pgk promoter (Lallemand et al., 1998). To 
detect the Cre-recombinase alleles carried by Tet2 mice, standard PCR and 
genotyping were performed using primers similar to the ones used in the study 
by Quivoron et al. (Quivoron et al., 2011). The mice bearing homozygous null 
mutation of Tet2 were grown until 10-14 weeks of age and then sacrificed for 
the Fas-mediated apoptosis experiment.  
4.3.4.3.1 Fas-mediated apoptosis assay using mouse B cells 
In order to study the Fas-mediated apoptosis pathway in mice, the first 
experiment that was performed was using B cells and a method adapted from 
Imtiyaz et al. (Imtiyaz et al., 2006). However, instead of isolating the B cells, I 
seeded the splenocytes from both wild type and TET2 knock out mice in 48 
well-plates at 1 x 106 cells /ml. The cells were left untreated or treated with 
soluble Fas ligand (Enzo Life Sciences, USA) at different concentrations and 
incubated for 16 hours. An enhancer (Enzo Life Sciences, USA), was added at 
0.5 ug/ml to each concentration of soluble Fas ligand, which acts as cross linker 
to enhance the apoptotic activity. The cells were gated for CD19 (Biolegend, 
UK), a specific marker of B cells.  The apoptosis and cell death were detected 
with a FITC-Annexin V detection kit (BD Biosciences, UK) which include the 
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FITC-Annexin V for apoptosis staining and Propidium Iodide for cell death 
staining and analysed by flow cytometry (Figure 4.3.7 ). The Annexin V staining 
utilises the principle that when the cells undergo apoptosis, they expose the 
phospholipid phosphatidylserine (PS) to the external environment. As Annexin 
V is a calcium-dependent phospholipid binding protein which has a high affinity 
to PS, it will identify apoptotic cells by binding to the exposed PS. In dead cells, 
the membranes are permeable to Propidium Iodide (PI) and allow the PI to stain 
the cells. Cells that are undergoing early apoptosis will be Annexin V positive 
and PI negative whereas cells that are either in the late stage of apoptosis or 
already dead will stain positive for both Annexin V and PI. Cells that are intact 
and viable will be negative for both Annexin V and PI staining.  
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Figure 4.3.7 : Annexin V vs Propidium Iodide (PI) staining analysed by 
flow cytometry. Splenocytes from five wild type (WT) and five Tet2 Knock out 
(KO) mice were seeded at 1x106 cells/well in a 48-well plate. Cells were left 
untreated (0 ng) or treated with different concentrations (25 ng/ml, 50 ng/ml, 
100 ng/ml) of soluble Fas ligand; enhancer (0.5 ug/ml) was added at each 
concentration. The cells were incubated for 16 hours. The cells were gated for 
CD19+ (B cells) and stained with Annexin V and PI and analysed by flow 
cytometry.  
 
To investigate the Fas mediated apoptosis pathway between the wild type and 
TET2 knock out mice,the % survival (Annexin V- PI-) of cells for each 
concentration was calculated.  
By assuming that the untreated cells were 100 % viable, the percentages of 
each treated cells were normalised to the untreated cells using the equation 
below :  
 
The normalised percentage of cell survival was calculated as above and plotted 
in a graph using Prism 4.0  Software ( GraphPad Software, USA) ( Figure 4.3.8). 
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Figure 4.3.8 : B cell apoptosis assay for wild type (WT) and TET2 Knock 
out (KO) mice . The normalised % of cell survival was plotted for five wild type 
and five knock out mice at each concentration of added Fas ligand (0 ng, 25 ng, 
50 ng, 100 ng). The statistical analysis was performed using Two way ANOVA 
and p < 0.05 is significantly different. 
 
Two way analysis of variance (ANOVA) was performed, testing for differences 
in apoptosis between WT and Tet2 KO mice at various concentrations of Fas 
ligand, and this analysis revealed statistically significant differences between 
WT and KO mice (p<0.05). Tet2 KO mice had consistently slightly higher 
normalised cell survival %  across all three concentrations compared to WT 
mice (Figure 4.3.8). 
 
4.3.4.3.2 Fas-mediated apoptosis assay using mouse T cells 
Since patient T cells showed documented abnormalities of Fas-mediated 
apoptosis, I also performed the Fas-mediated apoptosis assay with mouse T 
cells.  Initially following a similar method to that used for human T cells, the 
mouse splenocytes were seeded at 1 x 106 cells/ml in 48-well plates and 
stimulated with Phytohaemagglutinin (PHA) at 5ug/ml for 72 hours. 
Subsequently, the dead cells were removed with Ficoll-paque (Sigma, UK) and 
viable cells were seeded in 96-well plates and cultured with Interleukin-2 (IL-2)  
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for 2 days. On the third day, soluble Fas Ligand (Enzo Life Sciences, USA) was 
added at different concentrations  ( 0ng, 25 ng, 50ng and 100ng) with enhancer 
at 0.5ug/ml overnight. The cells were gated for CD3+ cells (T cells) and 
apoptosis and cell death were measured as before. 
 
 
Figure 4.3.9 : T cell apoptosis assay in wild type mice A) Splenocytes were 
seeded at 1x106 cells/ml in a 48-well plate, stimulated with PHA for 3 days, 
ficolled and viable cells were treated with IL-2 for 2 days. On day 3, cells were 
stimulated with different concentration of sFasL (0ng, 25ng, 50ng, 100ng) 
overnight. The cells were gated for CD3+ and stained with Annexin V and PI 
and analysed by flow cytometry. Data is representative of one of three 
independent experiments. B) The normalised cell survival % was calculated 
using the equation described in section 4.3.1.3. The normalised cell survival % 
was plotted on a graph using Prism 4.0 software. Data is representative of three 
independent experiments. 
 
To optimise the T cell apoptosis assay, pilot experiments were performed using 
wild type mice. As expected, all three optimisation experiments demonstrated 
that the normalised cell survival % was reduced with increased concentration of 
soluble Fas Ligand (Figure 4.3.9(B)), implying that this method works 
successfully. Background rates of cell death were however quite high (50-60 %). 
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  Figure 4.3.10 : T cell apoptosis assay in three wild type (WT) and three 
Tet2 knock out (KO) mice. Cells were seeded at 1x106 cells/ml in a 48-well 
plate and stimulated with PHA (5ug/ml) for 3 days. Dead cells were then 
removed using Ficoll-paque (Sigma,USA). Viable cells were seeded and treated 
with IL-2 (100IU/ml) for 2 days and stimulated with sFasL at different 
concentrations ( 0ng, 25ng, 50ng, 100ng) with enhancer (0.5ug/ml) overnight. 
The cells were stained with anti-CD3 (T cells), Annexin V and PI and analysed 
by flow cytometry. 
 
However, unexpectedly, when the same method was used to assay Tet2 knock 
out mice and local wild type controls, rates of cell death following the PHA 
stimulation step were very high. As a result, the viability of untreated cells in 
each assay was poor, ranging between 20-30% (Figure 4.3.10), implying that 
most of the cells were already dead before stimulation with sFasL. No clear 
difference was evident between Tet2KO and wild type mice but it was not clear 
that the experiment would have been capable of revealing such an effect and it 
was considered noninformative. 
 
 
 
 
185 
 
On review of the methodology, the choice of phytohaemagglutinin to provide 
mitogenic stimulation was felt to have been misguided since it is known to 
produce high rates of activation-induced cell death in mouse T cells. With the 
guidance of a colleague, Dr Arian Laurence (Institute of Cellular Medicine, 
Newcastle University), a new method was established. This requires the 
isolation of a pure homogeneous naïve CD4+ T cell population using the 
CD4+CD62L+T cell isolation kit (Miltenyi Biotec, UK). The isolated naïve CD4+ 
T cells were stimulated with plate-coated anti-CD3 (10ug/ml) and anti-CD28 
(10ug/ml) antibodies for 3 days. The cells were treated with IL-2 (100IU/ml) on 
days 1 and 2, providing an additional survival signal. On day 3, the cells were 
stimulated with soluble Fas Ligand at different concentrations (0 ng/ml, 50ng/ml, 
100ng/ml) with enhancer (0.5ug/ml) overnight. As before, the cells were stained 
with Annexin V and Propidium Iodide (BD Biosciences, UK) and analysed by 
flow cytometry. 
 
 
Figure 4.3.11 : CD4+ T cell apoptosis assay with wild type mouse T cells. A) 
CD4+ T cells were isolated from wild type mouse splenocytes using the 
CD4+CD62L+ T cell isolation kit (Miltenyi Biotec, UK). Cells were seeded at 
1x106 cells/ml in a 24-well plate, pre-coated with anti-CD3 (10ug/ml) and anti-
CD28(10ug/ml) antibodies and incubated for 3 days. The cells were treated with 
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IL-2 (100IU/ml) every day for 2 days. On day 3, the cells were stimulated with 
different concentrations of sFasL (0ng, 50ng, 100ng) with enhancer (0.5ug/ml) 
overnight. The cells were stained with Annexin V and Propidium Iodide (PI) and 
analysed with flow cytometry. Data represents one of the three independent 
experiments. B) The normalised cell survival % was calculated using the 
equation described in section 4.3.1.3. The normalised cell survival % was 
plotted on the graph using Prism 4.0 software. Data is representative of three 
independent experiments. 
 
To optimise the experiment, the new method was performed using wild type 
mice. The experiment demonstrated that most of the cells were viable (Annexin 
V-PI-: 83.3%) before stimulation with sFasL (Figure 4.3.11(A)). Once  treated 
with sFasL at 50ng and 100ng, the % viable cells (Annexin V-PI-) was reduced 
as expected. This method is therefore ready to take forward to assay Fas-
mediated apoptosis in Tet2 knockout and wild type control mice. Currently, the 
number of Tet2 knock out mice is very low and the colony is being expanded 
again. Therefore, the new method has not been performed yet on both wild type 
and Tet2 knock out mice. 
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4.3.5 Discussion 
Both patients presented with lymphoproliferative disease, lymphoma and 
autoimmunity. In addition, the laboratory findings demonstrated significantly 
increased DNT cells and defective Fas-mediated apoptosis. These phenotypes 
are the main criteria in diagnosing ALPS (Rao and Oliveira, 2011). Both patients 
were screened for known ALPS mutations, but no mutations in known disease 
genes were identified. The homozygous TET2 missense mutation p.H1382R 
was identified by whole exome sequencing and homozygosity mapping. Tet2-
deficient mice in a study by Quivoron et al.  developed hepatosplenomegaly, an 
increased number of DNT cells in thymocytes and features of autoimmunity 
such as thrombocytopenia and anaemia; all these phenotypes are thought to be 
due to an apoptosis defect (Quivoron et al., 2011). However, so far, to my 
knowledge, there is no published evidence that links TET2 to apoptosis. 
In order to demonstrate that TET2 is involved in regulating apoptosis, the first 
approach was to perform a microarray analysis. Microarray is used to measure 
the changes of expression levels of large numbers of genes simultaneously and 
it allows the description of genome-wide expression changes in health and 
disease conditions (Tarca et al., 2006). Given the enzymatic function of TET2 
as an epigenetic regulator, we postulated that the expression of apoptosis-
related genes would be altered in patients compared to healthy controls. An 
Illumina HT-12 Array, performed by ServiceXS, Netherlands, was chosen. This 
beadchip targets 47 000 genes derived from the National Center for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 
(http://www.Illumina.com). For both patient and healthy controls, between 8 000 
– 12 000 genes were detected in all samples and the same number of genes 
were detected in several in house samples which were used as controls.  
As mentioned, the microarray analysis data were analysed using Lumi and 
Limma Bioconductor packages. From the analysis, 16 pro-apoptosis and 18 
anti-apoptosis genes were identified to be dysregulated which was either 
downregulated or upregulated in patient compared to healthy controls B cells. It 
is widely known that all microarray data should be validated as it can produce 
false positive results and vary greatly with platform and procedures used (Morey 
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et al., 2006). The most common method used for validation is qRT-PCR due to 
its detection sensitivity and low sample requirement. To validate the microarray 
analysis data, only 5 genes were chosen because of very limited material for 
patient replicates and controls samples. However, differential expression could 
not be confirmed as 4 of the 5 genes were similarly expressed in patient and 
control cells, indicating that the microarray data were invalid. There could be 
several reasons that give rise to the invalid data. 
Before performing the microarray, all the RNA samples were analysed for its 
quality and integrity by Bioanalyser (Agilent Technologies, USA). The RNA 
integrity number (RIN) for the two patient’s replicate samples were 6.10 and 
6.30. The perfect RIN for downstream applications such as microarray analysis 
and qRT-PCR is above 7 (Fleige and Pfaffl, 2006). An RNA sample with a RIN 
less than 7 is considered to be a slightly degraded and contaminated and RIN 
less than 5 is a degraded and low quality sample. It is crucial to have a good 
quality RNA in order to obtain accurate gene expression results.  Although there 
is evidence supporting that good and reliable microarray data can be obtained 
from RIN above 5 (Fleige and Pfaffl, 2006), I think that the RIN less than 7 of 
patient replicate samples could contribute to the invalid data as it could provide 
a false-positive result on the abundance of the gene expression in the samples. 
In addition, it has been demonstrated that for a sensitive and reliable 
quantitative measurement of low abundance mRNA gene expression by qRT-
PCR, it requires an intact, good quality and integrity of RNA samples 
(Vermeulen et al., 2011). Hence, it is critically important to obtain an intact and 
non-degraded RNA samples so that the microarray analysis and qRT-PCR 
results provide a meaningful, reliable and valid gene expression data. 
Another factor that could influence the validation results was the fold change of 
the genes. DUSP1 was shown to be upregulated in qRT-PCR and this 
corresponded to the microarray data. In the microarray data, DUSP1 was 11.3-
fold upregulated in the patient, suggesting that maybe a high fold change is 
needed for the qRT-PCR to get a similar result to the microarray analysis. For 
other genes such as Smad3, TIA1 and TRAF5, the fold change was small, 
between 2 to 2.5, therefore the differences in expression could not be detected 
between patient and controls by qRT-PCR.  
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It is proposed to have at least three replicates for a reliable and sufficient 
analysis. It is important to have sufficient replicates 1) so that the variation in the 
experiment can be measured and statistical tests can be applied to detect the 
differences, and 2) to enhance the precision of the gene expression 
measurements to allow smaller changes to be detected 
(http://www.Illumina.com). However, due to the patients’ illness only very limited 
material was available; only two biological replicates could be obtained from the 
patient. This could affect the quality of the data and lead to the invalidity of the 
results.  
Another approach to investigate the defective apoptosis was by using a Tet2 
knock out mouse model in which to analyse Fas-mediated apoptosis. A mouse 
model was chosen instead of knocking down TET2 in a cell line because 
epigenetic effects are cumulative during development and involved in regulating 
gene transcription. If knocking down the gene in cell lines, most probably TET2-
dependent epigenetic changes influencing gene transcription had occurred 
earlier and are thus maintained. Therefore, we might not be able to see 
differences between knock down and wild type cells. The statistical analysis 
demonstrated there was a difference of cell survival in which the overall cell 
survival was higher in B cells from Tet2 knock out mice compared to B cells 
from wild type mice, but the differences were very small, making it difficult to 
derive a definite conclusion from the experiment. However, it should be noted 
that the Tet2-deficient mouse models, the Tet2 floxed allele mice (which 
possess loxP sites flanking exon 3 of the Tet2 gene) were crossed to mice 
carrying the Cre-recombinase under the Pgk promoter, generating mice bearing 
a homozygous null mutation of Tet2 whereas both patients bear a homozygous 
missense mutation of TET2, substituting A>G in exon 9. Therefore the effect 
could still be different in the patient B cells, and could not rule out the possibility 
the defect may still be in the B cells. However, this could not be confirmed since 
the Fas mediated apoptosis assay has never been performed using patient B 
cells.  
Next, I wanted to investigate Fas-mediated apoptosis in mouse T cells to see if 
there is a stronger effect. This is also being suggested by the fact that the Fas-
mediated apoptosis assay was performed on both patients’ T cells before 
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transplant, which showed a defect in the Fas-mediated apoptosis. The first 
experiment performed on wild type and Tet2 knock out mice where the T cells 
were blasted with PHA was unsuccessful as most of the T cells were dead. 
Another method was applied where the cells were stimulated with plate-coated 
anti-CD3/CD28 and treated with IL-2 every day until soluble Fas Ligand was 
added to the cells. It was demonstrated that mouse T cells grow well when 
stimulated with either Con A (Mukherjee et al., 2005) or anti-CD3 or anti-
CD3/CD28. This method was successful as it was shown in wild type mice that 
more cells were viable before treatment with soluble Fas Ligand. For future 
work and once the Tet2 knock out mice are available again, this method can be 
applied to investigate the effect of Tet2 on Fas-mediated apoptosis in T cells. 
So far, both approaches that were performed in order to investigate the effect of 
TET2 on lymphocyte apoptosis were unsuccessful and no conclusion could be 
derived yet. More future work especially using T cells is required to enable us to 
understand the disease phenotypes in the patients that was caused by TET2 
mutation.
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Chapter 5: Discussion and future work 
In this study, I identified novel gene defects that cause two different PIDs. 
These two newly identified disease genes contribute to the current list of gene 
defects in the PID classification (Picard et al., 2015).  IFNAR2 deficiency, which 
I identified in a patient with fatal illness after routine MMR vaccination, results in 
isolated susceptibility to viral infection. Recognition of this phenotype provides 
better knowledge and understanding of the narrow role of type I IFN in human 
antiviral immunity, similar to the previously described STAT2 mutation 
(Hambleton et al., 2013) . The TET2 mutation that was identified in patients with 
immune dysregulation, resulting in ALPS with lymphoma in both patients, 
provides new insights into immune function and the apparently restricted non 
redundant role of this important protein. So far, to my knowledge, no genes 
involved in epigenetic regulation have been described to cause PID.  
Clinical impact 
Besides adding to knowledge regarding immune function, these discoveries 
provide a molecular diagnosis for the patients. The ability to group patients 
according to molecular diagnosis can ultimately lead to better knowledge of the 
natural history of disease and hence prognosis. In addition, it can also inform 
better treatment of future patients with the same defect.  
For the newborn baby and future patients with IFNAR2 deficiency, HSCT is not 
likely to represent a curative treatment since IFNAR2 acts ubiquitously and not 
just within the immune system. Not only would HSCT be unlikely to correct the 
defect, it would pose an extremely high risk of transplant-associated viral 
infection during the inevitable period of immune suppression. In contrast, HSCT 
should still be considered a treatment option for future patients with TET2 
deficiency, despite the poor outcome of HSCT for both patients described in this 
thesis. Patient 1 developed split chimerism and recurrent ALPS, whereas 
patient 2 died after rejecting a haploidentical T-cell depleted transplant. The 
precise reasons for this outcome after HSCT are unclear and probably 
multifactorial, but it seems likely that the underlying defect contributed by 
favouring graft rejection (as seen in mixed chimeric mouse models).  
Considering the predominant haematological phenotype of TET2 deficiency, it 
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seems plausible that HSCT with 100% donor chimerism could offer a cure. As 
an alternative to HSCT, future TET2 patients might instead be treated with 
sirolimus, an mTor inhibitor, as recently this medication has become the 
treatment of choice for ALPS patients (Teachey, 2012).  
By identifying the IFNAR2 mutation in the newborn baby, preventive measures 
can be taken such as avoidance of the live MMR vaccine that contributed to the 
demise of the deceased sibling. Currently the infant is also receiving both 
prophylactic aciclovir and subcutaneous immunoglobulin to bolster antiviral 
defences.  Further useful information for possible treatment options comes from 
our microarray measuring transcriptional responses to both IFNα/β and IFNγ 
using patient and control cells. It was shown that both type I and type II IFN 
induce similar ISGs, emphasising that IFNγ also provides antiviral effects that 
may partially compensate for the lack of type I IFN. This is helpful in suggesting 
that exogenous IFNγ might be a useful treatment in the face of uncontrolled 
viral infection in the patient.  
Scientific implications 
This work raises further questions that need to be answered by performing 
more experiments in vitro. It was demonstrated that both type I and II IFNs 
upregulated a similar set of genes in the control cells at one time point; type I-
induced ISGs were even upregulated by IFNγ in the patient cells, showing that it 
occurs independent of an IFNAR-mediated feedback loop. It would be 
interesting to look at the functional response i.e. antiviral effect of IFNγ as it 
might be possible that this IFN upregulates the same ISGs at the transcription 
level but in terms of the function it may be less compared to IFNα. This can be 
done by treating patient and control cells with IFNγ and infected them with 
different viruses and observe the antiviral effect i.e. virus replication in these 
cells.  
Recently, there were several studies demonstrating that type I IFN plays a role 
in mycobacterial infection (Manca et al., 2001; Berry et al., 2010; Desvignes et 
al., 2012; McNab et al., 2014). For example, one study produced transcriptomic 
data which were interpreted as showing that both type I and type II IFN ISGs 
were upregulated in patients with Mycobacterium infection (Berry et al., 2010). 
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Since my work demonstrated that both types of IFN upregulated a similar set of 
genes, it brings into question the contribution of type I IFN to this transcriptional 
signature. Irrespective of that, whether type I IFN protects or predisposes to 
mycobacterial infection is controversial. McNab et al. demonstrated that type I 
IFNs have a detrimental effect on mycobacterial infection by inhibiting the 
release of IL-12, IL-1β and TNFα from infected macrophages, thus preventing 
the cells from achieving the activated state required for mycobacterial killing 
(McNab et al., 2014). In contrast, Desvignes et al, tested the role of type I IFN 
by measuring the additive effect of IFNAR knock-out on IFNGR knock-out 
background. They observed that upon infecting the mice with Mycobacterium 
Tuberculosis, mice deficient in both type I and II signalling showed more severe 
mycobacterial infection and died earlier compared to the single knock-out 
IFNGR-/- mice (Desvignes et al., 2012).  They concluded that type I IFN plays a 
protective role against mycobacterial infection, most probably by aiding the 
recruitment of T cells (Desvignes et al., 2012).  
My recent findings suggest the opportunity for future work to clarify the role of 
type I IFN in mycobacterial immunity using the patient cells as a model. With 
current emerging techniques, patient fibroblasts can be reprogrammed into 
iPSCs and then differentiated into a wide variety of cell types including 
macrophages. This would provide the opportunity to interrogate the role of type 
I IFN in mycobacterial infection in the relevant human cell type. Furthermore, 
the use of genome editing techniques such as CRISPR/Cas9 (see below) 
provides the opportunity to introduce or repair mutations in a specific manner, 
thus providing an ideal control for patient iPSCs on the same genetic 
background.  
Recent advances have led to the use of iPSCs in modelling many diseases 
including PIDs. In the latter field, iPSCs can be differentiated into HSC 
progenitors which later differentiate into either myeloid progenitor or lymphoid 
progenitor cells (Weinacht et al., 2012), depending on the relevant cell type. 
This is a promising method because in theory, iPSCs could provide an unlimited 
cell source for the study of PIDs (Weinacht et al., 2012). Induced PSCs have 
been successfully used to generate NK cells (Ni et al., 2011) and B cells 
(Carpenter et al., 2011) although in general lymphoid differentiation remains 
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challenging. In terms of providing relevant material for the study of PID, Zou et 
al. were able to differentiate iPSCs from patients who had been diagnosed with 
chronic granulomatous disease (CGD) into neutrophils and recapitulate the 
failure to generate reactive oxygen species upon activation, which is typical for 
this disease (Zou et al., 2011). The ability to generate alternative cell types from 
iPSCs could help to overcome the limitations of scarce patient material, which is 
a major problem in the field of PID research.  Several factors contribute 
including the fact that patients are often acutely ill infants, in whom the 
abundance of the relevant cell type may be reduced as part of the disease state; 
it may not be possible to obtain the relevant tissue before death or 
transplantation.  
This is the major limitation that I encountered in performing the functional 
studies for TET2 using patient material, when availability of fresh immune cells 
was limiting. Patient 2 is dead and patient 1 had a bone marrow transplant 
substituting his defective immune cells with healthy ones from a matched donor. 
However, as he developed mixed chimerism with donor T cells and recipient B 
cells, there was the potential to obtain TET2-deficient B cells. Yet, as he 
intermittently received rituximab, a drug that depletes B cells, their availability 
was very limited.  The generation of an EBV B-cell line was attempted using 
patients cells in order to provide immortalized B cells, however, it was 
unsuccessful. Therefore, to overcome the very limited material from the patients, 
and to investigate the effect of TET2 deficiency within the stem cell 
compartment, we generated iPSCs from patients’ fibroblasts. In chapter 4.2, I 
have briefly mentioned the technique used to generate iPSCs. My colleague, Dr 
Katarzyna Tilgner, performed a pilot study measuring the 5hmC level of patient 
iPSCs and control human embryonic stem cells (hESCs). Ongoing work 
involves differentiating these patient iPSCs into HSCs, followed by further 
differentiation into T and B lymphocytes.  
In parallel, another novel approach that is currently used in PID modelling and 
gene correction is genome editing using engineered endonucleases which 
include Zinc finger nucleases (ZFNs), Transcription Activator-Like Effector 
Nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR associated 9(Cas9) (Ott de Bruin et al., 2015). 
195 
 
These methods can be used to correct the defective PID gene (Ott de Bruin et 
al., 2015) and/or to model PIDs by introducing disease-associated mutations, 
allowing the generation of knock-out cell lines or mouse models (Ott de Bruin et 
al., 2015). In general, these engineered endonucleases create a double 
stranded break (DSB) in the specific genomic site that needs to be modified 
(Sander and Joung, 2014). The nuclease-induced DSB can then be repaired 
either through the error-prone process of non-homologous end-joining (NHEJ) 
which can produce insertion and/or deletion mutations of variable length at the 
site of the DSB or  through the homology-directed repair (HDR) that can 
produce precise point mutations or insert the desired sequences through 
recombination of the target locus from a single-stranded or double-stranded 
DNA donor template (Sander and Joung, 2014). Various studies have 
successfully demonstrated correction of the defective gene in human stem cells 
using these genome editing tools (Hockemeyer et al., 2011; Zou et al., 2011; 
Ott de Bruin et al., 2015). For example, Zou et al. successfully used ZFNs to 
correct CGD patient-derived iPSCs which restored the ability of the cells to 
generate functional neutrophils (Zou et al., 2011).  
Since these genome editing tools have shown to be successful, for future work, 
CRISPR/Cas9 correction of the TET2 mutation in patient iPSCs will be 
performed. The corrected cells will provide an ideal control for the patient iPSCs 
in further functional work with their differentiated progeny. In addition, the 
CRISPR/Cas9 technique could also be used to introduce the patients’ specific 
missense mutation to generate a mouse that more faithfully models their 
disease than the full knock out described in chapter 4.3. 
For the TET2 patients, as has been mentioned in the chapter 4.2 discussion 
section, investigation of the epigenome including mapping of 
hydroxymethylation will most likely be required to understand disease 
mechanism. New advanced techniques such as single cell epigenomic analysis 
(Smallwood et al., 2014) can be considered for the small quantities of 
cryopreserved material still available from patients. However, with current 
knowledge it will be difficult to interpret the result in terms of comparing 
differences of hydroxymethylation in the epigenome with a suitable and 
appropriate control. Nevertheless with new emerging projects such as 
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EpiGenome, ENCODE and Blueprint which are funded by organisations such 
as National Institute of Health (NIH) and International Human Epigenome 
Consortium (IHEC) for the European societies, this problem could be solved. 
These projects are involved in mapping the epigenome involving DNA 
methylation and other epigenetic changes in normal blood cells. Hence, these 
projects will be able to provide the reference epigenome for normal blood cells.  
Finally, to conclude, IFNAR2 and TET2 are novel disease genes and have 
never before been described in PIDs. The suggested future work will hopefully 
be able to elucidate further the role of each gene in the cellular pathways and 
mechanisms of host defence and regulation of the human immune system.
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Supplementary Figure 1: B cells isolation purity assessment of patient replicate and controls 
samples for microarray analysis for the study of the novel defect of autoimmune 
lymphoproliferative disease,. Left panel : representative of  FSC/SSC dot plot and the gated 
cells were shown in right panel .  Right panel : representative of the purity of B cells. 
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Supplementary Figure 2 : RIN number of each patient replicate and 
controls B cells RNA . RNA quality and integrity was determined using Lab on-
Chip analysis on the Agilent 2100 Bioanalyzer (Agilent Technologies) before 
performing microarray analysis (Illumina HT-12) for the study of the novel defect 
of autoimmune lymphoproliferative disease. 
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Supplementary Figure 3 : RIN number of  unstimulated and 
IFNα,IFNβ,IFNγ-stimulated controls and patients samples. RNA quality and 
integrity was determined using Lab on-Chip analysis on the Agilent 2100 
Bioanalyzer (Agilent Technologies) before performing microarray analysis 
(Illumina HT-12 (2x)) for the study of the novel defect of IFN signalling. 
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